CURRICULUM VITAE AND BIBLIOGRAPHY

Part I: General Information

Date Prepared: April 6, 2009

Name: **TERRY BARTON STROM, M.D.**

Business Address: Beth Israel Deaconess Medical Center
The Transplant Institute
330 Brookline Avenue, E/CLS 608
Boston, MA 02215 USA

Office Address: Beth Israel Deaconess Medical Center
The Transplant Institute
Center for Life Sciences (CLS) Building
3 Blackfan Circle, CLS 608
Boston, MA 02115 USA

E-mail: tstrom@bidmc.harvard.edu

Office Telephone: 617-735-2880
Office Fax: 617-735-2902

Place of Birth: Chicago, Illinois

Education:

1959-60 University of Illinois, Chicago, IL
1960-62 University of Illinois, Urbana, IL
1962-66 M.D., University of Illinois College of Medicine, Chicago, IL

Post Doctoral Training:

1966-1967 Intern, University of Illinois Hospital, Chicago, IL
1967-1968 Junior Medical Resident, University of Illinois Hospital, Chicago, IL
1970-1971 Senior Medical Resident, Beth Israel Hospital, Boston, MA

Certification:

1967 Illinois Licensure Registration
1970 Massachusetts Licensure Registration (#35684)
1970 DEA #BS1867122
1972 Diplomat, American Board of Internal Medicine

Academic Appointments:

1973-1974 Instructor in Medicine, Harvard Medical School, Boston, MA
1974-1978 Assistant Professor of Medicine, Harvard Medical School, Boston, MA
1978-1988 Associate Professor of Medicine, Harvard Medical School, Boston, MA

Academic Appointments:

1988- Professor of Medicine, Harvard Medical School, Boston, MA

2003- Professor of Surgery, Harvard Medical School, Boston, MA
2007- Adjunct Professor, University of London, King's College of London, London, UK

Hospital Appointments:

1973-1974 Junior Associate in Medicine, Peter Bent Brigham Hospital, Boston, MA
1973-1983 Medical Director, Renal Transplant Service, Peter Bent Brigham Hosp. (Brigham and Women's), Boston, MA
1973-1983 Associate Director, Laboratory of Immunogenetics and Transplantation, Peter Bent Brigham Hospital (Brigham and Women's), Boston, MA
1981-1984 Associate in Medicine, Beth Israel Hospital, Boston, MA
1983-1999 Medical Director, Renal Transplant Service, Beth Israel Hospital, Boston, MA
1984- Physician, Brigham and Women's Hospital, Boston, MA
1984- Physician, Beth Israel Hospital, Boston, MA
1989-1996 Director, Division of Immunology, Department of Medicine, Beth Israel Hospital, Boston, MA
1996-2004 Director, Division of Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
2004- Co-Director Transplant Center, Beth Israel Deaconess Medical Center, Boston, MA
2004- Director, Transplant Research Center, Beth Israel Deaconess Medical Center, Boston, MA
2004- Director, Division of Transplant Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
2004-2006 Chair, Stem Cell Interest Group, Beth Israel Deaconess Medical Center, Boston, MA

Major Committee Assignments:

Medical School and Medical Center:
1975-1976 Admissions Committee, Harvard Medical School
1989-1990 *Ad hoc* Scientific Misconduct Panel
1989-1992 Academic Review Committee
1990-1993 Faculty of Medicine's Subcommittee of Professors, Harvard Medical School
1996-1998 Clinical Trials Unit Research Operations Committee, Beth Israel Deaconess Medical Center, Boston, MA
1998- Research Council, Beth Israel Deaconess Medical Center, Boston, MA
1999-2002 Committee to establish MMSc Degree in Medical Education Systems Management, Harvard Medical School, Boston, MA
2001 Research and Technology Development Committee, Beth Israel Deaconess Medical Center, Boston, MA
2002- CLS Vivarium Committee, Beth Israel Deaconess Medical Center, Boston, MA
2007- Executive Committee, Harvard Longwood Medical Area Training Grant in Transplantation, Beth Israel Deaconess Medical Center, Children's Hospital Boston, Brigham and Women's Hospital, Boston MA

National and Regional:
1975-1987 Scientific Organizing Committee, New England Immunology Committee
1982-1984 Advisory Panel, Cellular Physiology Program, National Science Foundation

National and Regional:

1985-1986	Congressional-appointed Task Force on Organ Transplantation, United States Dept of Health and Human Services, Health Resources and Services Administration
1986-1989	Medical Advisory Panel, The Medical Foundation Research Committee, The Medical Foundation
1987-1991	Advisory Panel, Allergy, Immunology and Transplantation Research Committee, National Institute of Allergy and Infectious Diseases
1993-	Advisors and Consultant Staff on Immunosuppressive Drugs, USFDA
1994-	Transplantation Task Force, National Kidney and Urologic Diseases Advisory Board, National Institutes of Health
1995-	Expert Panel on Immunological Interventions for Promoting Transplant Tolerance, National Institute of Allergy and Infectious Disease, Bethesda, MD
1995-	Rita Allen Foundation, Scientific Advisory Committee, New York, New York
1998-	NIAID Panel on Ethical Issues in Clinical Transplantation for the Induction of Transplant Tolerance
1998-	*Ad hoc* Participant, National Advisory Allergy and Infectious Diseases Council, Dept of Health and Human Services, National Institutes of Health, Bethesda, MD
1998-	Transplantation Society Membership Committee
1998-	Transplantation Society Communications Committee, Chair
1998-1999	Consultant, Antiviral Drugs Advisory Committee, Food and Drug Administration, Division of Special Pathogens and Immunologic Drug Products
1999-	Immune Tolerance Network, Steering Committee
1998-2000	Immune Tolerance Network, Leader, Tolerance Assay Development Committee
1999-	Immune Tolerance Network, Ethics Committee
2000-	Immune Tolerance Network, Co-chair, Tolerance Assay Development Committee
2002-	American Society of Transplantation, Co-chair, Ad Hoc Cellular Transplantation Committee
2002	American Society of Nephrology Nominations Committee
2003-2004	American Society of Transplantation Ad Hoc Cellular Transplantation Committee
2003	NIDDK Advisory Committee Meeting on Islet Transplantation
2003-	NIAID Non-human Primate Research Steering Committee
2004-	Nature Clinical Practice Nephrology Advisory Board
2004-2007	Alliance for Lupus Research Scientific Advisory Board
2005-2006	Juvenile Diabetes Research Foundation Review Panel for Autoimmunity Centers Program
2007-	Massachusetts Society for Medical Research, Board of Directors
2006-2007	XXII International Congress of Transplantation Society, Basic Science Program Section Panel (Sydney, Australia)
01/25/2008	Common Mechanisms Review, Scientific Reviews, Juvenile Diabetes Research Foundation Executive Office, New York, NY
02/26/2008	Juvenile Diabetes Research Foundation Review Panel, “Inflammation and Beta Cell Regenerations”
06/26/2008	NIH IAR Special Emphasis Panel/Scientific Review Group 2008/10 ZRG1 RUS-C (03)M - Nephrology Overflow Applications

Professional Societies:

1973	American Society of Nephrology
1973	International Society of Nephrology

Professional Societies:

1973	American Federation for Clinical Research
1976	American Association of Immunologists
1976	Transplantation Society
1981	Co-organizer, Transplantation Society Symposium "Effector Mechanisms of Allograft Rejection"
1982	American Society of Transplant Physicians, now American Society of Transplantation (Founding Member)
1983	American Society for Histocompatibility and Immunogenetics
1986	Clinical Immunology Society
1987	Chairman, Program Committee Clinical Immunology Society
1989	Organizing Committee Transplantation Society Symposium: "Mechanisms of Allograft Tolerance", Lake Louise, Alberta, Canada
1989	Co-organizer, American Society of Nephrology Symposium: "T-cell Activation", Les Embiez, France
1993	Co-organizer, International Society of Nephrology, Immunology Theme, Intl Congress, Jerusalem, Israel
1995	Organizing Committee, American Society of Nephrology Annual Meeting
1995	Co-organizer, American Society of Nephrology meeting, "The Immunologic Basis of Renal Disease. Paradigms for the 21st Century" Nov. 5-8, 1995; San Diego, CA
1995	Molecular Medicine Society, Manhasset, New York
2004	Cell Transplant Society

Editorial Board:

1979-1993	International Journal of Immunopharmacology
1979-1998	Immunopharmacology
1981-1991	American Journal of Kidney Disease
1983-1987	Disease Markers
1984-1987	Transplantation
1984-1986	Transplantation and Immunology Letter
1984-1986	Progress in Transplantation
1986-1990	Clinical Transplantation
1987-1990	Brain, Behavior, and Immunity
1988-1990	Clinical Aspects of Autoimmunity
1990-1996	Kidney International Consulting Editor
1991-1995	Transplantation Science
1996-1998	Journal of the American Society of Nephrology
1997-2000	Transplantation Proceedings
1998-2002	Graft
2000-	Brasilian Journal of Transplantation
2000-	Current Opinions in Organ Transplantation
2000-2005	Contributing Editor, Journal of Immunology
2007-	Consulting Editor, Journal of Clinical Investigation
2007-	Associate Editor, Journal of the American Society of Nephrology

Awards and Honors:

1959-1966	Illinois State Scholar
1959-1961	Academic Honors Day Award, University of Illinois

Awards and Honors:

1960-1962	Student Senate, University of Illinois

1976-1981	Research Career Development Awardee, National Institutes of Health
1979	American Society for Clinical Investigation
1987	Association of American Physicians
1981	President, American Society of Transplant Physicians
1987-1991	Councilor, Clinical Immunology Society
1989	Interurban Clinical Club
1989	M.A. (Honorary) Harvard University
1989-1990	President, Clinical Immunology Society
1989-1996	Councilor, American Society of Transplant Physicians
1990	D. Sc. (Honorary) Hahnemann University
1990-1996	Councilor, International Society of Nephrology
1990	Rupert Billingham Visiting Professor of Medicine, Vanderbilt University
1991-1995	Councilor, International Society of Immunopharmacology
1991	Lilly Lecturer, Royal College of Physicians, London, England
1992	Visiting Professor, University of Toronto, Toronto, Ontario, Canada
1992	Citation, The Best Doctors in America
1995	Sandoz Visiting Professor, Renal Unit, Guy's Hospital, London, England
1995	John Kapp Clark Visiting Lecturer, Dept of Medicine, University of Pennsylvania, PA
1995	Bernard Pimstone Memorial Lecturer, Groote Schuuer Hospital University of Cape Town, South Africa
1995	Fellow, Molecular Medicine Society, Manhasset, NY
1996-2000	Councilor, Transplantation Society
1997	The First Annual Sandoz Transplant Established Investigator; Award of the American Society of Transplant Physicians, Chicago, IL
1998	Visiting Professor, University of Texas-Houston/The Hermann Hospital Renal Transplant Service Division of Immunology and Organ Transplantation, Houston, TX
2001	Roche American Society of Transplantation Distinguished Achievement Award, Chicago, IL
2002-	Information Sciences Institute (ISI) Highly Cited Researcher
2004-	Councilor, Cell Transplant Society
2006	Homer W. Smith Award for “Exceptional Contributions to the Field of Nephrology” from the American Society of Nephrology
2007	Guest Professor, Rupert Billingham Lectureship in Transplant Immunology, Vanderbilt Transplant Center, Vanderbilt University
2008	Recipient of the Visiting Research Professor in Transplantation, University of Toronto, Multi organ Transplant Program, Research Day in Transplantation and Immunology, Toronto General Hospital, Toronto, ONTARIO
2008	Recognition for Contribution to Alliance for Lupus Research as a Member of the Scientific Advisory Board (2004-2007), New York, NY

Part II: Research, Teaching, and Clinical Contributions

A. Narrative Report of Research, Teaching, and Clinical Contributions:

Our goal is to safely render transplant recipients tolerant to their transplants and restore self tolerance, thereby enabling transplant survival in the absence of maintenance in immunosuppressive medications and curing patients with autoimmune disorders such as Type 1 diabetes mellitus. Through use of basic and translational science, we are pursing this goal. At a basic level, we are analyzing the molecular pathways that foster commitment to T cell tissue destructive– and tissue protective-subsets as well as those that decommission such commitments. We use this knowledge to design molecules and regimens that foster immune tolerance. Therapies are tested in both mouse and non-human primate models. To date, our work has led to the FDA approved use of anti-CD25 monoclonal antibodies in transplantation and autoimmunity and an IL2-diphtheria toxin related fusion protein for treatment of T-cell malignancies. These new regimens, one includes use of Ig fusion proteins that use designed and tested in mouse and monkey models, are funded for clinical trials in new onset Type 1 diabetes and islet transplantation. To aid deployment of potentially tolerizing therapies we have also identified molecular signatures that are present in peripheral blood mononuclear cells well in advance of clinically evident kidney transplant rejection. The validity of this signature is now being tested in doubled blind trials.

B. Funding Information:

Current Funding

2003-2009 NIH U01 AI 055795, Principal Investigator; (Program Director: O. Salvatierra) New NAPRTCS in Steroid Free Immunosuppression

2004-2009 NIH U01 AI063589, Principal Investigator; (Program Director: A. Shaked); Molecular Profiling and Immunomodulatory Intervention (CTOT)

2004-2009 NIH U01 AI063589, Principal Investigator; (Program Director: M. Sayegh); Novel Therapies of Chronic Allograft Dysfunction (CTOT)

2005-2010 NIH U19 AI066705, Principal Investigator; (Program Director: J. Madsen); Cardiac Allograft Tolerance in Non-human Primates

2005-2013 NIH U01 AI77816, Principal Investigator; (Program Director: W. Harmon); Novel Therapies for Chronic Renal Allograft Dysfunction in Children

2006-2011 JDRF 7-2005-1329, Principal Investigator/Program Director; Human Islet Transplantation at BIDMC

2008-2012 JDRF 4-2004-368, Principal Investigator; (Program Director: D. Mathis); JDRF Center on Immunological Tolerance in Type 1 Diabetes

2007-2012 NIH P01 AI041521, Principal Investigator; (Program Director: L. Turka); On the Role of Regulatory T Cells in Transplantation

2007-2012 NIPH PPG U19 DK080652, Principal Investigator/Program Director; Inflammation and T cell memory: inter-related barriers to allograft tolerance

2007-2012 NIH PPG 1U19AI074639; Program Director; “Inflammation and T cell memory: inter-related barriers to allograft tolerance.”

2008-2012 JDRF 4-2007-1057; Principal Investigator; (Program Director: D. Mathis); “Autoimmunity/Inflammation in Connection with Type-1 Diabetes.”

2008-2013 NIH P01 AI 073748, Co-Investigator; (Program Director V. Kuchroo) “TIM Family of Genes: Regulation of the Allograft Response by TIM Proteins”

Past Funding

1976-1981 KO4 AI00155; Principal Investigator; Career Development Award "Regulation of the cellular events in transplant immunity"

1977-1980 NIH RO1 AM21094; Principal Investigator; "T cell activation and de novo expression of receptors"

1979-1981 Sandoz Pharmaceuticals "Cyclosporin A (OL 27-400) Clinical Trial Study No. 1 (Kidney transplantation)"

1980-1983 NIADDK RO1 AM02601; Principal Investigator; "Insulin, T cell growth factor, and immunosenescence"

1980-1995 Seragen; Principal Investigator; "Construction and testing of immunosuppressive fusion proteins"

1982-1984 The Kroc Foundation; Principal Investigator; "The relationship between immunosenescence and responsiveness to insulin and T cell growth factor"

1983-1986 NIH NO1-AI32687; Principal Investigator; "Development and clinical evaluation of rapid cellular crossmatching technique suitable for use in cadaveric organ transplantation"

1983-1989 NIDDK RO1 DK33929; Principal Investigator; "A dissection of T cell activation"

1985 National Science Foundation; Principal Investigator; "T cell activation and de novo expression of receptors"

1985-1995 NIAID RO1 AI22882; Principal Investigator; "Protein engineering of IL-2 toxin"

1986-1987 Juvenile Diabetes Foundation International; Principal Investigator; "IL-2 receptor targeted immunotherapy in murine diabetes mellitus"

1988-1990 Juvenile Diabetes Foundation International; Principal Investigator; "IL-2 receptor positive autoimmune lymphocytes; characterization and therapeutic elimination"

1988-1991 Eleanor Naylor Dana Charitable Trust; Principal Investigator; "Strategies for achieving long term graft acceptance/tolerance"

1988-1992 NIH NOAI82512; Principal Investigator; "Evaluation of monoclonal antibodies with specificity for the IL-2 receptor in the prevention of renal allograft rejection"

1988-1993 NIAID PO1 AI23360; Principal Investigator; "Specific immunotherapy in primate renal transplantation"

1988-1993 NIH UO1 CA48626; Principal Investigator; "Growth factor receptor targeted toxin for leukemia/lymphoma"

1990-1991 Diabetes Research and Education Foundation; Principal Investigator; "The molecular immunology of diabetes mellitus"

1990-1991 Sterling Drugs; Principal Investigator; "Study of immunosuppressive properties of cyclosporine solubilized with fish oil"

1990-1993 Roche Institute-Harvard Medical School; Co-Principal Investigator; "Role of T cells in collagen arthritis"

1991-1992 Eleanor Naylor Dana Charitable Trust; Principal Investigator; "IL-2 receptor directed immunotherapy in transplantation"

1991-1992 Searle, Inc.; Principal Investigator; "Immunity, prostaglandins and transcriptional regulation"

1992-1993 Lewis Foundation; Principal Investigator; "Development of a mouse model of AIDS"

1992-1995 NIH RO1 DK44626; Principal Investigator; "Molecular characterization of renal allograft rejection"

1993-1994 Asahi Chemical Industry America, Inc.; Principal Investigator; "The study of mizoribine in NOD mice"

1993-1995 March of Dimes; Principal Investigator; "The mechanism by which IL-2 activates Raf-1"

Past Funding

1994-1995 Ares Serono; Principal Investigator; "The mechanism by which IL-2 activates Raf-1"

1994-1996 Wyeth Ayerst; Principal Investigator; "Intergraft gene expression Study Pilot Biopsies"

1994-1996 Juvenile Diabetes Foundation; Principal Investigator; "Cellular and molecular mechanism of islet allograft rejection and tolerance"

1994-1997 American Cancer Society; Principal Investigator; "Structural requirements for IL-2R chain/Raf-1 interactions"

1994-1999 NIAID UO1 AI37206; Principal Investigator; for Core Scientific Laboratory at BIDMC "Controlled trial of induction therapy in renal transplantation" (North American Pediatric Renal Transplant Cooperative Study)

1995-1997 NIAID AI125132; Principal Investigator; "Immunological Studies of Rejection"

1995-1998 NIAID RO1 AI37798; Principal Investigator; "Affecting graft survival with donor immune tissue"

1996-1997 Genetics Institute; Principal Investigator; "Anti-IL-12 Mab treatment of islet allograft recipients"

1996-1997 Ares Serono; Principal Investigator; "Testing of CD4 peptide in transplantation models"

1996-1998 Juvenile Diabetes Foundation; Principal Investigator; "The role of B7 related costimulation signals in islet cell transplantation"

1996-1999 Baxter; Principal Investigator; "Molecular diagnostics in adult renal transplantation"

1996-1999 Genetics Institute, Principal Investigator; “Anti-B7 antibody treatment of transplant recipients”

1996-2001 NIH AI40167; Principal Investigator for Core Scientific Laboratory at BIDMC Principal Investigator; "Cooperative Clinical Trial in Adult Transplantation"

1997-1999 JDF #197059; Principal Investigator; "The role of novel T cell growth factors (TCGFs) in tolerance"

1997 Sandoz Established Investigator's Award; Principal Investigator

1997-2001 NIH RO1 DK52019-01A1; Co-Principal Investigator; "Gene transfer approach to prevent transplant rejection"

1997-2002 NIH 1PO AI GF41521; Principal Investigator; "Cytokines and the induction and maintenance of transplant tolerance"

1998-1999 Wyeth Ayerst; Principal Investigator; “Sirolimus vs. azathioprine with standard immunosuppressive therapy in renal allograft recipients”

1998-1999 Novartis #981015 (CTU #); Co-Principal Investigator; "Simulect with steroid withdrawal vs. Simulect with standard steroid treatment to prevent renal transplant rejection"

1998-1999 Wyeth Ayerst CTU "A comparative study of the effect of sirolimus vs. azathioprine, administered concomitantly with standard immunosuppressive therapy in renal allograft recipients"

1998-1999 NIH (Emmes) UO1 AI40167; Scientific Core: Principal Investigator; "Cooperative clinical trial in adult transplantation"

1998-1999 NIH AI25132 (Emmes/NIH) "Adult Study Imm1 Protocol" (Quantitative PCR Assays)

1998-2002 NIH RO1 AI42298; Principal Investigator; "The role of non T cell growth factors (TCGFs) in rejection

1998-2002 NIH/NIAID RO142298 (Supplement) "Mechanistic studies of immune parameters underlying graft rejection"

Past Funding

1998-2003 Roche; Co-Principal Investigator; "Immunosuppression withdrawal in stable renal allograft recipients treated with triple therapy"

1998-2004 JDF/Harvard; Principal Investigator for Project #22 "Molecular diagnostics and islet cell transplantation"

1998-2004 "Harvard Center for Islet Transplantation "Islet allograft tolerance in diabetic NOD recipients"

1999-2000 NIH; Co-Principal Investigator; "Collaborative Network for Clinical Research on Immune Tolerance"

1999-2001 Genetics Institute; Principal Investigator; "B7.1 and B7.2 Antibodies, Rapamycin"

1999-2003 Roche; Principal Investigator; "In vivo blockade of T-cell activation in allograft recipients"

1999-2003 NIH U01 AI46134 NAPRTCS; Co-Principal Investigator; "Clinical Trials in Primary and Repeat Transplants"

1999-2003 NIH/NIAID U01 AI46135; Co-Principal Investigator; "CD40L blockade in pediatric transplantation"

1999-2004 Investigator; Juvenile Diabetes Foundation/Harvard Center for Islet Transplantation "Islet allograft tolerance in diabetic NOD recipients"

1999-2004 NIH/NIAID; Co-Principal Investigator; "Tolerance to islet allografts in type 1 diabetes"

1999-2004 NIH/NIDDK; Co-Principal Investigator; "Islet tolerance induction based on anti-CD154 antibody"

2000-2004 NIH DK56963; Co-Principal Investigator; "Tolerance to islet allograft in type 1 diabetes"

2004-2005 NIH U01 AI06359; Co-Principal Investigator; "Clinical Trials in Transplantation"; Principal Investigator, Program Director: A. Shaked

1999-2006 NIH NO1 AI95380; Principal Investigator; "Immune Tolerance Network, Collaborative Network for Clinical Research on Immune Tolerance"

2000-2005 NIH ITN supplement; Principal Investigator; "PCR Core for gene expression profiling"

2001-2006 NIH RO1 AI50987; Principal Investigator; "Novel approaches to achieve allograft tolerance"

2002-2006 NIH/ITN N01-AI-15416; Principal Investigator; "Collaborative Network for Clinical Research on Immune Tolerance- PCR Core for Gene Expression Profiling

2004-2006 JDRF 4-2004-368; Principal Investigator; (Program Director: D. Mathis) JDRF Center for Immunological Tolerance in Type 1 Diabetes; Islet Allograft Tolerance in Diabetic NOD recipients

2005 JDRF 4-2004-368; Principal Investigator; "JDRF Center on Immunological Tolerance in Type 1 Diabetes."

2003-2006 Forest Health; Principal Investigator; "The role of Th1 and Th2 cells in the immune response to cancer "

2004-2007 NIH DK067632; Co-Investigator; (Principal Investigator: XX Zheng) "A new approach to reverse onset of autoimmune diabetes."

2005-2007 NIH U19-A1051731; Principal Investigator; (Program Director: C. Larsen) "Tolerance induction for primate islet transplantation."

2002-2007 NIH U01 AI 51706; Co-Investigator; (Program Director: Hugh Auchincloss, M.D., MGH) "Tolerance Induction for Primate Islet Transplantation."

2002-2008 NIH PO1 AI 041521; Principal Investigator; (Program Director: L. Turka) "On the role of reg T cells in transplantation."

Past Funding

2003-2008 NIH UO1 AI 055795; Principal Investigator; (Program Director: O. Salvatierra) ”New NAPRTCS in steroid free immunosuppression.”
2007-2008 National Kidney Foundation; Principal Investigator (Program Director: J. Markmann) “Center for Protein Therapeutics.”

C. Report of Current Research Activities:

Project

Our goal is safely render transplant recipients tolerant to their transplants and restore self tolerance, thereby enabling transplant survival in the absence of maintenance in immunosuppressive medications and curing patients with autoimmune disorders such as Type 1 diabetes mellitus. Through use of basic and translational science, we are pursing this goal. At a basic level, we are analyzing the molecular pathways that foster commitment to T cell tissue destructive– and tissue protective-subsets as well as those that decommission such commitments. We use this knowledge to design molecules and regimens that foster immune tolerance. Therapies are tested in both mouse and non-human primate models. To date, our work has led to the FDA approved use of anti-CD25 monoclonal antibodies in transplantation and autoimmunity and an IL2-diphtheria toxin related fusion protein for treatment of T-cell malignancies. These new regimens, one includes use of Ig fusion proteins that use designed and tested in mouse and monkey models, are funded for clinical trials in new onset Type 1 diabetes and islet transplantation. To aid deployment of potentially tolerizing therapies we have also identified molecular signatures that are present in peripheral blood mononuclear cells well in advance of clinically evident kidney transplant rejection. The validity of this signature is now being tested in doubled blind trials.

Bench research

The following represents a list of funded projects:
1) Tolerance induction for primate islet transplantation
2) New strategy of tolerance induction in non-human primate islet allograft model
3) Tolerance induction for primate islet
4) Thoracic allograft tolerance in non-human primates
5) Human islet transplant center – a pipeline to induce tolerance
6) A new approach to reverse the onset of autoimmune diabetes
7) Inflammation and T cell memory: inter-related barriers to allograft tolerance
8) On the role of reg T cells in transplantation
9) To test the new Aralast-NP on the role of inflammation and autoimmunity in the NOD mouse
10) To test the effect of anti-α vB6 mAb on syngeneic and allogeneic skin

Area being developed for funding

Imaging of islet transplant using “color-coded” T-cells. In this system, T-cell subsets express different colors and can be followed *in vivo* after islet transplantation.

D. Report of Teaching:

Local invited teaching presentations

TEACHING EXPERIENCE:

1973-1982	Attending Physician, Renal Service, Brigham and Women's Hospital, Boston, MA
1974-1982	Attending Physician, Medical Service, Brigham and Women's Hospital, Boston, MA
1975-1982	Lecturer in Harvard Medical School, Principles of Clinical Immunology (Course 205)
1978	Lecturer on Transplantation, American Academy of Allergy Course, "An Intensive Review: Adult and Pediatric Allergy"
1983-1984	Lecturer on Cyclosporine, Harvard Continuing Medical Education Course on "New Drugs"
1983-1984	Co-Director, Harvard Medical School, Principles of Clinical Immunology (Course 205)
1983-	Attending Physician, Renal Service, Beth Israel Hospital, Boston, MA
1983-	Attending Physician, Medical Service, Beth Israel Hospital, Boston, MA
1983-1989	Lecturer on Transplantation, Immunology for Non-immunologists, Post-graduate course, Harvard Medical School
11/02/1984	"The immunologic mechanisms of graft rejection." Brigham and Women's Hospital Post-Graduate Renal Course. Boston, MA
1985-1986	Course Director, Harvard Medical School, Principles of Clinical Immunology (Course 205)
1986-1988	Instructor, Harvard Medical School, Basic Immunology (Immunology 700)
04/04/1991	"Renal transplant clinical therapy and management", Brigham and Women's Hospital Course on Renal Transplantation, Westin Hotel, Boston, MA
05/07/1991	"Immunology" Society of Black Academic Surgeons, Harvard Medical School, Boston, MA
02/16/1994	"Clinical application of molecular immunology" Harvard Medical School Dept of Continuing Education Course on "Recent Advances in the Study of Renal Diseases, Boston, MA
05/22/1994	"Are we close to inducing tolerance?" Advances in Nephrology Beth Israel Renal Course, Boston, MA
10/21/1994	"Suppressing the immune response: Tolerance and immunosuppressive therapy" Harvard Medical School Continuing Education Course on "Basic Science for Clinicians: The Scientific Underpinnings of Modern Clinical Medicine." Beth Israel Hospital, Boston, MA
12/07/1994	"Transplant immunology for the internist: Are we close to inducing tolerance?" Harvard Medical School Dept of Continuing Education Course on "Update in Internal Medicine", Westin Hotel, Boston, MA
01/05/1995	"Immunobiology of renal transplantation" Harvard Medical School HST320. Interhospital clinical elective advanced study in renal pathophysiology. Medical Education Center, Boston, MA
05/07/1995	"New methods to prevent rejection" Nephrology 1995, Harvard Medical School Department of Continuing Education, Copley Plaza Hotel, Boston, MA
05/1995	Co-director, Nephrology 1995, Harvard Medical School, Dept of Continuing Education, & Dept of Medicine, Beth Israel Hosp. Copley Plaza Hotel, Boston, MA
05/1996	Co-director, Nephrology, 1996, Harvard Medical School Dept of Continuing Education, and Dept of Medicine, Beth Israel Hospital, Boston, MA

TEACHING EXPERIENCE:

05/1997 Co-director, Nephrology, 1997, Harvard Medical School Dept of Continuing Education, and Dept of Medicine, Beth Israel Deaconess Med. Center, Boston, MA

05/04/1997 "New methods to prevent rejection" Nephrology 1997, Harvard Medical School Department of Continuing Education, Copley Plaza Hotel, Boston, MA

09/17/1998 "New tools for diagnosis of allograft dysfunction." Contemporary issues in nephrology and pre-board review Harvard Continuing Medical Education Course, Boston, MA

2004 Ethics of Science, Course Director, Harvard Medical School, Boston, MA

02/05/2007 "Training T Cells to be Well-Behaved", Pasteur Institute, Harvard Medical School, Boston, MA

10/22/2007 "An Update on Transplant Immunology", Allergy and Immunology Conference at Brigham and Women's Hospital, Boston, MA

03/10/2008 "Are Transplants Tolerable?", Clinical Physiology Grand Rounds, Beth Israel Deaconess Medical Center, Boston, MA

Advisory and Supervisory Responsibilities in Clinical or Laboratory Setting:

1998-Present PI, Transplant Immunology Laboratory

Names of Advisees or Trainees:

Trainee Last Name	First Name	Degree	Title	Years	Education	Title of Project	Current Position
Alexopoulos	Sophoclis	Post-doc	M.D.	2003-2005	Columbia Univ. College of Physicians & Surgeons, NY	T reg cells in allograft tolerance	Resident, Department of Surgery, BIDMC/HMS
Amanullah	Farhana	Research Fellow	M.D.	2001-2002	SUNY Upstate Medical Center, NY	The role of apoptosis in T cell tolerance	Assistant Professor, Sindh Institute of Urology and Transplantation, Dow Medical College, Karachi, Pakistan
Avihingsanon	Yingyos	Post-doc	M.D.	1999-2002	Chulalongkom University, Thailand	Molecular diagnostic approach to renal transplant function	Assistant Professor, Chulalongkorn University Hospital, Bangkok, Thailand

Balasubramanian	Savithri	Post-doc	Ph.D.	2005-Present	Center for Cellular & Molecular Biology, Hyderabad, India	Tolerance induction	Research Fellow, BIDMC/HMS
Bodonyi-Kovacs	Gabor	Post-doc	M.D.	2006-2007	University of Szeged, Szeged, Hungary	Transcriptional profiling of 0 hour kidney biopsies	add
Chen	Ming	Post-doc	M.D., Ph.D.	2006-2007	Medical College of Yangzhou University	Tolerance induction	add
Degauque	Nicolas	Post-doc	Ph.D.	2005-2007	University of Nantes, Nantes, France	The maintenance of allograft induction and tolerance	add
Demirci	Gulcin	Post-doc	M.D., Ph.D.	1999-Present	Medizinische Hochschule Hannover, Germany	Targeting novel T cell growth factors in diabetes	Assistant Professor of Surgery, University of Regensburg, Germany
Domenig	Christoph	Post-doc (jointly with XX Zheng)	M.D.	2001-2003	University of Innsbruck, Austria	New therapeutic strategies to achieve tolerance	Surgical Resident, General Hospital, Vienna, Austria
Dwyer	Karen	Post-doc	M.D.	2004-2006	University of Melbourne; Australia	Tolerance induction in islet transplantation	Physician, Fitzroy, Australia
El Essawy	Abdel Basset	Post-doc	M.D.	2003-Present	Mansoura University, Egypt	Proteomic analysis for transplant rejection	add
Fan	Zhigang	Post-doc	M.D., Ph.D.	2006-Present	Medical School, Sun Yet-sen University, China	Tolerance in islet transplantation	Research Fellow, BIDMC/HMS JDRF
Ferrari-Lacraz	Sylvie	Post-doc	M.D.	1997-2001	University of Geneva School of Medicine,	The role of IL-15 in cytopathic T-cell	Assistant Professor, University

					Switzerland	immunity.	Hospital of Geneva, Switzerland
Gao	Wenda	Post-doc	Ph.D.	2002-Present	New England Medical Center, Tufts University	Allograft tolerance	Instructor in Medicine, BIDMC/HMS
Gupta	Shipra	Post-doc	Ph.D.	2008-Present	All India Institute of Medical Sciences, India	Tim 4 Proteins	Research Fellow, BIDMC/HMS
Kang	Hee Gyung	Post-doc	M.D.	2003-2005	Seoul National University, Korea	Immuno-suppression and tolerance	Assistant Professor of Medicine, Seoul National University South Korea
Kilpatrick	Elizabeth	Post-doc	Ph.D.	2004-2006	U Mass. Med School, MA	Allograft rejection and tolerance	Instructor, Immunology, Emmanuel College, Boston, MA
Kunstle	Gerald	Post-doc	Ph.D.	1999-2001	University of Konstanz, Germany	Induction of allo-and autoimmune tolerance against islet allografts in diabetic NOD mice	Assistant Professor, University of Konstanz, Germany
Laine	Jarmo	Post-doc	M.D.	1998-2001	Hospital for Children and Adolescents, Finland	The role of AKT in T cell biology	Director, Stem Cell & Transplant Service, Red Cross, Helsinki, Finland
Lee	Jong Soo	Post-doc	M.D.	2004-2006	Ulsan University, South Korea	Tolerance induction in kidney transplantat	Research Fellow, BIDMC/HMS

						ion	
Li	Yong Sheng	Post-doc	M.D.	1995-1999	Capital Medical University, China	The role of Th1 dependent immunity in allograft rejection	Industry, Cambridge, MA
Li	Xian C.	Post-doc	M.D.	1995-1999	University of Western Ontario, Canada	The role of B7 costimulatory molecules in graft rejection and tolerance	Assistant Professor, BIDMC/Harvard Medical School
Liu	Peter	Post-doc	M.D.	2005-Present	Dana Farber Cancer Institute, Boston, MA	Transgenic models and tolerance	Research Fellow, BIDMC/HMS
Lu	Yan	Post-doc	M.D.	2005-Present	Medical School of Peking University, Beijing, China	Tolerance induction & allograft rejection	Research Fellow, BIDMC/HMS
Ma	Naili	Post-doc	M.D., Ph.D.	1998-2000	Schepens Eye Institute, MA	Molecular diagnostic approach to renal transplant function	Research Fellow, BIDMC/HMS
Mariat	Christophe	Post-doc	M.D.	2003-2005	Hôpital Universitaire de St. Etienne, France	TIM family in immunological tolerance	Assistant Professor, University of St. Etienne, St. Etienne, France.
Mix	T. Christian	Post-doc	M.D.	2000-2001	New England Medical Center, Boston, MA	Allograft tolerance and induction	Instructor, New England Medical Center
Nawaz	Haq	Post-doc	Ph.D.	2008	Agakhan University, Karachi, Pakistan	Tim 4 Proteins	Research Student, BIDMC/HMS
Putheti	Prabhakar	Post-doc	Ph.D.	2006-Present	Karolinska Institute, Sweden	Autoimmunity	Research Fellow, BIDMC/HMS
Sanchez-Fueyo	Alberto	Post-doc (jointly	M.D.	1999-2002	University of Barcelona, Spain	The role of regulatory cells in	Assistant Professor,

		with XX Zheng)				transplantation	University of Barcelona, Spain
Thornley	Thomas B.	Post-doc	Ph.D.	2007-Present	University of Mass. Medical School, MA	Tim 4 Proteins	Research Fellow, BIDMC/HMS
Vu	Minh Diem	Post-doc	Ph.D.	2003-2006	Montreal University, Canada	Transplantation immunology	Research Scientist in Transplantation, Roche Pharmacology., Palo Alto, CA
Wang	Candace	Post-doc	M.D.	1999-2000	Boston University School of Medicine	Allograft tolerance	Assistant Professor, Renal Division, Washington University, St. Louis, MO
Xu	Xuemin M.	Post-doc	M.D.	2004-Present	Capital Medical University, Beijing, China	Novel costimulatory molecules in transplant tolerance	Research Fellow, BIDMC/HMS
Yu	Guang	Post-Doc	M.D., Ph.D.	2004-Present	University of Montreal, Canada	Induction and maintenance of allograft tolerance.	Research Fellow, BIDMC/HMS
Zhang	Dong	Post-doc	M.D., Ph.D.	2004-Present	Beijing Friendship Hospital, China	The maintenance of allograft tolerance	Research Fellow, BIDMC/HMS

INVITED LECTURER/SPEAKER:

09/11/1984 "Lymphocyte activation and de novo expression of the interleukin-2 receptor." Dana Farber Cancer Institute Basic Immunology Seminar Series. Boston, MA

09/20/1984 "The immunology and immunopharmacology of renal transplantation." Beth Israel Hospital Medical Grand Rounds. Boston, MA

11/01/1984 "The immunopharmacology of graft rejection." Medical College of Pennsylvania. Medical Grand Rounds. Philadelphia, PA

INVITED LECTURER/SPEAKER:

11/05/1984 "Cyclosporine and potential application for autoimmune disease." Brigham and Women's Hospital Rheumatology Grand Rounds. Boston, MA
01/19/1985 "Renal transplantation: New therapeutic approaches." Waltham Hospital Medical Grand Rounds. Waltham, MA
01/29/1985 "The immunopharmacology of graft rejection." American Council on Transplantation. Plenary Speaker. Washington, DC
02/28/1985 "Renal transplantation: An update." University of MA; University Hospital, Medical Grand Rounds. Worcester, MA
03/04/1985 "The cellular basis of rejection." University of Munich Medical School Basic Immunology Seminar. Munich, Germany
03/06/1985 "The cellular basis of graft rejection." First Congress of Aspiration Cytology in Organ Transplantation. Invited Plenary Speaker. Mayerhof, Austria
04/10/1985 "Lymphocyte activation and de novo expression of IL-2 receptors." Dartmouth Medical School Basic Immunology Series. Hanover, NH
04/21/1985 "Immunopharmacology of graft rejection." National Kidney Foundation Science Writer's Symposium. New York City, NY
04/30/1985 "The immunopharmacology of graft rejection." Manhattan VA Hospital Medical Grand Rounds. New York City, NY
10/15/1985 "The immunology and immunopharmacology of kidney transplantation." Western Dialysis Association Symposium. Invited Speaker. Acapulco, Mexico
11/03/1985 "ARF in renal transplantation." University of Pittsburgh Symposium on Acute Renal Failure. Pittsburgh, PA
01/21/1986 "The immunobiology of renal transplantation." University of Pennsylvania Medical Grand Rounds, Philadelphia, PA
01/21/1986 "The Immunology of Renal Transplantation: Therapeutic Implications" University of Pennsylvania Hospital Medical Grand Rounds, Philadelphia, PA
01/23/1986 "Renal transplantation immunosuppressive therapy." Cedar-Sinai Medical Center Medical Grand Rounds Los Angeles, CA
02/14/1986 "The IL-2 receptor as a target of inquiry and therapy." Tufts Medical School Basic Immunology Lecture Series. Boston, MA
02/25/1986 "Renal transplantation: An update." University of Miami Postgraduate Course in Nephrology. Orlando, FL
04/09/1986 "The IL-2 receptor as a target of immunotherapy." Red Cross Symposium on Transplantation. Plenary Speaker. Washington, DC
04/09/1986 "The immunology of organ transplantation." Tufts-New England Medical Center Clinical Immunology Lecture Series. Boston, MA
08/08/1986 "The mode of action of immunosuppressive therapy." Congress of the International Society of Transplantation. Plenary Speaker. Helsinki, Finland
09/04/1986 "Renal transplantation: Accentuate the positive and minimize the negative." National Kidney Foundation Annual Illinois Chapter Dinner. Featured Speaker. Chicago, IL
09/04/1986 "The interleukin-2 receptor as a target of inquiry and therapy" University of Chicago Renal Grand Rounds. Chicago, IL
09/18/1986 "Targeting the interleukin-2 receptor with antibodies and IL-2 toxins." Montefiore Medical Center Symposium on Therapeutic Use of Monoclonal Antibodies. Invited Speaker. New York City, NY
09/26/1986 "Immunotherapy and kidney transplantation." Brigham and Women's Hospital-Beth Israel Hospital Renal Grand Rounds. Boston, MA

INVITED LECTURER/SPEAKER:

10/10/1986 "The IL-2 receptor as a target of immunosuppressive therapy." Annual Meeting of the Clinical Immunology Society. Program Chairman and Plenary Speaker. Baltimore, MD

10/11/1986 "The interleukin-2 receptor as a target of inquiry and therapy." Clinical Immunology Society Annual Meeting. Invited Speaker. Baltimore, MD

10/26/1986 "The immunology and Immunopharmacology of graft rejection." American Kidney Foundation Annual Symposium. San Francisco, CA

05/05/1987 "The cellular basis of graft rejection." International Transplantation Society Symposium on Graft Infiltrating Lymphocytes. Plenary Session Speaker. La Baule, France

06/25/1987 "The interleukin-2 receptor as a target of inquiry and therapy." International Society of Immunology Congress Plenary Session Speaker. Toronto, Canada

07/11/1987 "Toward more selective immunosuppressive therapies." International Society of Nephrology Congress Plenary Session Speaker. London, England

09/17/1987 "The immunobiology of kidney transplantation." Beth Israel Hospital Medical Grand Rounds. Boston, MA

09/18/1987 "The immunobiology of kidney transplantation." New England Deaconess Hospital Medical Grand Rounds. Boston, MA

10/06/1987 "The interleukin-2 receptor as a target of immunotherapy." International Transplant Society Symposium on Immunosuppressive Therapy. Co-organizer. Plenary Speaker. Barcelona, Spain

10/22/1987 "The mode of action of immunosuppressive drugs." Burroughs Wellcome Symposium on Transplantation. Co-organizer and speaker. Boca Raton, FL

11/20/1987 "Renal transplantation: Toward more selective immunotherapies." Brigham and Women's Hospital Medical Grand Rounds. Boston, MA

12/14/1987 Symposium on Pro-inflammatory Peptides. American Nephrology Society. Chairman. Washington, DC

01/01/1988 "The role of CD4 in T-cell activation." Biogen Inc. Seminar. Cambridge, MA

01/22/1988 "Renal transplantation: Toward more selective immunosuppression." Cedar-Sinai Medical Center Medical Grand Rounds. Los Angeles, CA

02/26/1988 "Interleukin-2 toxin: A magic recombinant bullet." Visiting Professor. Yale Medical School. New Haven, CT

03/16/1988 "Interleukin-2 toxin: A recombinant magic bullet." Harvard Medical School Immunology Lecture Series. Boston, MA

03/28/1988 "The mechanism of graft rejection." Course on Renal Transplantation Brigham and Women's Hospital. Boston, MA

04/12/1988 "Development of a recombinant interleukin-2 toxin." Tufts Medical School Immunology Lecture Series. Boston, MA

04/25/1988 "Interleukin-2 toxin: A new selective therapy for immunosuppression." National Kidney Foundation Symposium for Scientific Press. New York City, NY

05/01/1988 "IL-2 toxin: A selective and potent immunosuppressant." 19th International Leukocyte Culture Conference. Banff, Alberta, Canada

05/05/1988 Med. Grand Rounds for Renal Transplantation. St. Vincent's Hospital. Worcester, MA

05/10/1988 "The mode of action of immunosuppressive agents used in clinical transplantation." Combined Brigham and Women's Hospital-Beth Israel Hospital Medical Lecture Series. Boston, MA

06/05/1988 "Toward more selective immunosuppressive treatment in kidney transplantation." American Urology Association National Kidney Foundation. Plenary Lecture. Boston, MA

INVITED LECTURER/SPEAKER:

06/15/1988 "Selective targeting of the IL-2 receptors in autoimmune diseases." First Congress on Immunointervention in Autoimmune Diseases. Paris, France
07/07/1988 "Selective targeting the therapeutic IL-2 receptors in auto-immune diseases." FASEB Symposium on Autoimmunity. Saxon River, VT
07/19/1988 "Selective targeting the therapeutic IL-2 receptors in auto-immune diseases." FASEB Symposium on Immunopharmacology, Saxton River, VT
05/09/1990 "Immunotherapy with human monoclonal antibodies, immunotoxins, gene fusion toxins." Hahnemann University Spring Convocation, Hahnemann University. Philadelphia, PA
05/28/1990 "The ethics of transplantation." Hahnemann University Honorary Doctor of Science Degree, Hahnemann University. Philadelphia, PA
09/25/1990 "IL-2 Receptor Directed Immunotherapy." Symposium sur les Marqueurs de l'Inflammation. Lyon, France
10/20/1990 30th Annual Scientific Symposium on Kidney Disease. Palm Springs, CA
10/22/1990 "The IL-2 receptor as a target of immunotherapy." The New York Academy of Sciences. New York, NY
11/03/1990 "IL-2 receptor as a target of therapy." The 162 Meeting of the Interurban Clinical Club. Boston, MA
03/05/1991 "A Trojan horse strategy for destroying unwanted T-cells." UCLA Keystone Symposia on Monoclonal Antibodies. Denver, CO
03/14/1991 "A Trojan horse strategy for destroying unwanted T-cells." Project Director's meeting for transplant biology, NIAID. Bethesda, MD
03/18/1991 "Clinical Transplantation." Lahey Clinic Grand Rounds. Burlington, MA
03/29/1991 "Clinical Transplantation in 1991." St. Elizabeth's Hospital Grand Rounds. Brighton, MA
04/09/1991 "Development of cytokine toxin fusion proteins." Interurban Club. Boston, MA
04/24/1991 "The IL-2 Receptor as a Target of Immunotherapy." Lilly Lectureship of the Royal College of Physicians. London, England
05/08/1991 "Organ transplant allocation: Should we use HLA typing?" MA Chapter of the National Kidney Foundation, Needham Sheraton. Needham, MA
05/19/1991 "T-cell activation of the mechanism of action of immunosuppressives." American Gastroenterology Association Meeting. Plenary Session talk. New Orleans, LA
06/06/1991 "A Trojan horse strategy for destroying unwanted T-cells." Museum of Fine Arts. Big BIH Event. Boston, MA
06/26/1991 "A Trojan horse strategy for destroying unwanted T-cells." Chicago Leukemia Research Foundation, Chicago, IL
08/08/1991 "Development of recombinant fusion proteins for treatment of allograft recipients." First International Congress Xenotransplantation, Plenary Session Talk. Minneapolis, MN
09/12/1991 "A Trojan horse strategy for destroying unwanted T-cells." Beth Israel Hospital Grand Rounds. Boston, MA
09/28/1991 "A Trojan horse strategy for destroying unwanted T-cells." New England Medical Center Grand Rounds. Boston, MA
09/29/1991 "A Trojan horse strategy for destroying unwanted T-cells." Symposia on T-cell activation and immunotherapy. Trinity College. Oxford, England
10/07/1991 "Update on transplant immunity including GVH." Children's and Brigham and Women's Hospital's Allergy and Immunology Division. Boston, MA
10/10/1991 Grand Rounds, North Shore Hospital. New York, NY

INVITED LECTURER/SPEAKER:

10/31/1991 "Immunobiology of transplant." The Medical Schools of New York-Departments of Transplantation First Annual Post-graduate Course, New York, NY
02/03/1992 "The immunopharmacology of graft rejection." Washington University School of Medicine Clinical Pulmonary Conference. St. Louis, MS
03/19/1992 "Current status of newer immunosuppressive agents." Frontiers in Renal Disease Meeting. Monte Carlo, Monaco
04/12/1992 "The immunopharmacology of graft rejection." Renal Physicians Association Meeting. Chicago, IL
04/22/1992 Harvard Renal Club. Cambridge, MA
05/20/1992 Hellenic Society of Nephrology. Alexandropoulis, Greece
05/30/1992 Symposium: Cytokines and Transplantation, Rush Presbyterian. Chicago, IL
06/03/1992 "Monoclonal therapy." Seminar, University of Toronto-Hospital for Sick Children, American College of Rheumatology Symposium. Toronto, Canada
08/07/1992 "Scientific Summation of the Congress." Invited speaker, The Transplantation Society meeting. Paris, France
10/08/1992 "IL-2 receptor targeted immunotherapy." Invited speaker, American College of Rheumatology meeting. Atlanta, Georgia
10/09/1992 Lecturer on Immunosuppression, American Academy of Allergy - National Institutes of Health, Post Graduate Education Course. Bethesda, MD
06/1993 Invited speaker and Program Chairman; 5 day program on Immunology as part of the International Society of Nephrology Congress, Jerusalem, Israel
10/12/1993 "Immunology of Transplantation." Brigham and Women's-Children's Hospital Allergy/Immunology Conference, Boston, MA
11/09/1993 "Preclinical and clinical development of cytokine toxins." American Association for Cancer Research meeting. Asheville, NC
11/15/1993 "Cellular mechanisms of allograft rejection and tolerance." The American Society of Nephrology Clinical Science Symposium on Immunobiology of Renal Transplantation, Boston, MA
12/1993 "Chronic Rejection." Invited speaker, French Society of Transplantation, Paris, France
12/1993 "The molecular mechanisms of rejection and tolerance." Invited speaker, Hopital Necker, University of Paris. Paris, France
02/11/1994 "The immunosuppressive effects of corticosteroids: Basic mechanisms." A Keystone Symposia: The Cellular and Molecular Regulation of the Acute Inflammatory Response. Tamarron, CO
04/02/1994 "A bioengineering approach to immunosuppressive therapy." Surgical Grand Rounds, Beth Israel Hospital. Boston, MA
04/07/1994 "Cytotoxic T lymphocytes." North American Pediatric Renal Transplant Cooperative Group. Newport Beach, CA
04/22/1994 "Mechanisms of allograft rejection and tolerance." 9th Annual Conference on Clinical Immunology. Anaheim, CA
12/04/1994 "Toward a molecular genetic approach to diagnose and anticipate rejection." Transplant Conference, Massachusetts General Hospital. Boston, MA
01/25/1995 "IL-2 is not necessary for rejection and IL-4 is not necessary for tolerance." Third Intl Symposium on Tolerance Induction. Plenary Session. Breckenridge, CO
01/31/1995 "The patient with chronic renal failure-an internist's primer" Medical Grand Rounds, MetroWest Medical Center. Framingham, MA
02/07/1995 "Th1/Th2 responses in transplantation." T Cell Diagnostics. Woburn, MA

INVITED LECTURER/SPEAKER:

02/17/1995 "Renal transplantation where we've come from and where we are going." Grand Rounds, Brigham and Women's Hospital. Boston, MA

02/22/1995 "A gene knockout strategy to study the allograft response." Transplantation Immunol Seminar, Deaconess Hospital. Boston, MA

03/01/1995 "Toward a molecular understanding of graft rejection and tolerance." Guy's Hospital. London, England

03/02/1995 "Detection of intragraft gene expression: a diagnostic strategy." University of London. London, England

03/03/1995 "Cytokine and cytokine receptor-based therapy." Guy's Hospital. London, England

03/09/1995 "Gene knockout strategy to study the allograft response." Massachusetts General Hospital Immunology Seminar Series. Boston, MA

04/07/1995 "Suppressing the immune response: Tolerance and immunosuppressive therapy." Basic Science Lecture Series, Harvard Medical School. Boston, MA

04/10/1995 "Renal Transplantation: Where we came from and where we are headed." Clark Lecturer, University of Pennsylvania. Philadelphia, PA

04/11/1995 "Th1/Th2 paradigm in transplantation reconsidered." Medical Grand Rounds, University of Pennsylvania. Philadelphia, PA

04/18/1995 "Transplant immunology for the internist: Are we close to inducing tolerance?" Medical Grand Rounds, New England Deaconess Hospital. Boston, MA

05/14/1995 "Genetically engineered proteins for immunoregulation." Therapeutic Antibodies in Transplantation Symposium of the American Society of Transplant Physicians. Chicago, IL

05/25/1995 "New drugs for renal transplant: clinical perspective." Istituto Di Ricerche Farmacologiche "Mario Negri". Bergamo, Italy

06/23/1995 "The use of Ig fusion proteins for fun and profit." PharMingen. San Diego, CA

09/20/1995 "Towards a molecular diagnostic approach to diagnose and prevent rejection." Southern African Transplantation Society Congress. Club Mykonos, Langebaan. Cape Town, South Africa

09/21/1995 "Genetically engineered proteins for immunoregulation." University of Cape Town and Groote Schuur Hospital, Department of Medicine, Cape Town, South Africa

10/03/1995 "Update on Transplant Immunology: New Mechanisms and Therapies." Renal Grand Rounds, North Shore University Hospital. Manhasset, NY

11/05/1995 "The Immunologic Basis of Renal Disease: Paradigms for the 21st Century", Co-Chair, American Society of Nephrology, Basic Science Committee. San Diego, CA

11/14/1995 "Molecular biology tools for the diagnosis of rejection." Cybercongress: Transplantation in the Next Millennium; Plenary Session IV Sheraton Washington Hotel, Washington, DC

11/29/1995 "Role of antibodies and role of genetically engineered proteins for immunoregulation." 5th Annual Postgraduate Course: New York 1995 Transplant. Medical Schools of New York, Dept of Transplantation, New York, NY

02/02/1996 "Suppressing the immune response: tolerance and immunosuppressive therapy." Basic Science Lecture Series, Beth Israel Hospital, Boston, MA

02/08/1996 "The mechanism of corticosteroid immunosuppressive activity." American College of Clinical Pharmacology. Monterey, CA

02/09/1996 "Introduction and Steroids." Advances in Pharmacotherapy of Organ Transplantation. Monterey CA

02/14/1996 "Genetically engineered proteins for immunoregulation." Immunologic Tolerance in Transplantation Symposium for American College of Clinical Pharmacy Winter Practice and Research Forum. Monterey, CA

INVITED LECTURER/SPEAKER:

03/07/1996 "A molecular diagnostic approach to transplantation management." Transplant Conference Lecture Series, New England Deaconess Hospital. Boston, MA
03/13/1996 "Mechanisms of graft rejection: Cells and cytokines." North American Pediatric Renal Transplant Cooperative Study, Sheraton Hotel. Washington, DC
03/18/1996 "Targeting cells of the immune system with Ig fusion proteins." Genetics Institute. Cambridge, MA
04/24/1996 "Immunology of Transplantation." Beth Israel Hospital-Department of Anesthesia. Boston, MA
04/30/1996 "Ig related fusion proteins as immunosuppressives and anti-tumor agents." Searle-Monsanto. St. Louis, MO
05/05/1996 "New methods to prevent rejection." Nephrology 1996, Harvard Medical School Department of Continuing Education, Copley Plaza Hotel. Boston, MA
05/10/1996 "Th1 and Th2 lymphocytes in organ transplantation." Necker Seminars. Paris, France
05/26/1996 "Gene transfectants: Therapeutic applications in transplantation." American Society of Transplant Physicians, Wyndham Anatole Hotel. Dallas, TX
05/29/1996 "Basic immunobiology of immunosuppression." American Society of Transplant Physicians, Wyndham Anatole Hotel. Dallas, TX
06/01/1996 "The role of Th1 and Th2 cells in the allograft response." Clinical Immunology Society, New Orleans, LA
06/03/1996 "The requirements for rejection: lessons from gene knockout mice." Allograft Transplantation Minisymposium for the AAI. New Orleans, LA
10/10/1996 "Gene expression analysis of transplant specimens." Transplant Lecture Series, New England Deaconess Hospital. Boston, MA
10/10/1996 "Review of biological agents being tested in the clinic." New England Deaconess Hospital. Boston, MA
10/11/1996 "Islet transplantation." Longwood Avenue Metabolism Seminar Series, Joslin Diabetic Center. Boston, MA
10/15/1996 "A molecular diagnosis approach to human kidney transplantation." Visiting Professor; Humboldt University zu Berlin. Berlin, Germany
10/16/1996 "Th1/Th2 paradigm." Universitatsklinikum Charite/Humbodlt University zu Berlin. Berlin, Germany
10/24/1996 "Tolerance - the holy grail of transplantation. Is it possible?" Yale Medical School, Grand Rounds. New Haven, CT
10/30/1996 "Human renal allograft rejection: Immune mechanisms molecular correlates and treatment strategies." New York University Medical Center, Medical Grand Rounds. New York, NY
11/06/1996 "Targeting Costimulation/Adhesion Molecules" Symposium on Biologic Targets for New Immunosuppressive Strategies. American Society of Nephrology. New Orleans, LA
02/04/1997 "Current transplant therapy: What we have and what we need." Tolerance and Immunotherapy in Allotransplantation meeting. San Diego, CA
02/16/1997 "Cytokines and cytokine receptors." First American Society of Transplant Physicians Winter Symposium. Phoenix, AZ
02/22/1997 "New approaches to diagnosis of allograft dysfunction." Harvard Medical School Course. Boston, MA
04/08/1997 "A molecular diagnostic approach to organ transplantation." Renal Grand Rounds, Brigham and Women's Hospital. Boston, MA

INVITED LECTURER/SPEAKER:

04/16/1997 "Molecular diagnostic strategies for management of organ transplantation." Medical Grand Rounds, University of Western Ontario. London, Ontario
04/16/1997 "The role of T cell individual growth factors in allograft responses." John Robarts Research Institute. London, Ontario
05/04/1997 "New methods to prevent rejection." Nephrology 1997, Harvard Medical School Department of Continuing Education, Copley Plaza Hotel. Boston, MA
05/10/1997 "Molecular diagnosis of graft dysfunction." American Society of Transplant Physicians annual meeting. Chicago, IL
05/14/1997 "Transplantation Tolerance: New thoughts on an old goal?" Clinical Science Symposium, American Society of Transplant Physicians. Chicago, IL
05/14/1997 "Clinical applicability: A look into the future." American Society of Transplant Physicians annual meeting. Chicago, IL
05/19/1997 "The Th1/Th2 paradigm in autoimmune diabetes and islet cell transplantation." Insulin Dependent Diabetes Symposium. Boston, MA
06/19/1997 "Renal allograft rejection." 4th Intl Symposium on Clinical Immunology, Rai Congress Center. Amsterdam, The Netherlands
09/25/1997 "New tool for diagnosis of allograft dysfunction." Harvard Medical School Dept of Continuing Education, Brigham and Women's Hospital Contemporary Issues in Nephrology. Boston, MA
09/30/1997 "The immunology of transplant rejection." Advances in Transplantation. Washington, DC
10/01/1997 "New pharmaceuticals in transplantation: monoclonals and new biologic agents." Advances in Transplantation. Washington, DC
10/01/1997 "The immunology of transplant rejection." Advances in Transplantation. Washington, DC
10/30/1997 "Anti-IL-12 effects in vivo: An enigme wrapped in a conundrum." Genetics Institute. Cambridge, MA
10/31/1997 "The Th1 Th2 paradigm in IDDM and transplantation. Autoimmunity is not Alloimmunity." Seventh New England Regional Workshop Autoimmune Diabetes Mellitus. Woods Hole, MA
11/14/1997 "A new therapeutic strategy for transplantation: Selective targeting of activated lymphocytes." Seoul, Korea
11/15/1997 "A molecular diagnostic approach to management of renal transplant recipients." 17th Autumn Congress, Korean Society of Nephrology. Pusan, Korea
12/03/1997 "Gene expression in biopsy and blood samples for the prediction and diagnosis of acute rejection." Novartis-sponsored International Workshop on Biological Markers in Transplantation. Basel, Switzerland
01/18/1998 "Can we predict chronic rejection: Novel Tools?" Second Annual ASTP Winter Symposium. San Juan, PR
02/12/1998 "The destruction of activated and malignant T cells: toxins and antibodies." Third International Conference on New Trends in Clinical and Experimental Immunosuppression. Geneva, Switzerland
02/18/1998 "Apoptosis." Chairman, New Dimensions in Transplantation. Florence, Italy
03/04/1998 "Organ Transplantation: New diagnostic and therapeutic strategies." Medical Grand Rounds, Newton Wellesley Hospital. Newton, MA
03/05/1998 "Organ transplantation: New Management Strategies." Grand Rounds, Beth Israel. Boston, MA; Deaconess Medical Center, Boston, MA
03/12/1998 "The complicated role of T-cell growth factors in the allograft response." Graduate Program in Immunology, Tufts University School of Medicine. Boston, MA

INVITED LECTURER/SPEAKER:

04/03/1998 "Organ Transplantation: New Strategies." Department of Surgery, University of Texas Houston Medical School. Houston, TX
04/09/1998 "Can we predict allograft rejection?" NIAID Meeting on Ethical Issues in Clinical Trials for the Induction of Transplant Tolerance. Arlington, VA
04/22/1998 "Peripheral transplant tolerance." Annual FASEB/AAI Major Symposium on tolerance. San Francisco, CA
04/30/1998 "Molecular biological markers in transplantation rejection." Biogen, Inc. Cambridge, MA
05/01/1998 "Tolerance, transplantation, and immunologic diseases: Advances and research opportunities." National Advisory Allergy and Infectious Diseases Council. Bethesda, MD
05/10/1998 "Targeting T cell signal transduction pathways." Chair, Sunrise Symposium, American Society of Transplant Physicians. Chicago, IL
05/10/1998 "Molecular mechanisms of immunosuppression by rapamycin and rapamycin analogues." American Society of Transplant Physicians. Chicago, IL
05/13/1998 "The role of T-cell growth factors (TCGFs) in vivo; diagnostic and therapeutic strategies." 2nd Central European Congress of Rheumatology. Warsaw, Poland
05/27/1998 "A molecular diagnostic approach to organ transplant patient management." Abbott Laboratories, Inc. Abbott Park, IL
06/01/1998 "Peripheral Tolerance." Department of Health and Human Services National Institutes of Health. Bethesda, MD
06/02/1998 "The role of T cell growth factors in the acquisition of peripheral tolerance." NIAID, Division of Allergy, Immunology and Transplantation Program Advisory Committee. Bethesda, MD
07/10/1998 "Peripheral events in acute and chronic rejection." Third International Congress on Pediatric Transplantation. Boston, MA
07/13/1998 "Cytokines, their receptors and their regulation." The Transplantation Society XVII World Congress. Montreal, CANADA
07/16/1998 "Cell Biology and Immune Responses." Chairperson, The Transplantation Society XVII World Congress. Montreal, Canada
07/19/1998 "Molecular base of allograft rejection." Fourth Congress of International Experimental Microsugery Society, London. Ontario, Canada
09/01/1998 "Peripheral tolerance is a many splendored thing." Joint Immunobiology and Transplantation Conference of New York Presbyterian Hospital. New York, NY
09/17/1998 "New tools for diagnosis of allograft dysfunction." Contemporary Issues in Nephrology. Boston, MA
09/19/1998 "Cytokines in graft rejection and tolerance: An ever-shifting paradigm." Transplantation in the next millennium. National Kidney Foundation. Boston, MA
10/06/1998 "Transplantation tolerance in our time." Beth Israel Deaconess Medical Center Transplant Center Conference, Beth Israel Deaconess Medical Center. Boston, MA
10/17/1998 "Peripheral tolerance: A tale of 10 blind men describing an elephant." New England Immunology Conference. Woods Hole, MA
10/22/1998 "The mechanisms driving peripheral tolerance: Implications for the clinic." The Dumont-UCLA Transplant Center Research Conference. Los Angeles, CA
10/25/1998 "Cytokines and effector molecules in the periphery: Can they predict what happens in the graft?" American Society of Nephrology Basic Science and Clinical Science Symposia Meeting. Skytop, PA
10/30/1998 "Role of T cell growth factors in the allograft response." Edouard Herriot Hospital. Paris, France

INVITED LECTURER/SPEAKER:

11/02/1998 "Molecular diagnostics of intra-graft events." Transplant Grand Rounds, Brigham and Women's Hospital. Boston, MA

11/04/1998 "Advances in Transplantation." Ob-Gyn Grand Rounds, Beth Israel Deaconess Medical Center. Boston, MA

11/05/1998 "Transplant Immunology." Interhospital Clinical Elective and Advanced Seminar in Renal Pathophysiology." Harvard Medical School. Boston, MA

11/13/1998 "New diagnostic and treatment strategies for organ transplantation." Medical Grand Rounds, New England Medical Center. Boston, MA

11/18/1998 "A new molecular diagnostic strategy for management of pediatric renal transplant recipients." Grand Rounds, Children's Hospital Medical Center. Boston, MA

11/19/1998 "Transplant Immunology." Interhospital Clinical Elective and Advanced Seminar in Renal Pathophysiology, Harvard Medical School. Boston, MA

12/07/1998 "The role of T-cell growth factors in the allograft response." Cytokines in Immune and Infectious Diseases, NIH/NIAID. Bethesda, MD

12/17/1998 "T cell growth factors produced by non-T-cell." Dept of Bone and Joint Institute, Beth Israel Deaconess Medical Center. Boston, MA

01/15/1999 "Immunologic monitoring: past, present and future." ASTP 3rd Annual winter Symposium; Post-Transplant Management in the 21st Century: New Challenges in Clinical Care. Kapalua, Hawaii

01/28/1999 "Tolerance in Transplantation." Grand Rounds, University of Pennsylvania Medical School. Philadelphia, PA

02/25/1999 "Renal transplantation: new therapeutic and diagnostic strategies." University of Massachusetts Medical Grand Rounds. Worcester, MA

03/24/1999 "Analyzing T-cell activation pathways." Keystone Symposia on Molecular and Cellular Biology of Transplantation. Lake Tahoe, NV

04/08/1999 "New methods to prevention of rejection." Plenary Session, Brazilian Congress of Transplantation. Rio de Janeiro, Brazil

04/09/1999 "Strategies for induction of tolerance in human transplantation." Plenary Session, Brazilian Congress of Transplantation. Rio de Janeiro, Brazil

04/29/1999 "Transplant tolerance: From the bench and enroute to the bedside." Renal Grand Rounds, Vanderbilt University Medical Center. Nashville, TN

04/30/1999 "A molecular diagnostic approach to organ transplantation." Vanderbilt Transplant Conference, Vanderbilt University Medical Center, Nashville, TN

05/17/1999 "What's New; What's Hot." Chair, Plenary and State of the Art; American Society of Transplantation 18th Annual Meeting. Chicago, IL

05/17/1999 "What's new; What's Hot." Chair, Plenary and State of the Art, American Society of Transplantation. Chicago, IL

05/18/1999 "Molecular diagnostics in adult renal transplantation." Baxter Extramural Grant Program 1999 Annual Meeting. Chicago, IL

05/25/1999 "Monitoring cytokines and effector molecules in the periphery: Can they predict what happens in the graft?" Amer. Soc of Neph 1998 Annual Scientific Meeting. Philadelphia, PA

06/02/1999 "T cell growth factors in allograft response." Gastroenterology Research Seminars, Beth Israel Deaconess Medical Center. Boston, MA

06/10/1999 "Manipulation of allo-recognition through T-cell growth factor." Sixth N.A.T. Meeting Targeting Recipients Immune Response through Bioreagents. Nantes, France

06/13/1999 "New methods to prevent rejection." Nephrology 1999 Course. Boston, MA

INVITED LECTURER/SPEAKER:

06/24/1999 "The IL-15R as an immunosuppressive target." Immunomodulation Session, FASEB Autoimmunity Conference. Faxton River, VT
07/28/1999 "General overview of cutting edge technologies and the study of immunotolerance and pharmacogenetics." Amersham Pharmacia Biotech. Piscataway, NJ
08/30/1999 "Medical Management of Transplantation." Didactic Renal Session, Department of Medicine, Beth Israel Deaconess Medical Center. Boston, MA
10/20/1999 "Cytokine monitoring." Post-transplant Immunosuppression: New Paradigms Course. Minneapolis, MN
10/21/1999 "Treatment of rejection." Post-transplant Immunosuppression: New Paradigms Course. Minneapolis, MN
11/03/1999 "Mechanisms and clinical applicability of transplantation tolerance." Renal Transplantation: From Bench to Clinic; ASN PGE Course. Miami Beach, FL
11/06/1999 "New Diagnostic Techniques." 1999 ASN Clinical Nephrology Symposia Annual Meeting. Miami, FL
11/07/1999 T-cell costimulation blockade: From bench to bedside, Symposium co-moderator; ASN Annual Meeting. Miami, FL
11/12/1999 "T-cell tolerance: a numbers game." Transplantation Grand Rounds, University of Pittsburgh School of Medicine. Pittsburgh, PA
12/03/1999 "Rapamycin: A novel mechanism of action and new opportunities for clinical transplantation." Temple University. Philadelphia, PA
12/03/1999 "Rapamycin: A novel mechanism of action and new opportunities for clinical transplantation." Hahneman University. Philadelphia, PA
12/13/1999 "Immune tolerance: size does matter." BASF. Worcester, MA
01/27/2000 "Immune tolerance: in this case, size matters." Grand Rounds, Brown University. Providence, RI
02/07/2000 "Mechanisms of allograft rejection." Brigham and Women's Hospital, Medical Staff. Boston, MA
02/07/2000 "T cells are dying to accept allografts." Transplant Grand Rounds, Brigham and Women's Hospital. Boston, MA
03/15/2000 "T cells are dying to accept allografts." Transplant Grand Rounds, Cornell New York Medical College. New York, NY
04/17/2000 "Perspectives on tolerance and rejection." Roche Laboratories, Cellcept-Rapamycin Advisory Board Meeting. New York, NY
05/14/2000 "Strategies to induce tolerance in humans. What is likely to succeed?" Transplant 2000, American Society of Transplantation. Chicago, IL
06/08/2000 "Cytokines in allograft rejection." Joint Conference of the MESOT and the AST. Beirut, Lebanon
06/08/2000 "Monitoring of allograft rejection." Joint Conference of the MESOT and the AST. Beirut, Lebanon
06/09/2000 "Philosophy of immunological monitoring to guide therapy." Joint Conference of the MESOT and the AST. Beirut, Lebanon
10/16/2000 "Costimulatory blockage: T cells are dying to accept transplants." ASN 33rd Annual Scientific Meeting. Toronto Ontario, Canada
02/08/2001 "Blueprint for a molecular diagnostic approach to patient management." Washington University School of Medicine. St. Louis, MO
02/09/2001 "New strategies towards tolerance in transplantation." Washington University School of Medicine. St. Louis, MO
04/18/2001 "Update on kidney transplantation." Medical Grand Rounds, Newton Wellesley Hospital. Newton, MA

INVITED LECTURER/SPEAKER:

05/19/2001 "The Road to Clinical Tolerance", AST Fifth Annual Winter Symposium. Mauna Lani, HI
08/22/2001 "2001: A transplant odyssey the future is here." Istanbul, Turkey
01/30/2002 "Therapeutic strategies to achieve allograft tolerance in the NOD mouse model." JDRF Center for Islet Transplantation. Boston, MA
02/12/2002 "Stem cells and the future of transplantation." UCLA Society of Nephrology, UCLA. Sepulveda, CA
02/22/2002 "Harnessing apoptosis to create islet transplant tolerance." Endocrine Grand Rounds, Beth Israel Deaconess Medical Center. Boston, MA
03/22/2002 "Stem cell transplants and regenerative medicine." Dartmouth-Hitchcock Medical School. Darmouth, NH
04/02/2002 "Beyond acute rejection: a new educational initiative." Bay State Medical Center, Springfield, MA
04/02/2002 "Bioinformatics." American Transplant Congress. Washington, DC
04/08/2002 "Immune tolerance and the role of the IL-15 pathway." Keystone Symposia on Immune Tolerance. Steamboat Springs, CO
05/03/2002 "Harnessing Apoptosis to Create Immune Tolerance." Johns Hopkins Medical School. Baltimore, MD
05/17/2002 "Regulatory Cells II: Mechanisms" Federation of Clinical Immunology Societies 34e Annual Meeting. Paris, France
05/19/2002 "Regulation of T cell function by IL-2 and IL-15." American Thoracic Society. Atlanta, GA
06/17/2002 "Cytokines and tolerance." FASEB Conference, Vermont Academy. Saxtons River, VT
08/27/2002 "Stem cells - Immunological monitoring for immune tolerance." Chair, Plenary Session, Transplantation Society. Miami, FL
09/20/2002 "A strategy to promote tolerance to normal or stem cell derived islet allografts." 12th Asian-Oceania Congress of Endocrinology. Taipei, Taiwan
11/03/2002 "Stem Cells in Biology and Transplantation." Symposium Moderator; ASN 35th Annual Meeting and Scientific Exposition. Philadelphia, PA
11/21/2002 "Cytokines and allograft rejection/tolerance." Club de la Transplantation 2002. Abbaye des Vaux de Cernay, France
12/19/2002 "Inciting mass suicide of activated T cells as a means to create tolerance." New England Medical Center. Boston, MA
02/02/2003 "Using apoptosis of activated T cells as means to produce tolerance." The 2003 Miami Nature Biotechnology Winter Symposium. 50 years on: From the double helix to molecular medicine. Miami Beach, FL
03/13/2003 Days of Molecular Medicine Symposium. La Jolla, CA
03/31/2003 "T cells are dying to reverse the diabetic state." Johnson, Newark NJ
06/03/2003 "Costimulation: Activation vs. Regulation." Co-Moderator, Mechanisms of Dominant Transplantation Tolerance, AST Congress. Washington, DC
06/20/2003 "Immune Tolerance" Newer approaches to a cure for type 1 Diabetes: Are they ready for prime time?" The Endocrine Society Annual Meeting. Philadelphia, PA
09/09/2003 "Immune tolerance: suicide is the way to." UCSF. San Diego, CA
09/16/2003 "Immune tolerance: a balancing act." Schepens Eye Institute. Boston, MA
11/13/2003 "Therapeutic approaches to T cell." American Society of Nephrology. San Diego, CA
06/17/2004 "A preclinical model for islet tolerance induction in the monkey." INSERM, Universite de Nantes. Nantes, France

INVITED LECTURER/SPEAKER:

06/29/2004 "A novel strategy to reverse the onset of diabetes in autoimmune NOD mice." JDRF Center. Boston, MA
09/06/2004 “T cells-mechanism and tolerance.” State of the Art Symposium, Transplant Society. Vienna, Austria
09/07/2004 “Innate and adaptive mechanisms of regulation.” Chair, Transplant Society. Vienna, Austria
09/27/2004 “TIM proteins and T cell subset gates.” Wyeth Pharmaceuticals. Madison, NJ
10/05/2004 “How to identify a good kidney for Transplantation.” ASN Transplantation Meeting. Arlington, VA
10/08/2004 “Research Day.” Beth Israel Deaconess Medical Center. Boston, MA
10/22/2004 “Transplantation Without Immunosuppresssion.” Diabetes Research Institute Foundation. New York, NY
11/02/2004 “PI Research Forum.” Beth Israel Deaconess Medical Center. Boston, MA
11/05/2004 "Checking or accelerating type 1 diabetes mellitus." 14th Annual New England Regional Workshop on Autoimmune Diabetes, Marine Biological Laboratories. Woods Hole, MA
11/18/2004 "New approaches to tolerance induction." Seventh International Congress of the Cell Transplant Society. Boston, MA
11/29/2004 “Transplantation and the immune response.” Developments in Stem Cell Therapy at the BIDMC, Harvard Conference Center. Boston, MA
03/18/2005 “Powermix and beyond- IL-2 agonist and IL-15 antagonist for tolerance induction.” Plenary Session, Canadian Society of Transplantation. Banff, Canada
04/06/2005 “Tipping the balance toward transplant tolerance.” British Transplantation Society. Belfast, United Kingdom
11/13/2005 “A roadmap to create transplant tolerance. “ Plenary Session Lecture, ASN Transplantation Meeting. Philadelphia, PA
01/20/2006 “Transplant immunology: a balancing act.” ASTS Winter Basic Science Course, The Fundamentals of -Basic Science Research. Camelback, AZ
02/18/2006 “Pro-apoptotic cytokine fusion proteins.” Fifth Plenary Session Lecture, Clinically Applicable Strategies to Induce Transplantation Tolerance, Seventh International Conference on New Trends in Immunosuppression and Immunotherapy. Berlin, Germany
03/17/2006 “Transplantation tolerance: translating laboratory successes to the clinic.” Symposium Guy’s and St. Thomas’ Hospital. London, England
07/22/2006 “Tilting the Immune Balance Toward Tolerance.” Plenary Session Lecture, Pre-Meeting Symposia, World Transplant Congress. Boston, MA
05/08/2007 “Strategies to Alter the Balance Between Alloreactive and Treg Cells.” American Transplant Congress 2007. San Francisco, CA
06/06-09/2007 Molecular diagnosis approach to transplantation, “Confounding Role of the Inflammation on Immune Tolerance”, AST Symposium at FOCIS 2007, AST Basic Science Committee, San Diego, CA
06/24-25/2007 The role of inflammation in triggering type 1 diabetes, “Too Hot To Handle – Inflammation And Killer Cells In Type 1 Diabetes”, American Diabetes Association, Chicago, IL
06/28-30/2007 Confounding role of the inflammation on immune tolerance, “Immune-Mediated Inflammation Diseases: From Bench To Bedside”, University of Pennsylvania (U Penn’s) Symposium, University of Pennsylvania School of Medicine, PA
09/15-19/2007 Novel Targets in Immunosuppression, “Potential New Therapeutic Targets For Use In Transplantation”, Novartis Early Bird Workshop, CTS-IPITA-IXA 2007 Joint Conference - Plenary Session, Scientific Program Committee, Minneapolis MN “

INVITED LECTURER/SPEAKER:

09/28/2007 "Molecular Diagnostic Approach to Clinical Transplantation", Guy's Hospital, King's College, London

10/25/2007 "The Adverse Effects of Subtle Inflammation on Renal Transplant Outcomes." Distinguished Lecturer for the Billingham Lectureship in Transplant Immunology, Vanderbilt University Medical Center. Nashville, TN

11/04/2007 State of the Art Lecture, "Regulation of Allograft Immunity by TIM Proteins", American Society of Nephrology (ASN) Renal Week, San Francisco, CA

01/08/2008 Confounding Influence of Inflammation on Tolerance, "Confounding Influence of Inflammation upon the Acquisition and Maintenance of Tolerance", Yale Medical School, Immunobiology Program, Brown University, Division of Nephrology, Rhode Island Hospital, RI

01/10/2008 "Confounding Influence of Inflammation upon the Acquisition and Maintenance of Tolerance", University of Toronto, Multi organ Transplant Program, Research Day in Transplantation and Immunology, Toronto General Hospital, Toronto, ONTARIO

01/31/2008 "Molecular Diagnostic Approach to Clinical Transplantation", Tolerance in Transplantation/Autoimmunity, Keystone Symposia 2008, Keystone Resort, Keystone, CO

04/05-08/2008 "The confounding role of inflammatory response upon tolerance induction", Amer. Assoc. of Immunologists Conference, Experimental Biology 2008, San Diego, CA

04/09-12/2008 "The Complexities of Tolerance in Transplantation", ISHLT 28th Annual Meeting and Scientific Sessions, Boston Marriott Copley Place and Hynes Convention Center, Boston, MA

05/15/2008 "Immune Tolerizing Therapies", TolerX Inc., Cambridge, MA

05/28/2008 "Immune Suppression Therapy: Opportunities and Risks", American Society of Gene Therapy (ASGT) 11th Annual Meeting, Hynes Convention Center, Boston, MA

06/25/2008 "Mechanisms of Tolerance Induction", 2008 AAPS National Biotechnology Conference, Metro Toronto Convention Centre, Toronto, Ontario

07/13-18/2008 "Novel costimulatory pathways in transplantation" FASEB Summer Research Conference, Transplantation Immunology, New Haven, CT

10/31/2008 "The Confounding Role of Inflammation in Tolerance", Transplantation Ground Rounds, Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Department of Surgery, Division of Transplantation and Center for Continuing Education in the Health Sciences, Montefiore University Hospital, Pittsburgh, PA

11/24/2008 "Why T Cells Misbehave", Renal Ground Series, Beth Israel Deaconess Medical Center, Boston, MA

03/26/2009 "Transplant Science: roads traveled and future bookings", Transplant Science: roads traveled and future bookings, 2nd Intensive Course in Renal Transplantation: 20 years later, Instituto de Urologia e Nefrologia – 40 years; Hotel S. Paul, São José do Rio Preto, Brazil

03/27/2009 "Clinical Transplantation: The Future", Transplant Science: roads traveled and future bookings, 2nd Intensive Course in Renal Transplantation: 20 years later, Instituto de Urologia e Nefrologia – 40 years; Hotel S. Paul, São José do Rio Preto, Brazil

Part III: Bibliography

Original Articles:

1. **Strom TB**, Levin BS, Dohrmann GJ, Pollak VE. The effects of antithymocyte globulin in NZB-NZW F1 mice. Proc Soc Exp Biol Med.1968; 129:261-4.

2. **Strom TB**, Muehrcke RC, Smith RD. Sickle cell anemia with nephrotic syndrome and renal vein obstruction. Arch Intern Med.1972; 129:104-8.

3. **Strom TB**, Deisseroth A, Morganroth J, Carpenter CB, Merrill JP. Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Natl Acad Sci USA. 1972; 69:2995-9.

4. Garovoy MR, Franco V, Zchaeck D, Carpenter CB, **Strom TB**, Merrill JP. Direct lymphocyte-mediated cytotoxicity. I. An assay of presensitization. Lancet. 1973; 1:573-6.

5. **Strom TB**, Garovoy MR, Carpenter CB, Merrill JP. Microtubule function in immune and non-immune lymphocyte-mediated cytotoxicity. Science. 1973; 181:171-3.

6. **Strom TB**, Carpenter CB, Merrill JP, Austen KF, Garovoy MR, Kaliner M. The modulating influence of the cyclic nucleotides on lymphocyte mediated cytotoxicity. J Exp Med.1973; 138:381-93.

7. **Strom TB**, Bear RA, Carpenter CB. Insulin-induced augmentation of lymphocyte-mediated cytotoxicity. Science. 1975; 187:1206-8.

8. Abbas AK, Corson JM, Carpenter CB, **Strom TB**, Merrill JP, Dammin GJ. Immunologic enhancement of rat renal allografts. III. Immunopathologic lesions and rejection in long surviving passively enhanced grafts. Am J Pathol. 1975; 79:255-70.

9. **Strom TB**, Tilney NL, Carpenter CB, Busch GJ. Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med.1975; 292:1257-63.

10. Tilney NL, **Strom TB**, MacPherson SG, Carpenter CB. Surface properties and functional characteristics of the infiltrating cells harvested from acutely rejecting cardiac allografts in inbred rats. Transplantation. 1975; 20:323-30.

11. **Strom TB**, Carpenter CB, Garovoy MR, Abbas AK, Corson JM, Bear RA, Soulillou JP. Modifications of the rat alloimmune response by enhancing antibodies and the role of blocking factors in the survival of renal grafts. Transplantation. 1975; 20:368-80.

12. Soulillou JP, Carpenter CB, Lundin AP, **Strom TB**. Augmentation of proliferation and in vitro production of cytotoxic cells by 2-ME in the rat. J Immunol. 1975; 115:1566-71.

13. Garovoy MR, **Strom TB**, Kaliner M, Carpenter CB. Antibody- dependent lymphocyte-mediated cytotoxicity: mechanism and modulation by cyclic nucleotides. Cell Immunol. 1975; 20:197-204.

14. **Strom TB**, Garovoy MR, Bear RA, Gribik M, Carpenter CB. A comparison of the effects of metabolic inhibitors upon direct and antibody-dependent lymphocyte mediated cytotoxicity. Cell Immunol. 1975; 20:247-56.

Original Articles:

15. Soulillou JP, Carpenter CB, d'Apice AJF, **Strom TB**. The role of non-classical Fc receptor-associated, Ag-B antigens (Ia) in rat allograft enhancement. J Exp Med.1976; 143:405-421.

16. Busch GJ, Schamberg JF, Moretz RC, **Strom TB**, Tilney NL, Carpenter CB. T and B cell patterns in irreversibly rejected human renal allografts. Correlation of morphology with surface markers and cytotoxic capacity of the isolated lymphoid infiltrates. Lab Invest. 1976; 35:272-1982.

17. Garovoy MR, **Strom TB**, Gribik M, Carpenter CB. Antibody-dependent lymphocyte-mediated cytotoxicity (Ab-LMC): definition of the "K cell" in the rat. Transplantation. 1976; 22:367-73.

18. Pletka PG, **Strom TB**, Hampers CL, Griffiths H, Wilson RE, Bernstein DS, Sherwood LM, Merrill JP. Secondary hyperparathyroidism in human kidney transplant recipients. Nephron. 1976; 17:371-81.

19. Rogers MP, Reich P, **Strom TB**, Carpenter CB. Behaviorally conditioned immuno-suppression: replication of a recent study. Psychosom Med.1976; 38:447-51.

20. Helderman JH, **Strom TB**. The insulin receptor: a marker of T cell activation after allograft. Proc Clin Dial Transplant Forum. 1976; 6:154-8.

21. Helderman JH, **Strom TB**. Emergence of insulin receptors upon alloimmune T cells in the rat. J Clin Invest. 1977; 59:338-44.

22. **Strom TB**, Tilney NL, Paradysz JM, Bancewicz J, Carpenter CB. Cellular components of allograft rejection: identity, specificity and cytotoxic function of cells acutely rejecting allografts. J Immunol. 1977; 118:2020-6.

23. Helderman JH, **Strom TB**. Specific insulin binding site on T and B lymphocytes as a marker of cell activation. Nature. 1978; 274:62-3.

24. Helderman JH, Reynolds TC, **Strom TB**. The insulin receptor as a universal marker of activated lymphocytes. Eur J Immunol. 1978; 8:589-95.

25. **Strom TB**, Helderman JH, Williams RM. Rapid murine mixed lymphocyte cultures assessed by emergence of T cell insulin receptors. Immunogenetics. 1978; 7:51-56.

26. Tilney NL, Graves MJ, **Strom TB**. Prolongation of organ allograft survival by syngeneic lymphoid cells. J Immunol. 1978; 121:1480-2.

27. Tilney NL, Notis-McConarty J, **Strom TB**. Specificity of cellular migration into cardiac allografts in rats. Transplantation. 1978; 26:181-6.

28. Tilney NL, **Strom TB**, Vineyard GC, Merrill JP. Factors contributing to the declining mortality rate in renal transplantation. N Eng J Med.1978; 299:1321-5.

Original Articles:

29. Gottlieb MN, Stephens MK, Lowrie EG, Griffiths HJ, Kenzora J, **Strom TB**, Lazarus JM, Tilney NL, Merrill JP. A longitudinal study of bone disease after successful renal transplantation. Nephron. 1978; 22:239-48.

30. Suthanthiran M, Gailiunas P, Person A, Fagan G, **Strom TB**, Carpenter CB, Garovoy MR. Accelerated graft loss: association with presensitization to donor B-cell "Ia" antigens. Transplant Proc. 1978; 10:471-73.

31. Suthanthiran M, Catto GR, Kaldany A, George K, Garovoy MR, **Strom TB**, Carpenter CB. Differential antibody responses to Ag-B (A region) and Ia (B region) antigens during enhancement of rat renal allografts. Transplantation. 1979; 28:4-9.

32. Helderman JH, **Strom TB**, Dupuy-d'Angeac A. A close relationship between cytotoxic T lymphocytes generated in the mixed lymphocyte culture and insulin receptor-bearing lym-phocytes: enrichment by density gradient centrifugation. Cell Immunol. 1979; 46:247-58.

33. Helderman JH, **Strom TB**. Role of protein and RNA synthesis in the development of insulin binding sites on activated thymus- derived lymphocytes. J Biol Chem. 1979; 254:7203-7.

34. Hendry WS, Tilney NL, Baldwin WM, Graves MJ, Milford EL, **Strom TB**, Carpenter CB. Transfer of specific unresponsiveness to organ allografts by thymocytes specific unresponsiveness by thymocyte transfer. J Exp Med.1979; 149:1042-55.

35. Helderman JH, **Strom TB**. Absence of a role for the cellular exoskeleton in the emergence of the T lymphocyte insulin receptor. Exp Cell Res. 1979; 123:119-26.

36. Lowry R, Goguen J, Carpenter CB, **Strom TB**, Garovoy MR. Improved B-cell typing for HLA-DR using nylon wool column enriched B- lymphocyte preparations. Tissue Antigens. 1979; 14:325-30.

37. Tilney NL, Garovoy MR, Busch GJ, **Strom TB**, Graves MJ, Carpenter CB. Rejected human renal allografts: recovery and characteristics of infiltrating cells and antibody. Transplantation. 1979; 8:421-26.

38. Kaldany A, Carpenter CB, Shadur CA, George K, Lundin AP 3rd, Suthanthiran M, **Strom TB**. Immunological properties of subcellular rat lymphocyte preparations. Primary allogeneic stimulation in vitro by fractions containing Ia (RT1-B), but not RT1-A, antigens. J Exp Med.1980; 151:910-24.

39. **Strom TB**, Helderman JH. Comparison of ligand-specific rat allosensitized lymphocyte insulin receptors as assessed in binding and functional (lymphocyte-mediated cytotoxicity) assays. Cell Immunol. 1980; 53:382-8.

40. Shapiro HM, **Strom TB**. Electrophysiology of T lymphocyte cholinergic receptors. Proc Natl Acad Sci USA. 1980; 77:4317-21.

Original Articles:

41. Tilney NL, MacLennon I, **Strom TB**, Baldwin WM 3rd. Effects of thymectomy, thoracic duct drainage and radiation on T and B lymphocyte distribution and cardiac allograft survival in rats. Transplantation. 1981; 31:26-30.

42. Helderman HJ, **Strom TB**, Garovoy MR. Rapid mixed lymphocyte culture testing by analysis of the insulin receptor on alloactivated T lymphocyte: implications for human tissue typing. J Clin Invest. 1981; 67:509-13.

43. Gozes Y, Caruso J, **Strom TB**. The absence of cryptic insulin receptors on resting lymphocytes. Diabetes. 1981; 30:314-6.

44. **Strom TB**, Lane MA, George K. The parallel time-dependent, bimodal change in lymphocyte cholinergic binding activity and cholinergic influence upon lymphocyte-mediated cytotoxicity after lymphocyte activation. J Immunol. 1981; 127:705-10.

45. Sheehy MJ, Miller NJ, Rappeport JM, Gozes Y, Parkman R, **Strom TB**, Yunis EJ. A patient with post-hepatitis B immune deficiency: nonspecific helper factor partially restores the in vitro immune response. Vox Sang. 1981; 40:346-51.

46. Hutchinson IF, Shadur CA, Duarte JS, **Strom TB**, Tilney NL. Cyclosporin A spares selectively lymphocytes with donor- specific suppressor characteristics. Transplantation. 1981; 32:210-6.

47. Tilney NL, Kohler TR, **Strom TB**. Cerebromeningitis in immunosuppressed recipients of renal allografts. Ann Surg. 1982; 195(1):104-9.

48. Duarte AJ, Carpenter CB, **Strom TB**. Expression of T cell differentiation antigens and Ia on rat cytotoxic T lymphocytes. J Immunol. 1982; 128(2):580-4.

49. Wang BS, Heacock EH, Chang-Xue Z, Tilney NL, **Strom TB**, Mannick A. Evidence for the presence of suppressor T lymphocytes in animals treated with cyclosporin A. J Immunol. 1982; 128(3):1382-5.

50. **Strom TB**, Bangs JD. Human serum-free mixed lymphocyte response: the stereospecific effect of insulin and its potentiation by transferrin. J Immunol. 1982; 128:1555-9.

51. Williams JM, Shapiro HM, Milford EL, **Strom TB**. Multiparameter flow cytometric analysis of lymphocyte subpopulation activation in lectin stimulated cultures. J Immunol. 1982; 28:2676-81.

52. Kupiec-Weglinski JW, Bordes-Aznar J, Clason AE, Duarte AJ, Araneda D, Carpenter CB, **Strom TB**, Tilney NL. Migration patterns of lymphocytes in untreated and immunologically manipulated recipients of organ allografts. Transplantation. 1982; 33:593-8.

53. Clason AE, Duarte AJ, Kupiec-Weglinski JW, Williams JN, Wang BS, **Strom TB**, Tilney NL. Restoration of allograft responsiveness in B rats by interleukin 2 and/or adherent cells. J Immunol. 1982; 29:252-9.

Original Articles:

54. Kirkman RL, **Strom TB**, Weir MR, Tilney NL. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation. 1982; 34:347-51.

55. Gozes Y, Moskowitz MA, **Strom TB**, Gozes I. Conditioned media from activated lymphocytes maintain sympathetic neurons in culture. Brain Res. 1982; 282:93-7.

56. Cotner T, Williams JM, Christenson L, Shapiro HM, **Strom TB**, Strominger J. Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med.1983; 157:461-72.

57. Bordes-Aznar J, Kupiec-Weglinski JW, Duarte AJ, Milford EL, **Strom TB**, Tilney NL. Function and migration of suppressor lymphocytes from cyclosporine treated heart graft recipients. Transplantation. 1983; 35:185-90.

58. **Strom TB**, Carpenter CB. Prostaglandin is an effective antirejection therapy in rat renal allograft recipients. Transplantation. 1983; 35:279-81.

59. Kaldany A, George K, Suthanthiran M, Catto GR, **Strom TB**, Carpenter CB. Long-term renal allograft survival in rats preimmunized with donor strain RT1B antigens. Transplantation. 1983; 35:289-93.

60. Wang BS, Zheng CX, Heacock EH, Tilney NL, **Strom TB**, Mannick JA. Inhibition of the production of a soluble helper mediator by cyclosporin A results in the failure to generate alloreactive cytolytic cells in mixed-lymphocyte culture. Clin Immunol Immunopathol. 1983; 27:160-9.

61. Lear PA, Heidecke CD, Kupiec-Weglinski JW, Araneda D, **Strom TB**, Tilney NL. Restoration of allograft responsiveness in B rats. II. Requirement for lymphoid populations and lymphokine. Transplantation. 1983; 36:412-7.

62. Kirkman RL, Araujo JL, Busch GJ, Carpenter CB, Milford EL, Reinherz EL, Schlossman SF, **Strom TB**, Tilney NL. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation. 1983; 36:620-6.

63. Shapiro HM, Glazer AN, Christenson L, Williams JM, **Strom TB**. Immunofluorescence measurement in a flow cytometer using low-power helium-neon laser excitation. Cytometry. 1983; 4:276-79.

64. Carpenter CB, Milford EL, Reinherz EL, Schlossman SF, Tilney NL, **Strom TB**, Kirkman RL, Busch GJ, Araujo JL. Monoclonal anti-T12 antibody as therapy for renal allograft rejection. Trans Assoc Am Physicians. 1983; 96:84-92.

65. Kelley VE, Fiers W, **Strom TB**. Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol. 1984; 132:240-5.

66. Williams JM, Loertscher R, Cotner T, Reddish M, Shapiro HM, Carpenter CB, Strominger JL, **Strom TB**. Dual parameter flow cytometric analysis DNA content, activation antigen expression, and T cell subset proliferation in the human mixed lymphocyte reaction. J Immunol. 1984; 132:2330-7.

Original Articles:

67. Tilney NL, Rocha A, **Strom TB**, Kirkman RL. Renal artery stenosis in transplant patients. Ann Surg. 1984; 199:454-60.

68. Heidecke CD, Kupiec-Weglinski JW, Lear PA, Abbud-Filho M, Araujo JL, Araneda D, **Strom TB**, Tilney NL. Interaction between T lymphocyte subsets supported by interleukin 2 rich lymphokines produce acute rejection of vascularized cardiac allografts in T cell deprived rats. J Immunol. 1984; 133:582-8.

69. Kupiec-Weglinski JW, Abbud-Filho MA, **Strom TB**, Tilney NL. Sparing of suppressor cells: a critical action of cyclosporine. Transplantation. 1984; 38:97-101.

70. Abbud-Filho M, Kupiec-Weglinski JW, Araujo JL, Heidecke CD, Tilney NL, **Strom TB**. Cyclosporine therapy of rat heart allograft recipients and release of interleukins (IL-1, IL-2, IL-3). A role for IL-3 in graft tolerance? J Immunol. 1984; 133:2582-6.

71. Tilney NL, Milford EL, Araujo JL, **Strom TB**, Carpenter CB, Kirkman RL. Experience with cyclosporine and steroids in clinical renal transplantation. Ann Surg. 1984; 200:605-13.

72. Williams JM, Ransil BJ, Shapiro HM, **Strom TB**. Accessory cell requirement for activation antigen expression and cell cycle progression by human T lymphocytes. J Immunol. 1984; 133:2986-95.

73. Rocher LL, Milford EL, Kirkman RL, Carpenter CB, **Strom TB**, Tilney NL. Conversion from cyclosporine to azathioprine in renal allograft recipients. Transplantation. 1984; 38:669-74.

74. Heagy W, Kelley VE, **Strom TB**, Mayer K, Shapiro HM, Mandel R, Finberg R. Decreased expression of human class II antigens on monocytes from patients with acquired immune deficiency syndrome. Increased expression with interferon-gamma. J Clin Invest. 1984; 74:2089-96.

75. Ythier AA, Williams JM, Shapiro HM, Kelley VE, **Strom TB**. The early (18-hr) human mixed lymphocyte reaction: identification and isolation of activated T cell clones. Cell Immunol. 1985; 91:215-26.

76. Kelley VE, Ferretti A, Izui S, **Strom TB**. A fish oil diet rich in eicosapentanoic acid reduces cyclooxygenase metabolites and suppresses lupus in MRL-lpr mice. J Immunol. 1985; 134:1914-9.

77. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, **Strom TB**. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs allograft survival in mice. J Exp Med.1985; 162:358-62.

78. Kupiec-Weglinski JW, Heidecke CD, Araujo JL, Abbud-Filho M, Towpik E, Araneda D, **Strom TB**, Tilney NL. Behavior of helper T lymphocytes in cyclosporine-mediated long-term graft acceptance in the rat. Cell Immunol. 1985; 93:168-77.

Original Articles:

79. Gaulton GN, Bangs J, Maddock S, Springer T, Eardley DD, **Strom TB**. Characterization of a monoclonal rat anti-mouse interleukin-2 (IL-2) receptor antibody and its use in the biochemical characterization of the murine IL-2 receptor. Clin Immunol. Immunopathol. 1985; 36:18-29.

80. Williams JM, Abbud-Filho M, Kelley VE, **Strom TB**. Interleukin-2 apparently upregulates its receptor and induces proliferation of various resting mononuclear leukocytes in the absence of antigen. Cell Immunol. 1985; 94:383-93.

81. Williams JM, DeLoria D, Hansen JA, Dinarello CA, Loertscher R, Shapiro HM, **Strom TB**. The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64. 1) monoclonal antibody and purified interleukin-1. J Immunol. 1985; 135:2249-55.

82. Hafler DA, Hemler ME, Christenson L, Williams JM, Shapiro HM, **Strom TB**, Strominger JL, Weiner HL. Investigation of in vivo activated T-cells in multiple sclerosis and inflammatory central nervous system diseases. Clin Immunol. Immunopathol. 1985; 37:163-71.

83. Williams JM, Dinarello CA, Rosenwasser LJ, Kelley V, Reddish M, **Strom TB**. Phorbol myristate acetate-protein complex mimics bioactivity of human IL-1. Lymphokine Res. 1985; 4:275-98.

84. Ythier AA, Abbud-Filho M, Williams JM, Loertscher R, Schuster MW, Nowill A, Hansen JA, Maltezos D, **Strom TB**. Interleukin 2 dependent release of interleukin 3 activity by T4+ human T cell clones. Proc Natl Acad Sci USA. 1985; 82:7020-24.

85. Maddock EO, Maddock SW, Kelley VE, **Strom TB**. Rapid stereospecific stimulation of lymphocytic metabolism by interleukin 2. J Immunol. 1985; 135:4004-8.

86. Heidecke CD, Araujo JL, Kupiec-Weglinski JW, Abbud-Filho M, Araneda D, Stadler J, Siewert J, **Strom TB**, Tilney NL. Lack of evidence for an active role for natural killer cells in acute rejection of organ allografts. Transplantation. 1985; 40:441-4.

87. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Koltun WA, Schoen FJ, Ythier A, **Strom TB**. The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection. Transplantation. 1985; 40:719-22.

88. Weir MR, Kirkman RL, **Strom TB**, Tilney NL. Liver disease in recipients of long-functioning renal allografts. Kidney Int. 1985; 28:839-44.

89. Knudsen PJ, **Strom TB**. Elevated intracellular cAMP levels inhibit interleukin 1 production by the tumor line U 937. Brit J Rheum. 1985; 24:65-8.

90. Miller RA, Rozans MK. Ythier AA, **Strom TB**: Stages of T-cell activation: continued antigen dependence of IL2 producing cells after IL2 receptor expression. J Immunol. 1986; 136:977-83.

91. Knudsen PJ, Dinarello CA, **Strom TB**. Purification and characterization of a unique interleukin 1 from the tumor cell line U937. J Immunol. 1986; 136:3311-6.

Original Articles:

92. Kelley VE, Farber NM, Williams JM, **Strom TB**. Inability of autoimmune mice with the lpr gene to spontaneously produce interleukin 3. Eur J Immunol. 1986; 16:464-7.

93. Abbud-Filho M, Ransil BJ, Kelley VE, Fiers W, **Strom TB**. Natural killer cell response to interferon. Clin Immunol. Immunopathol. 1986; 39:264-76.

94. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, **Strom TB**. Anti-interleukin-2 receptor monoclonal antibody spares T suppressor cells and prevents or reverses acute allograft rejection. Proc Natl Acad Sci USA. 1986; 83:2624-7.

95. Kelley VE, **Strom TB**. Spleen cell factor inhibits lymphoproliferation, abnormal Ia expression and overt autoimmunity in MRL-lpr mice. Clin Immunol. Immunopathol. 1986; 41:145-53.

96. Kelley VE, Naor D, Tarcic N, Gaulton GN, **Strom TB**. Anti-interleukin 2 receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic antigens. J Immunol. 1986; 137:2122-4.

97. Surman OS, Williams J, Sheehan DV, **Strom TB**, Jones KJ, Coleman J. Immunological response to stress in agoraphobia and panic attacks. Bio Psychiatry 1986; 21:768-74.

98. Schneider TM, Kupiec-Weglinski JW, Towpik E, Padberg W, Araneda D, Diamantstein T, **Strom TB**, Tilney NL. Development of suppressor lymphocytes during acute rejection of rat cardiac allografts and preservation of suppression by anti-IL-2- receptor monoclonal antibody. Transplantation 1986; 42:191-6.

99. Knudsen PJ, Dinarello CA, **Strom TB**. Prostaglandins inhibit posttranscriptionally inhibitonocyte expression of interleuin 1 activity by increasing intracellular yclic adenosine monophosphate. J Immunol. 1986; 137:3189-94.

100. Kelley VE, Gaulton GN, **Strom TB**. Inhibitory effects of anti-interleukin-2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: The role of complement and epitope. J Immunol. 1987; 138:2771-5.

101. Kupiec-Weglinski JW, Padberg W, Uhteg LC, Ma L, Lord RH, Araneda D, **Strom TB**, Diamantstein T, Tilney NL: Selective immunosuppression with anti-interleukin-2 receptor targeted therapy: helper and suppressor cell activity in rat recipients of cardiac allografts. Eur J Immunol. 1987; 17:313-9.

102. Padberg WM, Lord RH, Kupiec-Weglinski JW, Williams JM, DiStefano R, Thornburg LE, Araneda D, **Strom TB**, Tilney NL. Two phenotypically distinct populations of T cells have suppressor capabilities simultaneously in the maintenance phase of immunological enhancement. J Immunol. 1987; 139:1751-7.

103. Loertscher R, Abbud-Filho M, Leichtman AB, Ythier AA, Williams JM, Carpenter CB, **Strom TB**. Differential effect of gamma-irradiated and heat-treated lymphocytes on T cell activation, and interleukin-2 and interleukin-3 release in the human mixed lymphocyte reaction. Transplantation. 1987; 44:673-80.

Original Articles:

104. Syndman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush, HL, Jr. Levey AS, **Strom TB**, Carpenter CB, Levey RH, Harmon WE, Zimmerman II CE, Shapiro ME, Steinman T, LoGerfo F, Idelson B, Schroter GPJ, Levin MJ, McIver J, Leszczynski, Grady GF. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med.1987; 317:1049-54.

105. Knudsen PJ, Dinarello CA, **Strom TB**: Glucocorticoids inhibits transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol. 1987; 139:4129-34.

106. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, **Strom TB** and Murphy JR. Diphtheria toxin receptor binding domain substitution with interleukin-2:genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Engineer. 1987; 1:493-8.

107. Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, **Strom TB**. Anti-interleukin-2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol. 1988; 140:59-61.

108. Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, and **Strom TB**. Interleukin 2 receptor-targeted cytotoxicity: Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin-2 fusion protein. J Exp Med.1988; 167:612-22.

109. Loertscher R, Leichtman AB, Williams JM, **Strom TB**. Blocking of T cell activation at the G1A/G1B interface of the cell cycle and prevention of expression of interleukin 2 receptors by alloactivated suppressor T lymphocytes. Transplantation. 1988; 45:194-201.

110. Kelley VE, Bacha P, Pankewycz O, Nichols JC, Murphy JR, **Strom TB**: Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci USA. 1988; 85:3980-4.

111. Waters C, Schmike P, Sanderson R, **Strom TB**, and Murphy JR. Receptor binding requirements for IL-2 toxin mediated cytotoxicity. J Cell Biochem. 1988; 12E(suppl):U312

112. Murphy JR, Bishai W, Williams D, Bacha P, Borowski M, Parker K, Boyd J, Waters C, **Strom TB**: Genetic assembly and selective toxicity of diphtheria toxin-related polypeptide hormone fusion proteins. Biochem Soc Symp. 1988; 53:9-23.

113. Murphy JR, Williams DP, Bacha P, Bishai W, Waters C, **Strom TB**. Cell receptor specific targeted toxins: genetic construction and characterization of an interleukin 2 diphtheria toxin-related fusion protein. J Recept Res. 1988; 8:467-80.

114. Pankewycz OG, Hassarjian R, Chang C, **Strom TB**, Kelley VE. Anti-interleukin-2 receptor monoclonal antibody therapy induces anti-idiotypic antibodies in mice that block both in vitro and in vivo activity. J Autoimmun. 1988; 1:119-30.

115. Johns MA, Sipe JD, Melton LB, **Strom TB**, McCabe WR. Endotoxin associated protein; Interleukin-1-like activity on serum amyloid A synthesis and T lymphocyte activation. Infect. Immunity. 1988; 56:1593-601.

Original Articles:

116. Reed MH, Shapiro ME, **Strom TB**, Letvin NL, Carpenter CB, Reimann KA, Weinberg DS, Waldmann TA, Kirkman RL. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation. 1988; 47:55-59.

117. Pankewycz OG, Mackie J, Hassarjian R, Murphy JR, **Strom TB**, Kelley VE: Interleukin-2 diphtheria toxin fusion protein prolongs murine islet cell engraftment. Transplantation. 1989; 47:318-22.

118. Kirkman RL, Bacha P, Barrett LV, Forte S, Murphy JR, **Strom TB**: Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein. Transplantation. 1989; 47:327-30.

119. Melton LB, Lakkis F, Moscovitch-Lopatin M, Smith BR, Williams JM, Rosoff PM, **Strom TB**. Antibody valence and induced signal transduction: The role of antibody valence in anti-CD3-induced signed transduction in isolated normal T cells. Clin Immunol. Immunopath. 1989; 50:171-83.

120. Walz G, Zanker B, Wieder K, Hadro E, Moscovitch-Lopatin M, Smith BR, **Strom TB**. Similar effects of cyclosporine and verapamil on lymphokine, interleukin-2 receptor and proto-oncogene expression. Transplantation. 1989; 47:331-4.

121. Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, **Strom TB**, Murphy JR, Takatsuki K. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989; 49:4042-6.

122. Kelley VE, Kirkman R, Bastos M, Barrett L, **Strom TB**. Substitution of fish oil for olive oil as a vehicle for cyclosporine enhances immunosuppression. Transplantation. 1989; 48:98-102.

123. Loertscher R, **Strom TB**. Differential regulation of activation associated receptor expression on CD4- and CD8- positive T-lymphocytes by allosensitized suppressor T cells. Transplantation. 1989; 48:473-8.

124. Shapiro ME, Kirkman RL, Carpenter CB, Milford EL, Tilney NL, Waldmann TA, Zimmerman CE, Ramos EL, **Strom TB**: Initial trials of the anti-human IL-2 receptor monoclonal antibody anti-Tac in clinical renal transplantation. Transplantation. 1989; 47:55-9.

125. Ramos EL, Leggat JE, Milford EL, Kirkman RL, Tilney NL, **Strom TB**, Shapiro ME, Waldmann TA, Wood IG, Rollins MR, Carpenter CB. Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2 R antibody. Transplantation. 1989; 48:415-20.

Original Articles:

126. Carpenter CB, Kirkman RL, Shapiro ME, Milford EL, Tilney NL, Waldmann TA, Zimmerman CE, Ramos EL, **Strom TB**. Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation. Amer J Kidney Dis. 1989; 14:54-7.

127. Walz G, Zanker B, Brand K, Waters C, Genbauffe F, Zeldis JB, Murphy JR, **Strom TB**. Sequential effects of interleukin-2 diphtheria toxin fusion protein on T-cell activation. Proc Natl Acad Sci USA. 1989; 86:9485-8.

128. Heagy W, **Strom TB**, Kelley VE, Collela J, Crumpacker C, Williams JM, Shapiro HM, Laubenstein L, Finberg R. Recombinant human gamma interferon enhances in vitro activation of lymphocytes isolated from patients with acquired immuno-deficiency syndrome. Infect Immun. 1989; 57: 3619-28.

129. Ramos EL, Leggat JE, Milford EL, Kirkman RL, Tilney NL, **Strom TB**, Shapiro ME, Waldmann TA, Carpenter CB. In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic. Trans Assoc Amer Physicians. 1989; 102:231-9.

130. Zanker B, Walz G, **Strom TB**. Expression von Aktivierungsgenen in T-Zellen und deren Inhibition durch Cyclosporin A und Verapamil. Nieren und Hochdruck-krankheiten. . 1989; 7:S269-71.

131. Pankewycz OG, Yui M, Kelley VE, **Strom TB**. The cascading interrelated roles of interleukin-1, interleukin-2, and interleukin-6 in anti-CD3 driven T-cell proliferation. Clin Immunol Immunopathol. 1990; 55:67-85.

132. Waters CA, Schimke PA, Snider CE, Itoh K, Smith KA, Nichols JC, **Strom TB**, Murphy JR. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin related interleukin-2 fusion protein into cells. Eur J Immunol. 1990; 20:785-91.

133. Walz G, Zanker B, Barth C, Wieder KJ, Clark SC, **Strom TB**. Transcriptional modulation of human IL-6 gene expression by verapamil. J Immunol. 1990; 144:4242-48.

134. Wieder KJ, Walz G, Zanker B, Sehajpal P, Sharma VK, Skolnik E, **Strom TB**, Suthanthiran M. Physiologic signaling in normal human T-cells: mRNA phenotyping by northern blot analysis and reverse transcription - polymerase chain reaction. Cell Immunol. 1990; 128:41-51.

135. Mackie JD, Pankewycz OG, Bastos MG, Kelley VE, and **Strom TB**. Dose-related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell transplantation and delayed type hypersensitivity. Transplantation. 1990; 49:1150-4.

136. Walz G, Zanker B, Melton L, Suthanthiran M, **Strom TB**. Possible association of the immunosuppressive and B cell lymphocyte-promoting properties of cyclosporine. Transplantation. 1990; 49:191-4.

Original Articles:

137. Lugasi H, Hajos S, Murphy JR, **Strom TB**, Nichols J, Penarroja C, Naor D. Murine spontaneous T-cell leukemia constitutively expressing IL-2 receptor - a model for human T cell malignancies expressing IL-2 receptor. Int J Cancer. 1990; 45:163-7.

138. Williams DP, Snider CE, **Strom TB**, Murphy JR. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2):Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem. 1990; 265:11885-9.

139. Walz G, Zanker B, Murphy JR, **Strom TB**. A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells. Transplantation. 1990; 49:198-201

140. Zanker B, Walz G, Wieder KJ, **Strom TB**. Evidence that glucocorticosteroids block expression of the human IL-6 gene by accessory cells. Transplantation. 1990; 49:183-5.

141. Williams DP, Wen Z, Watson RS, Boyd J, **Strom TB**, Murphy JR. Cellular processing of the interleukin-2 fusion +oxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J Biol Chem. 1990; 265:20673-7.

142. Bastos MG, Pankewycz OG, Rubin-Kelley VE, Murphy JR, **Strom TB**. Concomitant administration of hapten and IL-2 toxin (DAB486 IL-2) results in specific deletion of antigen activated T-cell clones. J Immunol. 1990; 145:3535-39.

143. Tilney NL, Chang A, Milford EL, Whitley WD, Lazarus JM, Ramos EL, **Strom TB**, Carpenter CB, Kirkman RL. Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts. Ann Surg 1990; 214:42-49.

144. Pankewycz O, **Strom TB**, Rubin-Kelley VE. Islet-infiltrating T-cell clones from non-obese diabetic mice that promote or prevent accelerated onset diabetes. Eur J Immunol. 1991; 21:873-9.

145. Sehajpal PK, Li B, Zanker B, Murthi VK, Subramaniam A, Sharma VK, Estin D, Skilnik EY, Wieder KJ, Walz G, Fotino M, Stenzel KH, **Strom TB**, Suthanthiran M. The molecular basis for the synergism between CD3 alpha beta T-cell receptor and the CD2 antigen-derived signals in promoting T-cell proliferation. Transplantation. 1991; 51:468-74.

146. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, **Strom TB**. Abrogation of glucocorticosteroid-mediated inhibition of T-cell proliferation by the synergistic action of IL-1, IL-6, and IFN gamma. J Immunol. 1991; 146:3523-27.

147. Grailer AP, Nichols JC, **Strom TB**, Sollinger HW, Burlingham WJ. Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein. Cell Immunol. 1991; 32:481-93.

148. Papp I, Wieder KJ, Sablinski T, O'Connell PH, Milford EL, **Strom TB**, Kupiec-Weglinski JW. Evidence for functional heterogeneity of rat CD4+T cells in vivo: Differential expression of IL-2 and IL-4 mRNA in recipients of cardiac allografts. J Immunol. 1992; 148:1308-14.

Original Articles:

149. Maslinski W, Murphy JR, **Strom TB**. Intoxication of high affinity IL-2 receptor positive thymocytes blocks early stages of T-cell maturation. Intl Immunol. 1992; 4:509-17.

150. Lipman ML, Stevens AC, Bleackley RC, Helderman JH, McCune TR, Harmon WE, Shapiro ME, Rosen S, **Strom TB**. The strong correlation of cytotoxic T lymphocyte specific serine protease gene transcripts strongly correlates with renal allograft rejection. Transplantation. 1992; 53:73-9.

151. Lakkis F, Landgraf B, Wen Z, **Strom TB**, Murphy JR. Phe-496 and Leu-497 are targeted fusion toxin DAB389-MIL-4 receptor. Protein Eng. 1992; 5:241-8.

152. Pacheco-Silva, A, Bastos MG, Muggia RA, Pankewycz O, Nichols J, Murphy JR, **Strom TB**, Rubin-Kelley VE. Interleukin 2 receptor targeted fusion toxin (DAB486 IL-2) treatment blocks diabetogenic autoimmunity in non-obese mice. Eur. J Immunol. 1992; 22:697-702.

153. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, Antonioli D, Peppercorn MA, **Strom TB**. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci. 1992; 37:818-26.

154. Diaz-Gallo C, Moscovitch-Lopatin M, **Strom TB**, Rubin-Kelley VR. An Anergic, islet-infiltrating T cell clones that suppresses murine diabetes secretes a factor that blocks interleukin 2/interleukin 4-dependent proliferation. Proc Natl Acad Sci USA. 1992; 89:8656-60.

155. Maslinski W, Remillard B, Tsudo M, **Strom TB**. IL-2 induces tyrosine kinase dependent translocation of active RAF-1 from the IL-2R into the cytosol. J Biol Chem. 1992; 267:15281-1984.

156. Barel D, Brennan DC, Jevnikar AM, Bastos M, **Strom TB**, Rubin-Kelley VR. Enhanced tumor necrosis factor in anti-CD3 antibody stimulated diabetic NOD mice: modulation by PGE1 and dietary lipid. Autoimmunity. 1992; 13:141-9.

157. O'Connell PJ, Pacheco-Silva A, Nickerson PW, Muggia RA, Bastos M, Kelley VR, **Strom TB**. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T-cell activation transcripts. J Immunol. 1993; 150:1093-104.

158. Wieder KJ, Hancock WW, Schmidbauer G, Corpier CL, Wieder I, Kobzik L, **Strom TB** and Kupiec-Weglinski JW. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B and IFN-gamma in rat recipients of cardiac allografts. J Immunol. 1993; 151:1158-66.

159. Lipman ML, Stevens AC, **Strom TB**. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol. 1994; 152:5120-7.

160. Zanker B, Marx S, **Strom TB**, Kohler H. The immunosuppressive effects of verapamil upon mitogen activated and allo-antigen inducible human cytotoxic T-lymphocytes. Intl J Immunopharmacol. 1994; 6:507-17.

Original Articles:

161. Yokoyama H, Zheng XX, **Strom TB**, Kelley VR. B7(+)-transfectant tubular epithelial cells induce T cell anergy, ignorance or proliferation. Kidney Intl. 1994; 45:1105-12

162. Zheng XX, **Strom TB**, Steele AW. Quantitative comparison of rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction. Transplantation. 1994; 58:87-92.

163. Nickerson PW, Steurer W, Steiger J, **Strom TB**. In pursuit of the "Holy Grail": Allograft tolerance. Kidney Intl, 1994; 45:S40-9.

164. Luke RG, **Strom TB**. Chronic renal failure. Stein JH (ed) In: Internal Medicine 4th Edition. Mosby Year Book, Inc. St. Louis, Missouri 1994; 2622-44.

165. Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S, Peppercorn MA, **Strom TB**. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharm Exp Thera. 1995; 272:339-406.

166. Bennett WM, Carpenter CB, Shapiro ME, **Strom TB**, Hefty D, Tillman M, Abrams J, Ryan D, Kelley VR. Delayed omega-3 fatty acid supplements in renal transplantation. Transplantation. 1995; 59:352-6.

167. Stevens AC, Lipman ML, Spivack JE, Roddey G, Bitton AM, Peppercorn MA, **Strom TB**. Enhanced intramucosal cytotoxic lymphocyte gene expression in ulcerative colitis. Inflammatory Bowel Dis. 1995; 101-7.

168. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, **Strom TB**. Administration of non-cytolytic IL-10/Fc in murine models of LPS-induced septic shock and allogeneic islet transplantation. J Immunol. 1995; 54:5590-600.

169. Meiisels IS, **Strom TB**, Roy-Chaudhury P, Abrams J, Shapiro ME. Renal allograft rejection in a patient with the Wiskott-Aldrich Syndrome. Transplantation. 1995; 59:1214-15.

170. Pavlakis M, Lipman ML, **Strom TB**. Intragraft T cell receptor transcript expression in human renal allografts. J Am Soc. Nephrol. 1995; 281-5.

171. Steurer W, Nickerson P, Steele AW, Steiger J, Zheng XX, **Strom TB**. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes grafts tolerance. J Immunol. 1995; 155:1165-74

172. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M **Strom TB**. IL-2 knockout recipient mice reject islet cell allografts J Immunol. 1995; 155:489-98.

173. Barth C, Pavlakis M, Lavery P, **Strom TB**, Loertscher R. Restricted TCR V Beta repertoire in the human mixed lymphocyte reaction is determined by the TCR on the responder cell and not by the stimulating antigen on the stimulator cell. Transplantation. 1996; 61:133-9.

Original Articles:

174. Wasowska B, Wieder KJ, Hancock WW, Zheng XX, Berse B, Binder J, **Strom TB**, Kupiec-Weglinski JW. Cytokine and alloantibody networks in long-term cardiac allografts in rat recipients treated with rapamycin. J Immunol. 1996; 156:395-404.

175. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, **Strom TB**, Burakoff SJ, Croop JM, Arceci RJ. Irradiated B7-1 transduced primary AML cells can be used as therapeutic vaccines in murine AML. Blood. 1996; 87:2938-46.

176. Flores-Villanueva PO, Zheng XX, **Strom TB** Stadecker MJ. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J Immunol. 1996; 3315-20.

177. Nickerson P, Zheng XX, Steiger J, Steele AW, Steurer W, Roy-Chaudhury P, Muller W, **Strom TB**. Prolonged islet allograft acceptance in the absence of interleukin-4 expression. Transplant Immunol. 1996; 4:81-5.

178. Wieder KJ, Chatis P, Boltax J, Wieder I, Nuovo G, **Strom TB**. Human immunodeficiency virus type 1 entry into murine cell lines and lymphocytes from transgenic mice expressing a glycoprotien120-binding mutant mouse CD4. AIDS Research and Human Retroviruses. 1996; 12:867-76.

179. Almawi WY, Saouda MS, Stevens AC, Lipman ML, Barth CM, **Strom TB**. Partial mediation of glucocorticoid anti-proliferative effects by lipocortins. J Immunol. 1996; 157:5231-9.

180. Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, **Strom TB**. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation. 1996; 62:543-5.

181. Chae DW, Nosaka Y, **Strom TB**, Maslinski W. The distribution of IL-15 receptor alpha-chains on human peripheral blood mono-nuclear cells and the effect of immunosuppressive drugs on receptor expression. J Immunol. 1996; 157:2813-9.

182. Restifo AC, Ivis-Woodward MA, Tran HM, Nickerson PW, **Strom TB**, Chapman JR, O'Connell PJ. The potential role of xenogeneic antigen presenting cells in T-cell co-stimulation. Xenotransplantation. 1996; 3:141-8.

183. Strehlau J, Pavlakis M, Lipman M, Maslinski W, Shapiro M, **Strom TB**. The intra-graft gene activation of markers reflecting T-cell-activation and cytotoxicity analyzed by quantitative RT-PCR in renal transplantation. Clin Nephrol. 1996; 46:30-3.

184. Strehlau J, Pavlakis M, Lipman M, Shapiro M, Harmon W, **Strom TB**. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA. 1997; 94:695-700.

185. Onodera K, Hancock WW, Graser E, Lehmann M, Sayegh MH, **Strom TB**, Volk H-D, Kupiec-Weglinski JW. Type 2 helper T cell-type cytokines and the development of "infectious" tolerance in rat cardiac allograft recipients. J Immunol. 1997; 158:1572-81.

Original Articles:

186. Borriello F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, **Strom TB**, Simpson EM, Freeman GJ, Sharpe AH. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity. 1997; 6:303-13.

187. Tran HM, Nickerson PW, Restifo AC, Woodward MA, Patel A, Allen RD, **Strom TB**, O'Connell PJ. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol. 1997; 159:2232-39.

188. Stevens AC, Matthews J, Andres P, Baffis V, Chae DW, Smith J, **Strom TB**, Maslinski W. Interleukin-15 signals T84 colonic epithelial cells in the absence of the interleukin-2 receptor beta chain. Amer J Physiol. 1997; 272:G1201-8.

189. Zheng XX, Steele AW, Hancock WW, Stevens AC, Nickerson PW, Roy-Chaudhury P, Tian Y, **Strom TB**. A non-cytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity and promotes suppressor phenomena in NOD mice. J Immunol. 1997; 58:4507-13.

190. Bousvaros A, Stevens AC, **Strom TB**, Murphy J, LaMont JT. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and intestinal lamina propria lymphocytes. Dig Dis Sci. 1997; 42:378-1986.

191. Perez VL, Van Parijs L, Biuckians A, Zheng XX, **Strom TB**, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. Apr. 1997; 6:411-17.

192. Tivol EA, Boyd S, McKeon S, Borriello F, Nickerson P, **Strom TB**, Sharpe AH. CTLA-4 Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4 deficient mice. J Immunol. 1997; 158:5091-4.

193. Muruve DA, Nicolson AG, Manfro RC, **Strom TB**, Sukhatme VP, Libermann TA. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Human Gene Ther. 1997; 8:955-63.

194. Roy-Chaudhury P, Nickerson PW, Manfro R, Zheng XX, Steiger J, Li YS, **Strom TB**. CTLA4-Ig attenuates accelerated rejection (pre-sensitization) in the mouse islet allograft model. Transplantation. 1997; 64:172-5

195. Zheng XX, Sayegh MH, Zheng X-G, Li Y, Linsley PS, Peach R, Borriello F, **Strom TB**, Sharpe AH, Turka LA. The role of donor and recipient B7-1 (CD80) in allograft rejection. J Immunol. 1997; 159:1169-73.

196. Muruve DA, Manfro RC, **Strom TB**, Libermann TA. Ex vivo adenovirus mediated gene delivery leads to long term expression in pancreatic islet transplants. Transplantation. 1997; 64:542-6.

197. Zhu G, Nicolson G, Zheng XX, **Strom TB**, Sukhatme VP. Adenovirus-mediated beta-galactosidase gene delivery to the liver leads to protein deposition in kidney glomeruli. Kidney Intl. 1997; 52:992-99.

Original Articles:

198. Tran HM, Nickerson PW, Patel A, **Strom TB**, Allen RD, O'Connell PJ. Short term suppression of the xeno-immune response with mCTLA4-Fc treatment. Xenotransplantation. 1997; 4:222-7.

199. Basadonna GP, Auersvald L, Khuong CQ, Zheng XX, Kashio N, Zekzer D, Minozzo M, Qian HY, Visser L, Diepstra A, Lazarovits AI, Poppema S, **Strom TB**, Rothstein DM. Antibody-mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy. Proc Natl Acad Sci USA 1998; 95:3821-6.

200. Zheng XX, Schachter AD, Vasconcellos L, Strehlau J, Tian Y, Shapiro M, Harmon W, **Strom TB**. Increased CD40 ligand gene expression during human renal and murine islet allograft rejection. Transplantation. 1998; 65:1512-14.

201. Kim YS, Maslinski W, Zheng XX, Stevens AC, Li XC, Tesch GH, Kelley VR, **Strom TB**. Targeting the IL-15 receptor with an antagonist IL-15 mutant Fc gamma2a protein blocks delayed type hypersensitivitiy. J Immunol. 1998; 160:5742-8.

202. Barouch DH, Santra S, Steenbeke TD, Zheng XX, Davies ME, Freed DC, Craiu A, **Strom TB**, Shiever JW, Letvin NL. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol. 1998; 161:1875-1982

203. Li XC, Roy-Chaudhury P, Hancock WW, Manfro R, Zand MS, Li Y, Zheng XX, Nickerson PW, Steiger J, Malek TR, **Strom TB**. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. J Immunol. 1998; 161:890-6.

204. Vasconcellos LM, Schachter AD, Zheng XX, Vasconcellos LH, Shapiro M, Harmon WE, **Strom TB**. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation. 1998; 66:562-66.

205. Li XC, Zand MS, Li Y, Zheng XX, **Strom TB**. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J Immunol. 1998; 161:2241-7.

206. Li Y, Zheng XX, Li XC, Zand MS, **Strom TB**. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: 387-8.

207. Li XC, Schachter AD, Zand MS, Li Y, Zheng XX, Harmon WE, **Strom TB**. Differential expression of T-cell growth factors in rejecting murine islet and human renal allografts: conspicuous absence of IL-9 despite expression of IL-2, IL-4, IL-7, and IL-15. Transplantation. 1998; 66:265-8.

208. Zheng XX, Schachter AD, Vasconcellos L, Strehlau J, Tian Y, Shapiro M, Harmon W, **Strom TB**. Increased CD40 ligand gene expression during human renal and murine islet allograft rejection. Transplantation 1998; 65:1512-5

Original Articles:

209. Schachter AD, Strehleu J, Zurakowski D, Vasconcellos L, Kim YS, Zheng XX, Gunshin Y, Overstreet SL, Benfield MR, Tejani A, Harmon WE, Herrin JT, **Strom TB**. Post transplant recurrent FSGS: Molecular insights and future directions. Nephron. 1999; 82:300-5

210. Zheng XX, Markees TG, Hancock WW, Li Y, Greiner DL, Li XC, Mordes JP, Sayegh MH, Rossini AA, **Strom TB**. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD 54 monoclonal antibody treatment. J Immunol. 1999; 162:4983-90.

211. Li XC, Li Y, Dodge I, Wells AD, Zheng XX, Turka LA, **Strom TB**. Induction of allograft tolerance in the absence of Fas-mediated apoptosis. J Immunol. 1999; 163:2500-7.

212. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, **Strom TB**. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med.1999; 5:1298-302.

213. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, Nunez G, Tang A, Sayegh M, Hancock WW, **Strom TB**, Turka LA. Requirement for T cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med.1999; 5:1303-7.

214. Feng X, Zheng XX, Yi S, Lehnert AM, **Strom TB**, O'Connell PJ. IL-10/Fc inhibits macrophage function and prolongs pancreatic islet xenograft survival. Transplantation. 1999; 68:1775-83.

215. Zheng XX, Steele AW, Hancock WW, Kawamoto K, Li XC, Nickerson PW, Li Y, Tian Y, **Strom TB**. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. J Immunol. 1999; 163:4041-8.

216. Zheng X, Zheng XX, Yi S, Lehnert AM, **Strom TB**, O'Connell PJ. IL-10/Fc inhibits macrophage function and prolongs pancreatic islet xenograft survival. Transplantation. 1999; 68:1775-83.

217. McKay DB, Irie HY, Hollander G, Ferrara, JLMF, **Strom TB**, Li Y, Burakoff SJ. Antigen induced unresponsiveness results in altered T-cell signaling. J Immunol. 1999; 163:6455-61.

218. Hendry WS, Tilney NL, Baldwin WM 3rd, Graves MJ, Milford E, **Strom TB**. Carpenter CB. Transfer of specific unresponsiveness to organ allografts by thymocytes. J Am Soc Nephrol. 1999; 10:2454-63.

219. Li XC, Zheng XX, **Strom TB**. T-cell growth factors in allograft rejection and tolerance. Transplant Proc. 1999; 31:342-3.

220. Li XC, Ima A, Li Y, Zheng XX, Malek TR, **Strom TB**. Blocking the common gamma-chain of cytokine receptors induces T-cell apoptosis and long-term islet allograft survival. J Immunol. 2000; 164:1193-9.

Original Articles:

221. Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, Frost JD, Krivulka GR, Lifton MA, Crabbs CL, Heidecker G, Perry HC, Davies M-E, Xie H, Nickerson CE, Steenbeke TD, Lord CI, Montefiori DC, **Strom TB**, Shiver JW, Lewis MG, Letvin NL. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA. 2000; 97:4192-7.

222. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, **Strom TB**, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Let Vin NL. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokines augmented DNA vaccination. Science. 2000; 290:486-92

223. Bristol IJ, Farmer MA, Cong Y, Zheng XX, **Strom TB**, Elson CO, Sundberg JP, Leiter EH. Heritable susceptibility for colitis in mice induced by IL-10 deficiency. Inflamm Bowel Dis. 2000; 6:290-302.

224. Zand MS, Li Y, Hancock W, Li XC, Roy-Chaudhury P, Zheng XX, **Strom TB**. Interleukin-2 and interferon-gamma double knockout mice reject heterotopic cardiac allografts. Transplantation. 2000; 70:1378-81.

225. Dodge IL, Demirci G, **Strom TB**, Li XC. Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation. 2000; 70:1104-6.

226. Schachter AD, Strehlau J, Zurakowski D, Vasconcellos L, Kim YS, Zheng XX, Gunshin Y, Overstreet SL, Benfield MR, Tejani A, Harmon WE, Herrin JT, **Strom TB**. Increased nuclear factor kappaB and angiotensinogen gene expression in post-transplant recurrent focal segmental glomerulosclerosis. Transplantation. 2000; 70:1107-10.

227. Emmanuilidis K, Weighardt H, Fleischmann T, Gerauer K, Maier S, Zheng XX, **Strom TB**. Hancock WW, Holzmann B, Heidecke C-D. Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis. J Immunol. 2001; 167:3919.

228. Li XC, Demirci G, Ferrari-Lacraz S, Groves C, Coyle A, Malek TR, **Strom TB**. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med. 2001; 7:1-4.

229. Wasowska BA, Zheng XX, **Strom TB**, Kupieck-Weglinski JW. Adjunctive rapamycin and CsA treatment inhibits monocyte/macrophage as cytokines/chemokines in sensitized cardiac graft recipients. Transplantation. 2001; 71:1179-83.

230. Craiu A, Barouch DH, Zheng XX, Kuroda MJ, Schmitz JE, Lifton MA, Steenbeke TD, Nickerson CE, Beaudry K, Frost JD, Reimann KA, **Strom TB**, Letvin NL. An IL-2/Ig fusion protein influences CD4+T lymphocytes in naïve and simian immunodeficiency virus-infected rhesus monkeys. AIDS Res and Hum Retroviruses. 2001; 17:873-1986.

231. Ferrari-Lacraz S, Zheng XX, Kim YS, Li Y, Maslinski W, Li XC, **Strom TB**. An antagonist IL-15/Fc protein prevents costimulation blockade resistant rejection. J Immunol. 2001; 167:3478-85.

Original Articles:

232. Shulzhenko N, Morgun A, Zheng XX, Diniz RV, Almeida DR, Ma N, **Strom TB**, Gerbase-DeLima M. Intragraft activation of genes encoding cytotoxic T lymphocyte effector molecules precedes the histological evidence of rejection in human cardiac transplantation. Transplantation. 2001; 72:1705-8.

233. Sanchez-Fueyo A, Weber M, Domenig C, **Strom TB**, Zheng XX. Tracking the immuno-regulatory mechanisms active during allograft tolerance. J Immunol. 2002; 168:2274-81.

234. Kishimoto K, Sandner S, Imitola J, Sho M, Li Y, Langmuir PB, Rothstein DM, **Strom TB**, Turka LA, Sayegh MH. Th1 cytokines programmed cell death in alloreactive T cell clone size in transplant tolerance. J Clin Invest. 2002; 109:1471-79

235. Sho M, Yamada A, Najafian N, Salama AD, Harada H, Sandner SE, Sanchez-Fueyo A, Zheng XX, **Strom TB**, Sayegh MH. Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol. 2002; 169:3744-51.

236. Sanchez-Fueyo A, Domenig C, **Strom TB**, Zheng XX. The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression. Transplantation. 2002; 74:898-900.

237. Kurowska M, Rudnicka W, Kontny E, Janicka I, Chorazy M, Kowalczewski J, Ziolkowska M, Ferrari-Lacraz S, **Strom TB**, Maslinski W. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J Immunol. 2002; 169:1760-7.

238. Avihingsanon Y, Ma N, Csizmadia E, Wang C, Pavlakis M, Giraldo M, **Strom TB**, Soares MP, Ferran C. Expression of protective genes in human renal allografts: a regulatory response to injury associated with graft rejection. Transplantation. 2002; 73:1079-85.

239. Sanchez-Fueyo A, Weber M, Domenig C, **Strom TB**, Zheng XX. Tracking the immunoregulatory mechanisms active during allograft tolerance. J Immunol. 2002; 168:2274-81.

240. Sho M, Yamada A, Najafian N, Salama AD, Harada H, Sandner SE, Sanchez-Fueyo A, Zheng XX, **Strom TB**, Sayegh MH. Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4 CD25+ cells, and the alloreactive T cell clone size. J Immunol. 2002.

241. Strehlau J, Schachter AD, Pavlakis M, Singh A, Tejani A, **Strom TB**. Activated intrarenal transcription of CTL-effectors and TGF-beta1 in children with focal segmental glomerulosclerosis. Kidney Int. 2002; 6:90-5.

242. Demirci G, Gao W, Zheng XX, Malek TR, **Strom TB**, Li XC. On CD28/CD40 ligand costimulation, common □□ signals, and the alloimmune response. J Immunol. 2002; 168:4382-90.

Original Articles:

243. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subundhi SK, Zheng XX, **Strom TB**, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4 + CD25+ regulatory T cells: J Immunol. 2003; 171:3348-52.

244. Zheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, **Strom TB**. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity. 2003; 19: 503-14.

245. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, **Strom TB**, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol. 2003; 171; 3348-52.

246. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX, Coyle AJ, **Strom TB**, Freeman GJ, Kuchroo VK. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003; 4:1102-10.

247. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, Gutierrez-Ramos JC, Coyle AJ, **Strom TB**. Tim-3 inhibits T helper type 1-mediated auto-and alloimmune responses and promotes immunological tolerance. Nature Immunol. 2003; 4:1093-101.

248. Gao W, Demirci G, **Strom TB**, Li XC. Stimulating PD-1 negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation. 2003:76:994-9.

249. Demirci G, **Strom TB**, Li XC. Islet allograft rejection in non-obese diabetic mice involves the common gamma-chain and CD28/CD154-dependent and –independent mechanisms. J Immunol. 2003; 17:3878-85.

250. Jarvinen LZ, Blazar BR, Adeyi OA, **Strom TB**, Noelle RJ. CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance. Transplantation. 2003; 76:1375-9.

251. Hleb M, Murphy S, Wagner EF, Hanna NN, Sharma N, Park J, Li XC, **Strom TB**, Padbury JF, Tseng YT, Sharma S. Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes. J Biol Chem. 2004; 279:31948-55.

252. Zhong X, Bai C, Gao W, **Strom TB**, and Rothstein TL. Suppression of expression and function of negative immune regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger. Int. Immunol. 2004; 16:1181-8.

253. Demirci G, Amanullah F, Kewalaramani R, Yagita H, **Strom TB**, Sayegh MH, Li XC. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol. 2004; 172:1691-8.

254. Ferrari-Lacraz S, Zanelli E , Neuberg M, Donsko E, Kim YS, Zheng XX, Hancock WW, Maslinski W, Li XC, **Strom TB**, Moll T. Targeting IL-15 receptor bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol. 2004; 173:5818-26.

Original Articles:

255. Avihingsanon Y, Ma N, Pavlakis M, Chon WJ, Uknis ME, Monaco AP, Ferran C, Stillman L, Schachter AD, Mottley C, Zheng XX, **Strom TB**. On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol. 2005; 16:1542-8.

256. Meyers JH, Chakravarti S, Schlesinger D, Illes Z, Waldner H, Umetsu SE, Kenny J, Zheng XX, Umetsu DT, DeKruyff RH, **Strom TB**, Kuchroo VK. TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol. 2005; 6:455-64.

257. Diem Vu M, Li Y, **Strom TB**, Li XC. Mycophenolate mofetil is compatible with CCD28/CD154 costimulatory blockade in preventing transplant rejection. Transplantation. 2005; 79:736

258. McDaid J, Yamashita K, Chora A, Ollinger R, **Strom TB**, Li XC, Bach FH, Soares MP. Heme oxygenase-1 modulates the allo-immune response by promoting activation-induced cell death of T cells. FASEB J. 2005; 19:458-60

259. Meyers JH, Chakravarti S, Schlesinger D, Illes Z, Waldne H, Kenny J, Zheng XX, Umetsu DT, DeKruyff RH, **Strom TB**, and Kuchroo VK. Tim-4 is the ligand for Tim-1, and the Tim-1/Tim-4 interaction regulates the development of Th2 responses. Natl Immunol. 2005; 6:455-64.

260. Avihingsanon Y, Ma N, Pavlakis M, Chon WJ, Uknis ME, Monaco AP, Ferran C, Stillman I, Schachter AD, Mottley C, Zheng X, **Strom TB**. On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol. 2005; 16:1542-8.

261. Domenig C, Sanchez-Fueyo A, Kurtz J, Alexopoulos SP, Mariat C, Sykes M, **Strom TB**, Zheng XX. Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol. J Immunol. 2005; 175:51-60.

262. Chakravarti S, Sabatos CA, Xiao S, Iles Z, Cha EK, Sobel RA, Zheng XX, **Strom TB**, Kuchroo VK. Tim-2 regulates T helper type 2 responses and autoimmunity. J Exp Med. 2005; 202:437-44.

263. Mariat C, Sanchez-Fueyo A, Alexopoulos SP, Kenny J, **Strom TB**, Zheng XX. Regulation of T cell dependent immune responses by TIM family members. Philos Trans R Soc Lond B Biol Sci. 2005; 360:1681-5.

264. Sho M, Kishimoto K, Harada H, Livak M, Sanchez-Fueyo A, Yamada A, Zheng XX, **Strom TB**, Basadonna GP, Sayegh MH, Rothstein DM. Requirements for induction and maintenance of peripheral tolerance in stringent allograft models. Proc Natl Acad Sci USA. 2005; 102:13230.

Original Articles:

265. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, **Strom TB**, Kuchroo VK. The Tim-3 ligand galectin-9 regulates T helper type 1 immunity. Nat Immunol. 2005; 6:1245-52.

266. Sanchez-Fueyo A, Sandner S. Habicht A, Mariat C, Kenny J, Degauque N, Zheng XX, **Strom TB**, Turka LA, Sayegh MH. Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol. 2006; 176:329-34.

267. Zheng XX, Gao W, Donskoy E, Neubreg M, Ruediger M, **Strom TB**, Moll T. An antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation. 2006; 81:109-16.

268. Koulmanda M, Smith RN, Qipo A, Weir G, Auchincloss H, **Strom TB**. Prolonged survival of allogeneic islets in cynomolgus monkeys after short-term anti-CD154-based therapy: nonimmunologic graft failure? Am J Transplant. 2006; 6:687-96.

269. El Essawy B, Out HH, Choy B, Zheng XX, Libermann TA, **Strom TB**. Proteomic analysis of the allograft response. Transplantation. 2006; 82: 267-74.

270. Lu LF, Lind EF, Gondek CD, Bennett KA, Gleeson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J, **Strom TB**, Zheng XX, Noelle RJ. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006; 442: 997-1002.

271. Kim YS, Yang SH, Kang HG, Seong EY, Lee SH, Gao W, Kenny J, Zheng XX, **Strom TB**. Distinctive role of donor strain immature dendritic cells in the creation of allograft tolerance. Int Immunol. 2006; 18: 1771-7.

272. Ferrari-Lacraz S, Zheng XX, Fueyo AS, Maslinski W, Moll T, **Strom TB**. CD8+ T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein. Transplantation. 2006; 82:1510-17.

273. Bettelli E, Carrier Y, Gao W, Korn T, **Strom TB**, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441:235-8.

274. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, **Strom TB**, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007; 448: 484-87.

275. Koulmanda M, Budo E, Bonner-Weir S, Qipo A, Putheti P, Degauque N, Shi H, Fan Z, Flier JS, Auchincloss H Jr, Zheng XX, **Strom TB**. Modification of adverse inflammation is required to cure new onset Type 1 diabetic hosts. Proc Natl Acad Sci USA. 2007; 104(32):13074-13079.

Original Articles:

276. Zhong X, Gao W, Degauque N, Bai C, Lu Y, Kenny J, Oukka M, **Strom TB**, Rothstein TL. Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. Eur J Immunol. 2007 Sep; 37(9):2400-4.

277. Koyama I, Nadazdin O, Boskovic S, Ochiai T, Smith RN, Sykes M, Sogawa H, Murakami T, **Strom TB**, Colvin RB, Sachs DH, Benichou G, Cosimi AB, Kawai T. Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant. 2007; 7: 1055-61.

278. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Backstrom BT, Sobel RA, Wucherpfennig KW, **Strom TB**, Oukka M, Kuchroo VK. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med. 2007; 13:423-31.

279. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, **Strom TB**, Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204: 1257-65.

280. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, **Strom TB**. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007; 7:1722-32.

281. Xiao, S. N. Najafian, J. Reddy, M. Albin, C. Zhu, E. Jensen, J. Imitola, T. Korn, A. C. Anderson, Z. Zhang, C. Gutierrez, T. Moll, R. A. Sobel, D. T. Umetsu, H. Yagita, H. Akiba, T. Strom, M. H. Sayegh, R. H. Dekruyff, S. J. Khoury, and V. K. Kuchroo. Differential engagement of Tim-1 during activation can positively or negatively costimulates T cell expansion and effector function. J Exp Med. 2007; 204:1691-1702.

282. Zhong M, Gao W, Degauque N, Bai C, Lu Y, Kenny J, Oukka M, **Strom TB**, Rothstein TL. Reciprocal generation of Th1/Th17 and Treg cells by B1 and B2 B cells. Eur J Immunol. 2007; 37: 2400-4.

283. Koulmanda, M. E. Budo, S. Bonner-Weir, A. Qipo, R. Putheti, N. Degauque, H. Shi, Z. Fan, J. S. Flier, H. Auchincloss, X. X. Zheng, and T. B. Strom. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci USA. 2007; 104: 13074-79.

284. Degauque N, Mariat C, Kenny J, Zhang D, Gao W, Vu MD, Alexopoulos S, Oukka M, Umetsu DT, Dekruyff RH, Kuchroo V, Zheng XX, **Strom TB**. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest. 2008; 118(2):735-741.

285. Muthukumarana PA, Zheng XX, Rosengard BR, **Strom TB**, Metcalfe SM. In primed allo-tolerance, TIM-3-Ig rapidly suppresses TGFbeta, but has no immediate effect on Foxp3. Transpl Int. 2008 Jun; 21(6):593-7

Original Articles:

286. Rodriguez-Manzanet R, Meyers JH, Balasubramanian S, Slavik J, Kassam N, Dardalhon V, Greenfield EA, Anderson AC, Sobel RA, Hafler DA, **Strom TB**, Kuchroo VK. TIM-4 expressed on APCs induces T cell expansion and survival. J Immunol. 2008 Apr 1; 180(7):4706-13.

287. Tzianabos AO, Holsti MA, Zheng XX, Stucchi AF, Kuchroo VK, **Strom TB**, Glimcher LH, Cruikshank WW. Functional Th1 cells are required for surgical adhesion formation in a murine model. J Immunol. 2008 May 15; 180(10):6970-6.

Reviews, Chapters, and Editorials:

1. **Strom TB**, Deisseroth A, Morganroth J, Carpenter CB, Merrill JP. Regulatory role of the cyclic nucleotides in alloimmune lymphocyte-mediated cytotoxicity. Effect of imidazole. Transplant Proc. 1973; 5:425-47.

2. Phillips SM, **Strom TB**, Corson JM, Carpenter CB, Merrill JP. Enhancing antibody: in vitro studies on the mechanism of action upon the sensitization and effector arc. Transplant Proc. 1973; 5:577-80.

3. Phillips SM, **Strom TB**, Corson JM, Carpenter CB, Merrill JP. Enhancing antibody: in vitro studies on the mechanism of action and specificity upon mouse lymphocytes. In: Proceedings of the Seventh Leukocyte Culture Conference, New York. Academic Press. 1973:601-11

4. **Strom TB**, Carpenter CB, Phillips SM, Garovoy MR, Merrill JP. Rejection and enhancement in an in vitro model of alloimmunity. Transplantation. 1973; 16:103-9.

5. Phillips SM, Carpenter CB, **Strom TB**. Cellular immunity in the mouse. 3. In vitro kinetic studies on the relationship between recognition and effector phases. Transplant Proc. 1973; 5:1669-73.

6. **Strom TB**, Sytkowski AJ, Carpenter CB, Merrill JP. Cholinergic receptor of cytotoxic T lymphocytes. Proc Natl Acad Sci USA. 1974; 71:1330-1333.

7. Wilson RE, Goldman MJ, Yen MC, Kassissieh SD, **Strom TB**, Kahn CR. Neuropathy in transplanted diabetic patients. Kidney Int. 1974; 6(Suppl I):90-94.

8. Tilney NL, **Strom TB**, MacPherson SG, Carpenter CB. Populations of infiltrating cells removed from rejecting rat cardiac allografts. Surg Forum. 1974; 25:289-92.

9. **Strom TB**, Sytkowski AJ, Carpenter CB, Merrill JP. The cholinergic receptor of cytotoxic lymphocytes. In: Proceedings of the Eighth Leukocyte Culture Conference, (Lymphocyte Recognition and Effector Mechanisms), New York. Academic Press. 1974; 509-13.

10. Carpenter CB, Garovoy MR, **Strom TB**, Merrill JP. Antibody dependent lymphocyte-mediated cytotoxicity. Role of cyclic nucleotides in the injury produced by unsensitized bone marrow derived (B) cells. In: Proceedings of the Eighth Leukocyte Culture Conference, (Lymphocyte Recognition and Effector Mechanisms), New York. Academic Press. 1974; 351-56.

Reviews, Chapters, and Editorials:

11. **Strom TB**, Deisseroth A, Morganroth J, Carpenter CB, Merrill JP. Modulation of cytotoxic T lymphocyte function by cyclic 3', 5' mononucleotides. In: Braun W, Lichtenstein LM, Parker CW, (eds.) Cyclic AMP, Cell Growth, and the Immune Response, New York. Springer-Verlag. 1974; 209-22.

12. **Strom TB**, Hirsch MS, Black PH, Carpenter CB, Merrill JP. Modulation of GVH proliferation by cyclic nucleotides. Transplant Proc. 1975; 7:305-7.

13. Hurst KS, Saldanha LF, Steinberg SM, Galen MA, Lowrie EG, Gagneux SA, Lazarus JM, **Strom TB**, Carpenter CB, Merrill JP. The effects of varying dialysis regimens on lymphocyte stimulation. Trans Am Soc Artif Intern Organs. 1975; 21:329-33.

14. Tilney NL, **Strom TB**, Bancewicz J, Carpenter CB. Studies on living cells harvested from acutely rejecting and enhanced rat cardiac allografts. Surgical Forum. 1975; 26:349-50.

15. Tilney NL, **Strom TB**, MacPherson SG, Carpenter CB. Studies on infiltrating host cells harvested from acutely rejecting rat cardiac allografts. Surgery. 1976; 79:209-17.

16. **Strom TB**, Garovoy MR, Carpenter CB. Pharmacologic modulation of cytotoxic lymphocytes by cyclic nucleotides. International Course on Transplantation, Lyon, Simeps-Editors, Villeurbanne, France. 1976; 85-96.

17. Carpenter CB, Soulillou JP, d'Apice AJF, **Strom TB**, Garovoy MR. The role of antibodies in the rejection and enhancement of rat organ allografts: non-AgB (Ia) antigens. Transplant Proc. 1976; 8:199-205

18. **Strom TB**, Soulillou JP, Carpenter CB. On the identity of lymphoid cells that stimulate the rat MLC and produce active enhancement. Transplant Proc. 1977; 9:965-68.

19. **Strom TB**, Carpenter CB Jr. Cragoe EJ Jr. Norris S, Devlin R, Perper RJ. Suppression of in vivo and in vitro alloimmunity by prostaglandins. Transplant Proc. 1977; 9:1075-79.

20. Busch GJ, Schamberg JF, Moretz RC, **Strom TB**, Tilney NL, Carpenter CB. Four patterns of human renal allograft rejection: a cytologic and in vitro analysis of the infiltrate in 2 irreversibly rejected kidneys. Transplant Proc. 1977; 9:37-42.

21. Tilney NL, **Strom TB**, Booth DB, Finnegan A, Lundin AP III, Carpenter CB. Identification, cytotoxicity, and suppressor activity of infiltrating cells from enhanced organ allografts. Transplant Proc. 1977; 9:713-15.

22. Catto GRD, Carpenter CB, **Strom TB**, Williams RM. Passive enhancement of rat renal allografts by antibodies to a non-SD (Ag-B) locus analogous to Ia and demonstration of linkage to the MHC. Transplant Proc. 1977; 9:957-60.

23. **Strom TB**, Merrill JP. Hepatitis B, transfusions and renal transplantation. (Editorial). N Eng J Med.1977; 296:225-6.

24. **Strom TB**, Lundin AP, Carpenter CB. The role of cyclic nucleotides in lymphocyte activation and function. Prog Clin Immunol. 1977; 3:115-53.

Reviews, Chapters, and Editorials:

25. Fearon DT, Daha MR, **Strom TB**, Weiler JM, Carpenter CB, Austen KF. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection. Transplant Proc. 1977; 9:729-39.

26. Gottlieb MN, Stephens MK, Lowrie EG, Griffiths NJL, Kenzora JR, **Strom TB**, Phillips E, Merrill JP. Bone disease following renal transplantation. In: David DS, ed.Calcium metabolism in renal disease and nephrolithiasis, New York. John Wiley and Sons, Inc. 1977; 279-92.

27. **Strom TB**, Carpenter CB. Regulation of alloimmunity by cyclic nucleotides. In: Hadden JW, Spreafico F, Grattini S, eds. Immunopharmacology - Comprehensive Immunology, Vol. 3, New York. Plenum Press. 1977; 47-59.

28. Hoette M, Kaldany A, Lundin AP III, Gottlieb MN, Suthanthiran M, Carpenter CB, **Strom TB**. In vitro modulation of phytohemagglutin-P induced blastogenesis by parathyroid hormone. In: Lucas DO, ed. Proceedings of the Eleventh Leukocyte Culture Conference (Regulatory Mechanisms in Lymphocyte Activation), New York. Academic Press. 1977; 453-5.

29. Helderman JH, **Strom TB**. The insulin receptor on the T cell: a marker of activation after stimulation. In: Lucas DO, ed. Proceedings of the Eleventh Leukocyte Culture Conference (Regulatory Mechanisms in Lymphocyte Activation), New York. Academic Press. 1977; 343-35.

30. Lundin AP III, Kaldany A, Paradysz JM, Carpenter CB, **Strom TB**. Characterization of the adherent splenic suppressor cells. In: Lucas DO, ed. Proceedings of the Eleventh Leukocyte Culture Conference (Regulatory Mechanisms in Lymphocyte Activation), New York. Academic Press. 1977; 800-1982.

31. Lundin AP III, Kaldany A, **Strom TB**, Tilney NL, Carpenter CB. Presence of splenic suppressor cells in allograft enhanced rats. In: Lucas DO, ed. Proceedings of the Eleventh Leukocyte Culture Conference (Regulatory Mechanisms in Lymphocyte Activation). New York. Academic Press. 1977; 803-5.

32. Kaldany A, Lundin AP III, George K, Suthanthiran M, Garovoy MR, Carpenter CB, **Strom TB**. In vitro stimulation of unprimed lymphocyte membrane fragments. In: Lucas DO, ed. Proceedings of the Eleventh Leukocyte Culture Conference (Regulatory Mechanisms in Lymphocyte Activation), New York. Academic Press. 1977; 397-9.

33. Lundin AP III, Kaldany A, **Strom TB**, Soulillou JP, Carpenter CB. Role of rat lymphocyte subpopulations in the mixed lymphocyte culture. In: Lucas DO, ed. Proceedings of the Eleventh Leukocyte Culture Conference (Regulatory Mechanisms in Lymphocyte Activation), New York. Academic Press. 1977; 611-13.

34. Gailiunas P Jr. Suthanthiran M, Person A, **Strom TB**, Carpenter CB, Garovoy MR. Posttransplant immunologic monitoring of the renal allograft recipient. Transplant Proc. 1978; 10:609-11.

Reviews, Chapters, and Editorials:

35. **Strom TB**, Helderman JH, Williams RM. Rapid mixed lymphocyte cultures assessed by emergence of T cell insulin receptors. Proc Clin Dial Transplant Forum. 1978; 7:126-130.

36. Suthanthiran M, Gailiunas P, Fagan G, **Strom TB**, Carpenter CB, Garovoy MR. Detection of antidonor "Ia" antibodies: a strong correlation of rejection. Transplant Proc. 1978; 10:605-7.

37. Kaldany A, Carpenter CB, Suthanthiran M, Garovoy MR, **Strom TB**, George K. HLA-D activity in lymphocyte subcellular fractions. Transplant Proc. 1978; 10:785-1988.

38. Carpenter CB, Catto GRD, Suthanthiran M, Kaldany A, Gailiunas P Jr, Garovoy MR, **Strom TB**. Specificity in allograft rejection. In: Siskind G, (ed.) Mechanisms in disease. New York. Grune and Stratton. 1978; 105-23.

39. **Strom TB**, Carpenter CB, Tilney NL, Suthanthiran M, Catto GRD, Lundin AP III, Milford EL. Intragraft immune events causing vascularized organ graft rejection. Transplant Proc. 1978; 10:389-94.

40. **Strom TB**. Renal transplantation: A bright outlook. Resident and Staff Physician. 1978; 24:58-68.

41. **Strom TB**, Lane MA, Helderman JH. Immunoregulation by hormones and neurotransmitters. In: 7th International Congress Nephrology. Karger, Basel. 1978; 585-1989

42. **Strom TB**, Kostick R, Tilney NL, Carpenter CB. A characterization of the nature and control of cellular allograft rejection. Nephron. 1978; 22:201-7.

43. Tilney NL, **Strom TB**, Milford EL. The role of suppression in the immune responses. In: Fitch F, Stuart FP, (eds.) Immunological tolerance and enhancement. Lancaster, England: Medical and Technical Publishing Co. Ltd. 1979; 125-48.

44. Hendry W, Tilney NL, Graves MJ, Baldwin WM 3rd, **Strom TB**. Suppressor cells in enhancement of organ allografts. Transplant Proc. 1979; 11:1454-55.

45. Helderman JH, **Strom TB**, Dupuy-d'Angeac A. Analysis of subpopulations of T blasts bearing insulin receptors obtained by l-g velocity sedimentation of murine mixed lymphocyte cultures. Transplant Proc. 1979; 11:1385-1986.

46. Milford EL, Carpenter CB, **Strom TB**, Paradysz JM. MLR-reactive thymocytes in the rat: Ia-positive stimulator and Ia-negative responder cells. Transplant Proc. 1979; 11:719-22.

47. Hutchinson IF, Shadur CA, Duarte A, Baldwin WM III, **Strom TB**, Tilney NL. Effects of cyclosporin A on host responses to cardiac allografts in rats. Surg Forum. 1980; 31:373-75.

48. **Strom TB**. Transplantation. In: Diamond LH, Balow JE, (eds.) Nephrology Reviews. 1980. New York. John Wiley & Sons Inc. 1980; 226-60.

Reviews, Chapters, and Editorials:

49. Carpenter CB, **Strom TB**. Transplantation immunology. In: Parker CW, (ed.) Clinical Immunology. Philadelphia. W. B. Saunders. 1980; 376-444.

50. **Strom TB**, Carpenter CB. Cyclic nucleotides in immunosuppression-neuroendocrine pharmacologic manipulation and in vivo immunoregulation of immunity acting via second messenger systems. Transplant Proc. 1980; 12:304-10.

51. **Strom TB**, Helderman JH. The role of insulin in development and modulation of the immune response. In: Brownlee M, (ed.) Handbook of diabetes mellitus - Islet cell function/insulin action, Vol. 2. New York. Garland STPM Press. 1980; 197-216.

52. **Strom TB**, Garovoy MR. Acute nephritis. In: Stein J, ed. The science and practice of clinical medicine: Vol. 7, Disorders of the Kidney/Electrolyte Metabolism. New York. Grune and Stratton. 1980; 144-47.

53. Garovoy MR, **Strom TB**. Post streptococcal glomerulonephritis. In: Stein J, (ed.) The science and practice of clinical medicine: Vol. 7. Disorders of the Kidney/ Electrolyte Metabolism. New York. Grune and Stratton. 1980; 288-92.

54. **Strom TB**, Garovoy MR. The causes of proliferative glomerulonephritis. In: Stein J, (ed.) The science and practice of clinical medicine: Vol. 7, Disorders of the Kidney/Electrolyte Metabolism. New York. Grune and Stratton. 1980; 287-1988.

55. Norman DJ, **Strom TB**. Acute renal failure. CAI Seminar for Practicing Physicians, Milliken Communications Corp. Course #36, January 1980.

56. Carpenter CB, **Strom TB**, Garovoy MR. Renal transplantation: immunobiology. In: Brenner BM, Rector FC Jr, (eds.) The kidney. Philadelphia. W. B. Saunders. 1981; 2544-98.

57. **Strom TB**, Tilney NL, Merrill JP. Renal transplantation: clinical management of the transplant recipient. In: Brenner BM, Rector FC Jr, (eds.) The kidney. Philadelphia. W. B. Saunders. 1981; 2618-58.

58. **Strom TB**, Lane MA, Helderman JH. Mediation of cellular immune reactivity by hormones and neurotransmitters. A comparison to the life sciences. In: Day S, (ed.) Integrated Medicine. 1981; 4:69-74.

59. **Strom TB**. Renal transplantation. In: Klahr S, Massry S, (eds.) Contemporary Nephrology, Vol. 1. New York. Plenum Press. 1981; 631-56.

60. **Strom TB**, Garovoy MR. Clinical and experimental aspects of renal allograft rejection. Am J Kidney Dis. 1981; 1:5-14.

61. **Strom TB**. Transplantation. In: Diamond LH, Balow JE, (eds.) Nephrology Reviews, 1981. New York. John Wiley & Sons Inc. 1981; 236-60.

Reviews, Chapters, and Editorials:

62. **Strom TB**, Tilney NL. Clinical management of the renal transplant recipient. In: Brenner BM, Stein JH, (eds.) Contemporary issues in nephrology, Vol. 7, New York. Churchill Livingston. 1981; 255-1986.

63. **Strom TB**, Smith KA, Lane MA, Helderman JH. Does age-associated deterioration in T cell regulation by neurotransmitters and T cell growth factor cause immunosenescence? In: Segre D, (ed.) National Institute on Aging Conference on the Immunologic Aspects of Aging. New York. Marcel Dekker. 1981; 391-414.

64. **Strom TB**, Tilney NL, Carpenter CB. Kidney transplantation in the treatment of terminal uremia. Ann Clin Res. 1981; 13:224-53.

65. Hutchinson IF, Shadur CA, Duarte A, Baldwin WM 3rd, **Strom TB**, Tilney NL. Mechanisms of cardiac allograft prolongation by cyclosporin-A. Transplant Proc. 1981; 13:412-13.

66. Wilson RE, Garovoy MR, **Strom TB**, Lowry RP, Busch GJ, Vineyard GC, Tilney NL. Passive enhancement of cadaver renal allografts: a prospective randomized trial of F(ab')2 therapy. Transplant Proc. 1981; 13:531-2.

67. Milford EL, Carpenter CB, **Strom TB**, Tilney NL. Suppression of renal allograft rejection by low density thymocytes. Transplant Proc. 1981; 13:626-8.

68. Helderman JH, Garovoy MR, **Strom TB**. B-cell alloantigen matching by the lymphocyte insulin receptor assay. Transplant Proc. 1981; 13:1042-3.

69. Shadur CA, **Strom TB**, Carpenter CB. In vitro generation of suppressor lymphocytes with subcellular membrane fragments. Transplant Proc. 1981; 13:1472-5.

70. Norman DJ, Black RM, Shadur CA, **Strom TB**, Carpenter CB. Continuous density gradient separation of allosensitized cells from a mixed lymphocyte culture. Transplant Proc. 1981; 13:1469-71.

71. Lowry RP, Shadur CA, Duarte AJS, **Strom TB**, Carpenter CB. Lymphocyte subsets in heart allograft rejection in a rat model: effect of in vitro generated suppressor cells. Transplant Proc. 1981; 13:1428-31.

72. **Strom TB**. The improving utility of renal transplantation in the management of end stage renal disease. Am J Med.1982; 73:105-24.

73. **Strom TB**. Clinical transplantation. In: Stites DP, Stobo J, Fudenberg HH, Wells JV, (eds.) In: Basic & Clinical Immunology; 4th edition, Los Altos: Lange Medical Publishing. 1982; 189-97.

74. **Strom TB**. Editorial retrospective: hepatitis B, transfusions and renal transplantation - Five years later. N Engl J Med.1982; 307:1114-42.

Reviews, Chapters, and Editorials:

75. Helderman JH, **Strom TB**. Pharmacokinetic properties of cellular receptors with special reference to lymphocytes. In: Rola-Pleszczynski M, Sirois P, (eds.) Research monographs In: Immunology, Vol. 4. Immunopharmacology. Amsterdam. Elsevier/North Holland Biomedical Press. 1982; 15-26.

76. Carpenter CB, **Strom TB**. Transplantation: immunogenetic and clinical aspects - Part I. Hosp Pract. 1982; 17:125-34.

77. **Strom TB**, Carpenter CB. Transplantation: immunogenetic and clinical aspects- Part II. Hosp Pract. 1983; 18:135-50.

78. Cotner T, Williams JM, **Strom TB**, Strominger JL. The relationship between early T cell activation antigens and T cell proliferation. In: Hadden JW, Chedid L, Dukor P, Spreafico F, Willoughby D. 2nd International Conference Immunopharmacology. Oxford. Pergamon Press. 1983; 63-8.

79. Moore FD Jr, Kohler TR, **Strom TB**, Tilney NL. The declining mortality from pneumonia in renal transplant patients. Infect Surg. 1983; 2:13-9.

80. Carpenter CB, **Strom TB**. Renal transplant rejection. In Lichtenstein LM, Fauci AS, (eds.) Current therapy in allergy and immunology. Toronto. B. C. Decker Inc. 1983; 183-6.

81. Goldzer RC, **Strom TB**, Tilney NL. Acute renal failure associated with renal transplantation. In: Brenner BM, Lazarus JM. Acute renal failure. Philadelphia. W. B. Saunders. 1983; 555-66.

82. **Strom TB**. Renal transplantation. In: Klahr S, Massry S, (eds.) Contemporary Nephrology, Vol. 2 New York. Plenum Press. 1983; 699-726.

83. Bordes-Aznar J, Tilney NL, **Strom TB**. Cyclosporin A spares suppressor T cells thus causing antigen specific immunosuppression in vivo. In: Fudenberg HH, Pontiggia P, Ogier C. (ed.) Immunomodulation and Thermotherapy in Cancer. Rome. Acta Medica. 1983; 77-97.

84. Tilney NL, Kupiec-Weglinski JW, Heidecke CD, Lear PA, **Strom TB**. Mechanisms of rejection and prolongation of vascularized organ allografts. Immunol Rev. 1983; 77:185-216.

85. Kupiec-Weglinski JW, Lear PA, Bordes-Aznar J, Heidecke CD, **Strom TB**, Tilney NL. Restoring immune responsiveness toward cardiac allografts in cyclosporin-A-treated rats. Transplantation Proc. 1983; XV:1917-8.

86. Tilney NL, Kirkman RL, Araujo JL, Carpenter CB, Milford EL, Reinherz EL, Schlossman SF, **Strom TB**. Use of cyclosporine and monoclonal antibodies in clinical renal transplantation. Transplant Proc. 1983; 15:2889-95.

Reviews, Chapters, and Editorials:

87. Lear PA, Heidecke CD, Kupiec-Weglinski J, Clason AE, **Strom TB**, Tilney NL. Reestablishment of immunologic responsiveness toward cardiac allografts in B rats. Transplant Proc. 1983; 15:349-351.

88. Bordes-Aznar J, Kupiec-Weglinski JW, Lear PA, **Strom TB**, Tilney NL. Kinetics of cyclosporin A induced unresponsiveness to cardiac allografts in rats. Transplant Proc. 1983; 15:500-3.

89. Kupiec-Weglinski J, Lear PA, Bordes-Aznar J, Tilney NL, **Strom TB**. Acute rejection in cyclosporin A treated graft recipients occurs following abrogation of suppressor cells. Transplant Proc. 1983; 15:531-3.

90. Kirkman RL, **Strom TB**, Weir MR, Tilney NL. The natural history of long-term renal transplantation. Transplant Proc. 1983; 15:1043-5.

91. Wang BS, Zheng CX, Heacock EH, **Strom TB**, Tilney NL, Mannick JA. A possible mechanism of action of cyclosporin A in inhibiting the induction of alloreactivity. Transplant Proc. 1983; 15:1915-6.

92. Bordes-Aznar J, Heidecke CD, **Strom TB**, Tilney NL. Restoring immune responsiveness toward cardiac allografts in cyclosporin-A-treated rats. Transplant Proc. 1983; 15:1917-8.

93. Williams JM, Christenson L, Araujo JL, Carpenter CB, Milford EL, Shapiro HM, **Strom TB**. A new approach to the monitoring of kidney transplant patients via flow cytometric analysis of T-cell subsets, activation antigens and DNA content. Transplant Proc. 1983; 15:1957-61.

94. Kupiec-Weglinski JW, Lear PA, Abbud-Filho M, **Strom TB**, Tilney NL. Populations of cyclophosphamide sensitive T suppressor cells maintain cyclosporine induced allograft survival. Transplant Proc. 1983; 15:2357-2663.

95. **Strom TB**, Loertscher R. Cyclosporine-induced nephrotoxicity. Inevitable and intractable? N Engl J Med.1984; 311:728-9.

96. Lertscher R, Abbud-Filho M, **Strom TB**. Cyclosporine: Fighting Transplant Rejection. Drug Therapy. 1984; 9:16-31.

97. **Strom TB**, Carpenter CB. Prophylaxis of allograft rejection. In: Glassock RJ, (ed.) Current Therapy in Nephrology and Hypertension. Philadelphia, PA. 1984; 376-380.

98. Carpenter CB, **Strom TB**. Immunosuppressive therapy for renal transplantation. Springer Semin Immunopathol. 1984; 7:43-57.

99. Carpenter CB, Milford EL, **Strom TB**, Kirkman RL, Tilney NL. Therapeutic Use of Monoclonal Antibodies in Transplantation. In: Morris PJ, Tilney NL, (eds.) Progress in Transplantation, Churchill Livingston, New York. 1984; 71-1989.

Reviews, Chapters, and Editorials:

100. **Strom TB**. Basic transplant immunobiology the mode of action of immunosuppressive agents utilized in clinical renal transplantation. Kidney Int. 1984; 26:353-65.

101. Loertscher R, Abbud-Filho M and **Strom TB**. Cyclosporine in renal transplantation. In: Robinson RR, (ed.) Proceedings of the IXth International Congress of Nephrology. New York. Springer-Verlag. 1984; 1662-73.

102. Loertscher R, **Strom TB**. Renal replacement therapy for diabetic nephropathy. Clin Diabetes. 1984; 2:97-116. Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, **Strom TB**. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Int Med.1984; 101:667-1982.

103. Carpenter CB, Ettenger RB, **Strom TB**, "Free market" approach to organ donation (letter). N Engl J Med.1984; 310:395-6.

104. **Strom TB**, Kupiec-Weglinski JW, Heidecke CD, Tilney NL. The cellular and molecular basis of allograft rejection: fact and fancy. Transplant Proc. 1985; 17:801-5.

105. Milford EL, Kirkman RL, Tilney NL, **Strom TB**, Carpenter CB. Clinical experience with cyclosporine and azathioprine at Brigham and Women's Hosp. Am J Kidney Dis. 1985; 6:313-7.

106. **Strom TB**. The cellular and molecular elements of allograft rejection. Transplantation Immunology Letter. 1985; 2:2-7.

107. **Strom TB**, Tilney NL. Renal transplantation: clinical management of the transplant recipient. In: Brenner BM, Rector RC Jr. (eds.) The Kidney, Philadelphia, W. B. Saunders. 1985; 1941-76.

108. **Strom TB**, Kupiec-Weglinski JW, Tilney NL. On the mechanisms of rejection of vascularized organ allografts: a review and an attempt at synthesis. In: Morris PJ, Tilney NL, (eds.) Progress in Transplantation, Vol. 2. New York. Churchill Livingston, 1985; 126-46.

109. **Strom TB**. Transplantation. In: Klahr S, Massry S, (eds.) Contemporary Nephrology, Vol. 3. New York. Plenum Press. 1985; 663-94.

110. Ythier AA, Williams JM, **Strom TB**. Clonal analysis of early (18 hours) alloactivated T lymphocytes in the human mixed lymphocyte reaction. Transplant Proc. 1985; 17:806-9.

111. Abbud-Filho M, Kupiec-Weglinski JW, Araujo JL, Heidecke CD, **Strom TB**. Interleukins and suppressor cells during cyclosporine A induced state of "tolerance. Transplant Proc. 1985; 17:1384-6.

112. Orlowska E, Maddock SM, Kelley VE, Fiers W, **Strom TB**. Interleukin-2 stimulated changes in cellular metabolism precede de novo DNA synthesis. Transplant Proc. 1985; 17:575-7.

113. Heidecke CD, Kupiec-Weglinski JW, Abbud-Filho M, Araujo JL, Lear PA, **Strom TB**, Tilney NL. T helper, T cytotoxic suppressor cells and lymphokine are critical in acute organ graft rejection in B rats. Transplant Proc. 1985; 17:866-8.

Reviews, Chapters, and Editorials:

114. Weir MR, Kirkman RL, **Strom TB**. The long term effects of hepatitis B virus in renal transplant recipients; analysis of morbidity and mortality. Transplant Proc. 1985; 17:163-4.

115. Carpenter CB, Milford EL, Kirkman RL, **Strom TB**, Lazarus JM, Tilney NL. Stability of renal allograft recipients after conversion from cyclosporine to azathioprine. Transplant Proc. 1985; 17:261-5.

116. Schneider TM, Kupiec-Weglinski JW, Towpik L, Diamantstein T, **Strom TB**, Tilney NL. Effects of lymphocytes and interleukin-2 receptor antibody on cardiac graft survival. Surgical Forum. 1985; 36:366-8.

117. Filho MA, Loertscher R, **Strom TB**. Ciclosporina em transplante renal. J Bras Nefrol. 1985; 7:60-6

118. **Strom TB**. Cellular and molecular elements of allograft rejection. Riv Immunol. Immunofarm. 1986; 6:229-34.

119. Tilney NL, Kupiec-Weglinski J, **Strom TB**. T cells and their products in host responsiveness 1986; 224:21-40. Prog Clin Biol Res 1986; 224:21-39.

120. **Strom TB**, Gaulton GN, Kelley VE, Diamanstein T, Kupiec-Weglinski J, Tilney NL, Kirkman RL. Treatment with anti-interleukin-2 receptor monoclonal antibody. Prog Clin Biol Res 1986; 224:227-38.

121. Schneider TM, Kupiec-Weglinski JW, Towpik E, **Strom TB**, Tilney NL. Studies on mechanisms of acute rejection of vascularized organ allografts. Hum Immunol. 1986; 15:320-29.

122. Salomon D, **Strom TB**. Diagnosis and treatment of rejection. In: Garovoy MR, Guttmann RD, (eds.) Renal Transplantation. New York. Churchill Livingston 1986; 125-56.

123. Tilney NL, **Strom TB**. Chemical suppression of the immune responses. In: PJ Morris and NL Tilney, (eds.) Progress in Transplantation. Vol. 3. New York. Churchill Livingstone (Edinburgh) 1986; 1-31.

124. **Strom TB**, Gaulton GN, Kelley VE, Kirkman RL. Anti-interleukin-2 receptor monoclonal antibody treatment prolongs allograft survival. In. Cinader, B and Miller RG, (eds.) Progress in Immunology VI. Orlando. Academic Press, Inc. 1986; 909-14.

125. Tilney NL, Milford EL, Carpenter CB, Lazarus JM, **Strom TB**, Kirkman RL: Long term results of cyclosporine treatment in renal transplantation. Transplant Proc. 1986; 18 (Suppl):179-85

126. Kupiec-Weglinski JW, Padberg W, Uhteg LC, **Strom TB**, Diamantstein T, Tilney NL. Interleukin 2 receptor (IL-2R) targeted therapy in organ transplantation. Surg. Forum. 1986; 37:374-77.

127. Melton LB, Lakkis FG, DeLoria D, Williams JW, and **Strom TB**. Requirements for primary T cell activation. Transplant Proc. 1987; 9:331-2.

Reviews, Chapters, and Editorials:

128. Kupiec-Weglinski JW, Padberg W, Uhteg LC, Towpik E, Lord RH, Ma L, Diamantstein T, **Strom TB**, and Tilney NL. Anti-interleukin-2 receptor (IL-2R) antibody against rejection of organ grafts. Transplant Proc. 1987; 19:591-3.

129. Kelley VE, **Strom TB**. Immunosuppression by anti-interleukin-2 receptor antibody, but not anti-L3T4, requires terminal complement components. Transplant Proc. 1987; 19:617.

130. Shapiro ME, Kirkman RL, Reed MH, Puskas JD, Mazoujian G, Letvin NL, Carpenter CB, Milford EL, Waldmann TA, **Strom TB**, Schlossman SH. Monoclonal anti-IL-2 receptor antibody in primate renal transplantation. Transplant Proc. 1987; 19:594-8.

131. Milford EL, Carpenter CB, Kirkman RL, Tilney NL, Mazoujian G, **Strom TB**, Lazarus JM, Schlossman SF, Guttmann RD, Lowry R, Rocher L, Campbell, Jr. DA, Salomon DR, Pfaff WW. Anti-T12 monoclonal antibody therapy of acute renal allograft rejection. Transplant Proc. 1987; 19:1910.

132. Padberg WM, DiStefano R, Lord RH, Araneda D, **Strom TB**, Diamantstein T, Tilney NL, Kupiec-Weglinski JW. Synergy between cyclosporine and other immunosuppressive regimens in experimental organ transplantation. Transplant Proc. 1987; 19:4234-5.

133. Loertscher R, Williams JM, Guttmann RD, **Strom TB**. Modification of the mixed lymphocyte reaction by alloactivated suppressor T lymphocytes and exogenous interleukin-2. Transplant Proc. 1987; 19:3385-7.

134. Kirkman RL, Barrett LV, **Strom TB**, Kelley VE. A fish oil vehicle increases the therapeutic index of cyclosporine. Surg. Forum. 1987; 38:394-5.

135. Luke R, **Strom TB**. Chronic renal failure. In: Stein JH, (ed.) Internal Medicine, 2nd edition. Boston. Little Brown, 1987; 762-83.

136. **Strom TB**, Gaulton GN, Kelley VE, Diamantstein T, Kupiec-Weglinski JW, Tilney NL, Kirkman RL. Treatment of cardiac transplant recipients with anti-interleukin-2 receptor monoclonal antibody In: Kowai G, Abelmann WH, (eds.) Cardiomyopathy, update. Tokyo. University of Tokyo Press. 1987; 173-9.

137. Kupiec-Weglinski JW, **Strom TB** and Tilney NL. Sparing of suppressor cells by cyclosporine in allograft recipients. In: Goldstein, G, Bach J-F, Wigzell, H. (ed.) Immune Regulation by Characterized Peptides. UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 41. New York. Alan R. Liss, 1987; 153-63.

138. Strom, TB. The immunopharmacology of graft rejection. Transplant Proc. 1987; 19:128-9.

139. **Strom TB**, Hayry P, Simmons R, Strober S. Summation of immunobiology poster discussions. Transplant Proc 1987; 19:635-7.

140. Strom, TB. Toward more selective therapies to block graft rejection. Am Kidney Foundation Nephrol Letter 1987; 2:13-20.

Reviews, Chapters, and Editorials:

141. Diamantstein T, Osawa H, Kirkman RL, Shapiro ME, **Strom TB**, Tilney NL, Kupiec-Weglinski JW. Interleukin-2 receptor - a target for immunosuppressive therapy. In: Morris PJ, Tilney NL, (eds.) Transplantation Rev. Orlando. Grune and Stratton 1987; 1:177-96.

142. Murphy JR, Bishai W, Williams DP, Bacha P, Borowski M, Parker K, Boyd J, Waters C, **Strom TB**. Genetic assembly and selective toxicity of diphtheria toxin-related polypeptide hormone fusion proteins. Biochem. Soc. Symp 1987; 53:9-23.

143. Tilney NL, **Strom TB**, Kupiec-Weglinski JW. Humoral and cellular mechanisms in acute allograft injury. J Pediat. 1987; 111:1000-3.

144. Bordes-Aznar J, Tilney NL, **Strom TB**. Ciclosporina: Perspectiva en el Transplante de Organos. In: Santiago-Delpin EA, Ruiz-Speare JO, (eds.) Mexico City. Salvat Mexicana De Edicones. 1987; 181-202.

145. Abbud-Filho M, Loertscher R, Kupiec-Weglinski J, Tilney NL, **Strom TB**. In: Intern. Symp. on Immunomodulators. Mem. Inst. Oswaldo 1987; 82:95-100 (Suppl. II).

146. **Strom TB**, Kelley VE, Murphy JR, Osawa H, Tilney NL, Shapiro ME, Kupiec-Weglinski JW, Diamantstein T, Gaulton GN, Kirkman RL. Interleukin receptor directed immuno-suppressive therapy. In: Webb DR, Pierce CW, Cohen S, (eds.), Molecular Basis of Lymphokine Action Human Press, Clifton. New Jersey. 1987:pp. 371-1989.

147. Williams JM, Kelley VE, Kirkman NL, Tilney NL, Shapiro ME, Murphy JR, **Strom TB**. T cell activation antigens: therapeutic implications. In: Van Oss C, (ed.) Immunological Investigations. Marcel Dekker, Inc. New York. 1987:pp. 687-723

148. Williams DP, Bacha P, Waters C, Bishai W, Parker K, **Strom TB**, Murphy JR. Interleukin-2 receptor targeted toxicity: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. In:Fehrenbach et al (Eds). The Bacterial Protein Toxins. Stuttgart:Gustav Fischer Verlag. 1987; 401-10.

149. Snydman DR, Werner BG, Tilney NL, Kirkman RL, Milford EL, Ch SI, Bush HL Jr. Levey AS, **Strom TB**, Carpenter CB, Berardi VP, Levey RH, Harmon WE, Zimmerman CE, Tenny A, Heinze-Lacey B, Shapiro ME, Steinman T, LoGerfo F, Idelson B, McIver J, Leszcyznski J, Grady GF. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: Interim comparison of randomized and an open label. Transplant Proc. 1988; 20(Suppl 8):24-30.

150. Reed MN, Shapiro ME, **Strom TB**, Milford EL, Carpenter CB, Letvin NL, Waldmann TA, Kirkman Rl. Prolongation of primate renal allografts with anti-Tac monoclonal antibody. Curr Surg. 1988; 45:28-30

151. **Strom TB**, Kelley VE, Murphy JR, Osawa H, Tilney NL, Shapiro ME, Kupiec-Weglinski JW, Diamantstein T, Gaulton GN, Kirkman RL. Interleukin-2 receptor directed

immunosuppressive therapy. In: Smith, K. (ed.), A Volume of Lymphokines, Orlando, Academic Press, Inc. 1988; 223-36.

152. Williams JM, **Strom TB**. De novo expression of receptors upon T-cells. In: Bray MA, Morley J, (eds.) Vol. 85. Handbook of Experimental Pharmacology; The Pharmacology of Lymphocytes. Springer Verlag. 1988; 37-48.

Reviews, Chapters, and Editorials:

153. Kupiec-Weglinski JW, **Strom TB**, Tilney NL. Interleukin-2 receptor targeted therapy - a new approach to combat allograft rejection. Nefrologia 1988; 8:303-10.

154. Tilney NL, **Strom TB**. Chemical manipulation of the immune response. In: Cerilli R, (ed.) Clinical Transplantation. St. Louis. CV Mosby, 1988; 118-36.

155. **Strom TB**, Tilney NL. Immunobiology and Immunopharmacology of Graft Rejection. In: Schrier RW, Gottschalk CW, (eds.) Diseases of the Kidney, 4th edition. Boston. Little Brown 1988; 177-3210.

156. **Strom TB**, Kelley VE, Murphy JR, Osawa H, Tilney NL, Shapiro ME, Kupiec-Weglinski JW, Diamantstein T, Gaulton GN, Kirkman RL. Interleukin-2 receptor directed immunosuppressive therapy. In: Webb DR, Pierce CW, Cohen S (eds). Molecular Basis of Lymphokine Action, Humana Press, New Jersey, 1988; 371-1989.

157. Reed MH, Shapiro ME, **Strom TB**, Milford EL, Carpenter CB, Letvin NL, Waldmann TA, Kirkman RL. Prolongation of primate renal allografts with anti-Tac monoclonal antibody. Curr Surg. 1988; 45:28-30.

158. Murphy JR, Kelley VE, **Strom TB**: IL-2-toxin:A step toward selective immunomodulation. Am J Kidney Dis. 1988; 11:159-62.

159. **Strom TB**. Today's biotechnology and tomorrow's anti-rejection therapy. Am J Kid Dis. 1988; 11:163-5.

160. Leichtman AB, Goldszer RC, **Strom TB**, Tilney NL. Acute renal failure associated with renal transplantation. In: Acute Renal Failure, 2nd ed. Brenner BM, Lazarus JM (eds.) Churchill Livingstone. New York. 1988; 659-73.

161. **Strom TB**, Murphy JR, Williams DP, Kelley VE. IL-2 toxin: A trojan horse strategy for controlling rejection. In: Lipsky PE, **Strom TB**, (eds.) Immunol. and Allergy Clin N Am. Therapeutic Advances in Clinical Immunology. Vol. 8, #1. Philadelphia. WB Saunders Co. 1988; 69-78.

162. Burdick JF, **Strom TB**. Immunosuppression in Transplantation. The Biology and Therapeutic Modalities. In: Belzer FO (ed.), Transplant Surgical Resource Series Vol. 2. Parsippany, New Jersey. Pro/Com, 1988; 1-32.

163. **Strom TB**. The cellular and molecular basis of allograft rejection: what do we know? Transplant Proc. 1988; 20:143-6.

Reviews, Chapters, and Editorials:

164. Kupiec-Weglinski JW, Hahn HJ, Kirkman RL, Volk HD, Mouzaki A, DiStefano R, Tellides G, Dallman M, Morris PJ, **Strom TB**, Tilney NL, and Diamantstein T. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin-2 receptor monoclonal antibody therapy. Transplant Proc. 1988; 20 (Suppl. 2):207-16.

165. Diamantstein T, Tilney NL, **Strom TB**, van der Meide, Hahn HJ, Volk H-D, Weetman AP, Kupiec-Weglinski JW. Interleukin-2 receptor targeted immunosuppressive therapy with anti-interleukin receptor monoclonal antibodies directed against the L- chain of the interleukin-2 receptor. Studies on selectivity and mode of action. In: Hadden JW (ed) Advances in Immunol. Pharmacology 4. Oxford. Pergamon Press. 1988

166. **Strom TB**, Murphy JR, Kelley VE. A trojan horse strategy for controlling rejection. In: Davison AM (ed.) Proceed. 10th Internat. Cong. Nephrology. London Bailliere Tindal. 1988; 1293-99.

167. **Strom TB**. Interstitial nephritis: A universal feature of allo-immunity post-kidney transplantation. In: Davison AM (ed) Proceed. 10th Internat. Cong. Nephrology. London Bailliere Tindal. 1988; 614-17.

168. Leichtman AB, **Strom TB**. Therapeutic approach to renal transplantation: Lichtenstein LM, Fauci AS, eds. Current therapy in allergy and rheumatology-3. Philadelphia. BC Decker Inc. 1988; 339-43.

169. Tilney NL, **Strom TB**, Kupiec-Weglinski JW. Pharmacological and immunological agonists and antagonists of cyclosporine. Transplant Proc. 1988; 20:(Suppl 3) 13-22.

170. Tilney NL, Padberg WM, Lord RH, Araneda D, **Strom TB**, Kupiec-Weglinski JW. Synergy between subtherapeutic doses of cyclosporine and immunobiological manipulations in rat heart graft recipients. Transplantation. 1988; 46 (Suppl):1225-85.

171. Shapiro ME, Kirkman RL, Murphy JR, Osawa H, Tilney NL, Kupiec-Weglinski JW, Diamantstein T, Gaulton GN, **Strom TB**. The interleukin-2 receptor as a target for immunosuppressive therapy. Transplantation Proc. 1988.

172. Kelley VE, Pankewycz O, Murphy JR, **Strom TB**. Targeting chimeric interleukin-2 toxin to its receptor blocks delayed type hypersensitivity. In: Lipsky PF, **Strom TB** (eds) Therapeutic Advances in Clinical Immunology and Allergy Clinics N. Am 1988; 8:129-130.

173. Leichtman AB, **Strom TB**. Therapeutic approach to renal transplantation: triple therapy and beyond. Transplant Proc. 1988; 20(Suppl 8) 1-6.

174. Williams DP, Bacha P, Kelley V, **Strom TB**, Murphy JR. Adenosine diphosphate ribosylation of elongation factor - 2 as a therapeutic target: genetic construction and selective action of a diphtheria-toxin related interleukin-2 fusion protein. In: ADP-ribose Transfer, Reactions: Mechanisms and Biological Significance. Jacobson MK, Jacobson EL (eds). Springer-Verlag, Heidelberg 1988; 478-1986.

Reviews, Chapters, and Editorials:

175. Kupiec-Weglinski JW, **Strom TB**, Diamantstein T, and Tilney NL. Interleukin-2 receptor targeted therapy. A new approach to combat allograft rejection. Nefrologia. 1988; VIII:303-10.

176. **Strom TB**: Case records of the Massachusetts General Hospital. Cyclosporine toxicity, with tubular and vascular lesions, after pancreatic and renal transplants in patient with juvenile-onset diabetes mellitus. N Eng J Med.1988; 318:31-40.

177. Kirkman RL, Shapiro ME, Carpenter CB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, **Strom TB**. Early experience with anti-Tac in clinical renal transplantation. Transplant Proc. 1989; 21:1766-8.

178. Mackie JD, Pankewycz OG, Hassarjian R, Murphy JR, Kelley VE, **Strom TB**. Immunotherapy using interleukin-2 diphtheria toxin chimer prolongs murine allografts. Transplant Proc. 1989; 21:2718-9.

179. Barrett LV, Murphy JR, **Strom TB**, Kirkman RL. Treatment with a diphtheria toxin-related interleukin-2 fusion protein prolongs cardiac allograft survival in mice. Transplant Proc. 1989; 21:1130-1.

180. Zanker B, Walz G, Wieder KJ, Moscovitch-Lopatin M, Smith BR, **Strom TB**. Verapamil selectively inhibits expression of interleukin-2 messenger RNA in mitogen activated mononuclear blood cells. Transplant Proc. 1989; 21:85-7.

181. Kelley VE, Mackie J, **Strom TB**. Cyclosporin A plus fish oil; accentuate the positive, eliminate the negative. Transpl Proc. 1989; 21:848-9.

182. Reed MH, Shapiro ME, **Strom TB**, Carpenter CB, Letvin NL, Reimann K, Weinberg DS, Waldmann TA, Kirkman RL. Anti-TAC MOAB prolongs renal allografts in cynomolgus monkeys. Transplant Proc. 1989; 21:1028-30.

183. Leichtman A, **Strom TB**. Allograft rejection. In: Massry SG, Glassock RJ, eds. Textbook of Nephrology, 2nd edition. Baltimore. Williams and Wilkins. 1989; 1499-1501.

184. **Strom TB**, Kelley VE. Toward more selective therapies to block autoimmunity. In: Eisenbarth G. Type 1 Immunotherapy of Diabetes and Selected Autoimmune Diseases. Boca Raton. CRC Press Inc 1989; 197-211.

185. **Strom TB**, Kelley VE. Toward more selective therapies to block undesired immune responses. Kidney Intl. 1989; 35:1026-33.

186. **Strom TB**, Murphy JR, Kelley VE. A Trojan horse strategy for controlling unwanted immunologic activity. In: Kaplan JG, Green DR, Bleackley CR. Cellular Basis of Immune Modulation. Alan R. Liss, New York. 1989; 537-46.

187. Pankewycz O, **Strom TB**, Kelley VE. Therapeutic strategies using monoclonal antibodies in autoimmune disease. Curr Opin Immunol. 1989; 1:757-63.

188. **Strom TB**. Immunosuppression in tissue and organ transplantation. L. Brent and R. Sells (eds) In: Balliere's Clinical Immunology and Allergy: International Practice and Research, Balliere Tindall, England. 1989; 39-56.

Reviews, Chapters, and Editorials:

189. Diamantstein T, Tilney NL, **Strom TB**, Van der Meide HP, Hahn HJ, Volk H-D, Weetman AP, Kupiec-Weglinski JW. Interleukin-2 receptor targeted immunosuppressive therapy with anti-interleukin-2 receptor monoclonal antibodies directed against the L-chain of the interleukin-2 receptor: Studies on selectivity and mode of action. In: Advances in Immunopharmacology. Pergamon Press. Hadden JW, Spreafico F, Yamamura Y, Austen KF, Dukor P, Masek K (eds) 1989; 4:95-104.

190. Diamantstein T, Kupiec-Weglinski JW, **Strom TB**, Tilney NL. Current stage of interleukin-2 receptor targeted therapy. Exp Clin Endocrinol 1989:93:114-24.

191. **Strom TB**, Colvin RB. Fever and changes in renal function after kidney and pancreas transplant in a 22-year-old diabetic woman (clinical conference) Medicina (Firenze) 1989:9:83-92 (Published in Italian).

192. Melton LB, **Strom TB**. Renal transplantation. In: Klahr S, Massry S, (eds.) Contemporary Nephrology, Vol. 5. New York. Plenum 1989; 489-504.

193. Carpenter CB, **Strom TB**. Immunogenetics of renal transplantation. In: Milford EL, Brenner BM, Stein JH (eds.) Renal Trans plantation. Churchill Livingston. NY, 1989; 1-20.

194. Waters CA, **Strom TB**, Murphy JR, Kelley VE, Kirkman RL. Targeting the IL-2 receptor with IL-2 toxin: a novel immunotherapeutic. In: Lymphokine receptor interaction. Fradelizi D, Bertoglio J (eds) John Libbe Eurotext Ltd. 1989; 163-70.

195. Kelley VE, Bastos M, Bennett W, **Strom TB**. Fish oil: Protects from cyclosporine induced nephrotoxicity and causes immunosuppression. In: Colloque Inserm Proc. Intl. Symp. Biomembranes and Nutrition. Leger CL, Bereziat G (eds). 1989; Vol. 195, 453-60.

196. Shapiro ME, Reed MH, **Strom TB**, Carpenter CB, Milford EL, Kirkman RL. The role of a primate model of renal transplantation in the development of new monoclonal antibodies. Amer J Kidney Dis 1989; 14:58-60.

197. Nichols JC, Genbauffe F, Waters C, Bacha P, O'Loughin J, Estis L, Woodworth T, Kiyokawa T, Takatsuki K, **Strom TB**, Murphy JR. Development of IL-2 toxin (DAB486-IL-2) for human clinical trials in IL-2 receptor positive malignancies. In: Rappuoli R, Alouf J, Fehrenbach, F, Freer J (eds) Bacterial Protein Toxins, Vol. 4, Gustav Fisher, Stuttgart, New York. 1989.

198. Kelley VE, Murphy JR, **Strom TB**. Therapeutic strategies that target the interleukin-2 receptor. In: Goetzl E (ed) Proc UCLA Conf. Molecular and cellular mechanisms of human hypersensitivity and anti-immunity. Alan R. Liss Inc. New York. 1989; 105:173-76.

199. Zanker B, Walz G, **Strom TB**. Expression von aktivierungsgenen in T-zellen und deren inhibition durch cyclosporin A und Verapamil. Nieren - und Hochdruckkrankheiten Jahrgang 18, Nr. 1989 S 269-71.

Reviews, Chapters, and Editorials:

200. Zanker B, **Strom TB**. Immunologie und Immunsuppressive Therapie der Nieren-transplantation. In:Blutreinigungsverfahren Technik und Klinik. Hans Eduard 0 Franz (ed) Georg Thieme Verlag Stuttgart. New York. 1990; 412-26.

201. Murphy JR and **Strom TB**. Diphtheria toxin-peptide hormone fusion proteins: Protein engineering and selective action of a new class of recombinant biological response modifiers. In: ADP-ribosylating toxins and G proteins: Insights into signal transduction. J. Moss and M. Vaughan, (eds.) American Society for Microbiology, Washington. 1990; 141-59.

202. **Strom, TB**. Immunosuppressive treatments that thwart transplant rejection. In: Clinical Aspects of Autoimmunity. 1990; 4:8-19.

203. O'Connell PJ, and **Strom, TB**. Prevention of renal allograft rejection. In: Current Therapy in Nephrology and Hypertension (RJ Glassock ed) 1990.

204. Williams DP, Snider CE, **Strom TB**, Murphy JR. Structure function analysis of interleukin 2-toxin:Fragment B requirements for the translocation of fragment A into the cytosol of target cells. In: Current Research in Protein Chemistry, J Villafranca (ed) Academic Press, 1990; 265:11885-9.

205. Almawi WY, Sewell KL, Hadro ET, Zanker B, **Strom TB**. Mode of action of the glucocorticosteroids as immunosuppressive agents. Oppenheim JJ, Powanda MG, Kluger MJ, Dinarello CA (eds) Wiley Liss, Inc. In: Molecular and Cellular Biology of Cytokines 1990; 321-26.

206. Luke RG, **Strom TB**. Chronic Renal Failure. In: Internal Medicine. Stein JH (Ed) Little, Brown and Co. Boston, MA 3rd Edition. 1990; 801-21.

207. **Strom TB**, Anderson PL, Rubin-Kelley VE, Williams DP, Kiyokawa T, Murphy JR. Immunotoxins and cytokine toxin fusion proteins. Seminars in Immun 1990; 2:467-79.

208. Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, **Strom TB**. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation. 1991; 23:107-13.

209. Kiyokawa T, Williams DP, Snider CE, **Strom TB**, Murphy JR. Protein engineering of DAB-IL-2 fusion toxins to increase biologic potency. Prot Engineer. 1991; 4:463-8.

210. Moscovitch-Lopatin M, Petrillo RJ, Pankewycz OG, Hadro E, Bleackley CR, **Strom TB**. Wieder KJ. Interleukin-2 counteracts the inhibition of cytotoxic T lymphocytes by cholera toxin in vitro and in vivo. Eur J Immunol. 1991; 21:1439-4.

211. Walz G, Stevens AC, Zanker B, Melton LB, Clark SC, Suthanthiran M, **Strom TB**: The role of interleukin-6 in mitogenic T-cell activation, detection of interleukin-2 heteronuclear RNA by polymerase chain reaction. Cell Immunol. 1991; 134:511-19.

212. Finberg RW, Wahl SM, Allen JB, Soman G, **Strom TB**, Murphy JR, Nichols JC. Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science. 1991; 252:1703-5.

Reviews, Chapters, and Editorials:

213. Almawi WY, Hadro ET, **Strom TB**. Evidence that glucorticosteroid-mediated immunosuppressive effect does not involve altering second messenger function. Transplantation. 1991; 52:133-40.

214. Remillard B, Petrillo R, Maslinski W, Tsudo M, **Strom TB**, Cantley L, Varticovski L. Interleuken-2- receptor regulates activation of phosphatidylinositol 3-kinase. J Biol Chem. 1991; 266:14167-70

215. Lakkis F, Steele A, Pacheco-Silva A, Rubin-Kelley V, **Strom TB**, Murphy JR. Interleukin-4 receptor targeted cytotoxicity: genetic construction, and in vivo immunosuppressive effects of diphtheria toxin-related murine interleukin-4 fusion toxins. Eur J Immunol. 1991; 21:2253-8.

216. Kunzendorf U, Walz G, Brockmoeller J, Neumayer HH, Jochimsen F, Roots I, Offermann G, **Strom TB**. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation. 1991; 52:280-4.

217. **Strom TB** and Carpenter CB. Immunobiology of Kidney Transplantation In: The Kidney: Management of the Patient with Renal Failure. Vol. II. 4th edition. Brenner BM, Rector FC Jr. (eds) Saunders, Philadelphia, PA. 1991; 2336-2360.

218. Kohler H, Zanker B, **Strom TB**. Immunbiologie der Transplantatabstossung und deren Pharmakologische Beeinflussung. (The immunobiology of transplant rejection and its pharmacological modification.) Dtsch Med Wochenschr. 1991; 116:264-9.

219. Murphy JR and **Strom TB**. Receptor-specific intoxication of tumor cells: Design, construction and properties of microbial toxin: Growth factor fusion proteins. In: Molecular Mechanisms and Their Clinical Application in Malignancies. Bergsagel DE (ed) Academic Press New York, NY. 1991; Vol. 12:85-107.

220. Waters CA, Snider CE, Itoh K, Poisson L, **Strom TB**, Murphy JR, Nichols JC. DAB486-IL-2 (IL-2 toxin) selectively inactivates high affinity IL-2 receptor bearing human PBMCs. In: Richard L. Edelson, (ed.) Annals NY Acad Sciences. 1991; Vol. 636:403-5.

221. Kupiec-Weglinski JW, **Strom TB**. IL-2R-targeted immunosuppressive therapy in organ transplantation. Drug News and Perspectives 1991; 4:601-7.

222. Snydman DR, Werner BG, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL Jr. Levey AS, **Strom TB**, Carpenter CB, Berardi VP, Levey RH, Harmon WE, Zimmerman CE, Katz A, Lacey Heinze B, Shapiro ME, Steinman T, LoGerfo F, Idelson B, McIver J, Leszczynski J, Griffith J, Grady GF. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: comparison of the randomized and open label trials. Transplant Proc. 1991; 23:1357-60.

223. O'Connell PJ, Pacheco-Silva A, Bastos M, Xu HW, Pankewycz O, Rubin-Kelley VE, **Strom TB**. Sequential analysis by polymerase chain reaction of mononuclear leukocyte activation-associated transcription in pancreatic islet cell allograft rejection. Transplant Proc. 1991; 23:811-2.

Reviews, Chapters, and Editorials:

224. Barth C, O'Connell P, Zanker B, **Strom TB**. Interleukin-7 (IL-7) and its effect on the expression of the intercellular adhesion molecule (ICAM-1) in T-cells. Transplant Proc. 1991; 23:824-5.

225. Papp I, Sablinski T, Wieder KJ, O'Connell PJ, Milford EL, **Strom TB** Kupiec-Weglinski JW. The differential effects of CD4 mAb therapy on intragraft expression of IL-2 and IL-4 genes. American College of Surgeons. 1991. Surgical Forum XLII:380-83.

226. Kim D, Porter DH, Siegel JB, Shapiro ME, **Strom TB**, Glotzer DJ: Use of a reperfusion catheter after angioplasty dissection for salvage of ischemic renal allograft: Case report. Cardiovasc Intervent Radiol. 1991; 14:179-1982.

227. **Strom TB**: Immunologic testing for clinical transplantation. In: N Rose, E Conway de Macrio, JL Fahey, H Friedman, GM Penn (eds.), Manual of Clinical Laboratory Immunology, 4th edition Amer Soc for Microbiol. Washington, DC. 1992; 954-59.

228. Schmidbauer G, Wieder KJ, Corpier CL, Wieder I, Sablinski T, **Strom TB**, Kupiec-Weglinski J. Transcription of interleukin-8-like and cytotoxic T cell specific serine esterase genes in allograft recipients is prevented by rapamycin treatment. Amer Coll of Surgeons Forum. 1992; Vol. XLIII, 416-19.

229. **Strom TB**: Graft rejection and immunosuppression in kidney transplantation. In: Cameron S, Davison AM, Grunfeld JP, Kerr D, Ritz E (eds). Oxford Textbook of Clinical Nephrology, Oxford Med. Publs, Oxford, England 1992; Vol. 2, 1551-9.

230. Shapiro ME, Kirkman RL, Kelley VR, Bacha P, Nichols JC, **Strom TB**. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents. In: Frankel AE (ed) Genetically Engineered Toxins. Marcel Dekker, Inc. New York. 1992; 383-93.

231. **Strom TB**, Tilney NL. Immunobiology and immunopharmacology of graft rejection. In: Schrier, Gottschalk (eds). Diseases of the Kidney, Little, Brown and Co. Boston. 1992, pp. 2879-2910.

232. **Strom TB**, Rubin-Kelley V, Woodworth TG, Murphy JR. Interleukin-2 receptor-directed immunosuppressive therapies: Antibody- or cytokine-based targeting molecules. In: Moller G (ed) Immunological Reviews, Munksgaard, Copenhagen, Denmark. 1992, 131-63.

233. Murphy JR, Lakkis FG, vanderSpek JC, Anderson P, **Strom TB**. Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease. Targeted Diagn Ther 1992; 7:365-1982.

234. **Strom TB**. Molecular immunology and immunopharmacology of allograft rejection. Kidney Int. Suppl. 1992; 38:S182-87.

235. **Strom TB**, Kelley VR, Woodworth TG, Murphy JR. IL-2 receptor-directed immunosuppressive therapies: antibody or cytokine-based targeting molecules. Immunol Rev. 1992:129:131-63.

Reviews, Chapters, and Editorials:

236. **Strom TB**. New tactics to curb diabetes causing autoimmunity. Donald Jewler (ed) In: Diabetes Spectrum, Alexandria, Virginia. 1992.

237. **Strom TB**, Rubin Kelley V, Woodworth TG, Murphy JR. Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules. In: Bach JR (ed) T-Cell Directed Immunointervention, Blackwell Scientific Pub, Oxford, England. 1993, . 221-56.

238. **Strom TB**, Rubin Kelley V, Murphy JR, Nichols J, Woodworth TG. IL-2R-directed therapies: Antibody- or cytokine-based targeting molecules. In: Creger WP (ed) Annu Rev. Med. Palo Alto, CA. 1993; 44:343-53.

239. **Strom TB**: Summation of the biologic aspects of the congress. Transplant Proc 1993; 25:1284-6.

240. **Strom TB**: Graft rejection and immunosuppression in kidney transplantation. In: Lachmann et al. (eds) Clinical Aspects of Immunology 5e, Blackwell Scientific Pub. Ltd. Oxford, England 1993; Vol. 2, 851-74.

241. O'Connell PJ, Corpier CL, Steele AW, **Strom TB**. Monoclonal antibody therapy in renal transplantation. Thompson AW, Catto GRD, (eds) In: Immunology of Renal Transplantation Edw. Arnold, Mill Road, Kent England 1993; pp 281-302.

242. **Strom TB**, Kelley VR, JR Murphy, Nichols J, Woodworth TG. Therapeutiques dirigees contre le recepteur de l'interleukin 2:utilisation des anticorps ou des cytokines. Flammarion Medicine-sciences - Actualities Nephrologiques Jean Hamburger (ed) Paris, France. 1993; 279-1988.

243. Nickerson P, Pacheco-Silva A, O'Connell PJ, Steurer W, Kelley VR, **Strom TB**. Analysis of cytokine transcripts in pancreatic islet cell allografts during rejection and tolerance induction. Transplant Proc. 1993; 25:984-5.

244. Maslinski W, Remillard B, Tsudo M, **Strom TB**. Interleukin-2 receptor signal transduction: translocation of active serine-threonine kinase Raf-1 from IL-2 receptor into cytosol depends on IL-2-induced tyrosine kinase activation. Transplant Proc. 1993; 25:109-10.

245. Zanker B, Marx S, **Strom TB**, Kohler H. The immunosuppressive effects of verapamil upon mitogen activated and allo-antigen inducible human cytotoxic T-lymphocytes. Intl J Immunopharmacol. 1994; 16:507-17.

246. Suthanthiran M, **Strom TB**. Renal transplantation. N Eng J Med.1994:331:365-76.

247. Suthanthiran M, **Strom TB**. Immunobiology of organ transplantation. In: Tejani AH, Fine RN, (eds) Pediatric Renal Transplantation, Wiley-Liss, Inc. New York, NY. 1994; 7-16.

248. **Strom TB**, Murphy JR, Woodworth TG, Kelley VR, Nichols J. IL-2 Receptor directed therapies: Antibody or cytokine based targeting molecules. In: Kupiec-Weglinski JW, Daniel F, Grosch S (ed) New Immunosuppressive Modalities and Anti-rejection Approaches in Organ Transplantation. Landes RG Co. Austin, Texas 1994; 125-33.

Reviews, Chapters, and Editorials:

249. **Strom TB**, Kelley VR, Murphy JR, Nichols J, Woodworth TG. Interleukin-2 receptor-directed therapies: antibody- or cytokine-based targeting molecules. Adv Nephrol Necker Hosp 1994; 23:347-56.

250. Hricik DE, Almawi WY, **Strom TB**. Trends in the use of glucocorticoids in renal transplantation. In: Transplantation. 1994; 57:979-1989.

251. Kupiec-Weglinski JW and **Strom TB**. Novel immunosuppressive approaches in organ transplantation. In: Immunology of Corneal Transplantation. Zierhut M, Pleyer U, Thiel HJ (Eds) Aeolus Press. The Netherlands. 1994; 213-31.

252. **Strom TB**, Waldmann H. Transplantation, Editorial overview. In: Current Biology Ltd. (ed) Current Opinion in Immunology 1994; 6:755-756.

253. Nickerson P, Steurer W, Steiger J, Zheng XX, Steele AW, **Strom TB**. Cytokines and the Th1/Th2 paradigm in transplantation. Current Biology Ltd. (ed.) Current Opinion in Immunology 1994; 6:757-64.

254. Suthanthiran M, **Strom TB**. Immunology and genetics of transplantation. In: Textbook of Nephrology. Massry SG, Glassock RJ (eds). 1994; 85:1629-37.

255. **Strom TB**, Steele AW, Nichols J. Genetically engineered proteins for immunoregulation. Transplantation Proc. 1995; 27(Suppl 1):18-20.

256. Kelley VR, **Strom TB**. A paradigm 1994: the allograft response. Blood Purif. 1995; 13:199-205.

257. Suthanthiran M, **Strom TB**. Immunobiology and immunopharmacology of organ allograft rejection. J Clin Immunol. 1995; 15:161-71.

258. Wasowska B, Wieder KJ, Hancock WW, Berse B, Binder J, **Strom TB**, Kupiec-Weglinski JW. Cytokine and alloantibody networks in long-term cardiac allografts in rapamycin treated sensitized rat recipients. Transplant Proc. 1995; 27:423-426.

259. Shapiro ME, Abrams JM, Brown RS, Steinman TI, **Strom TB**. Successful pancreas-renal transplantation without anti-T-cell antibody induction. Transplant Proc. 1995; 27:3087-1988.

Reviews, Chapters, and Editorials:

260. **Strom TB**, Suthanthiran M. Therapeutic approach to organ transplantation. In: Therapeutic Immunology. Austen KF, Burakoff SJ, Rosen FS, **Strom TB** (eds). Blackwell Scientific. Cambridge, MA. 1996; 451-56.

261. Suthanthiran M, **Strom TB**. Renal Transplantation. In: Therapeutic Immunology. Austen KF, Burakoff SJ, Rosen FS, **Strom TB** (eds) Blackwell Scientific. Cambridge, MA. 1996; 457-64.

262. Suthanthiran M, **Strom TB**. Human renal allograft rejection: immune mechanisms molecular correlates and treatment strategies. Nephrology (Australia). 1996; 2:1-12.

263. Nickerson, P, Zheng XX, Steiger J, Steele, AW, Steiger J, Roy-Chaudhury P, Muller W, **Strom TB**. Tolerance prolongee d'allo-greffe d'ilots pancreatiques en l'absence d'expression d'IL-4. In: Actualites Nephrologiques Jean Hamburger Hopital Necker 1996. (Funck-Brentano JL, Bach JF, Kreis H, Grunfeld JP, eds) Flammarion Medicine-Sciences, Paris, France. 1996; 215-24.

264. Tilney NL, **Strom TB**. (Chapter 46) Acute rejection. In: Transplantation Biology: Cellular and molecular aspects. Tilney NL, **Strom TB**, Paul L (eds) Lippincott-Raven Pubs. New York, NY. 1996; 557-65.

265. **Strom TB**, Nichols J, Steele AW (Chapter 55) Immunoglobulin and cytokine based fusion proteins for therapy. In: Transplantation Biology: Cellular and molecular aspects. Tilney NL, **Strom TB**, Paul L (eds) Lippincott-Raven Pubs. New York, NY. 1996; 673-78.

266. Nickerson P, Steiger J, Zheng XX, Steele AW, Steurer W, Roy-Chaudhury P, **Strom TB**. (Chapter 35) Cytokine networks in transplantation. In: Transplantation Biology: Cellular and molecular aspects. Tilney NL, **Strom TB**, Paul L (eds) Lippincott-Raven Pubs. New York, NY. 1996; 391-401.

267. **Strom TB**, Nichols J. Cytokine toxin fusion proteins. In: (Chapter 31) Therapeutic Immunology. Austen KF, Burakoff SJ, Rosen FS, **Strom TB** (eds) Blackwell Scientific. 1996; 398-405.

268. Strehlau J, Pavlakis M, Lipman M, Maslinski W, Shapiro M, **Strom TB**. The intragraft gene activation of markers reflecting T-cell activation and cytotoxicity analyzed by quantitative RT-PCR in renal transplantation. Clin Nephrol. 1996; 46:30-33.

269. **Strom TB**, Suthanthiran M. Treatment of organ transplant recipients. In: Current Therapy in Allergy, Immunology and Rheumatology (Lichtenstein LM, Fauci AS eds) Mosby Year Book Inc. Philadelphia, PA 1996; 111-15.

270. Suthanthiran M, Morris RE, and **Strom TB**. Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis. 1996; 28:159-72.

271. **Strom TB** and Suthanthiran M. Therapeutic approach to organ transplantation. Nephrol Dial Transplant. 1996; 11:1176-81.

272. **Strom TB**, Roy-Chaudhury P, Manfro R, Zheng XX, Nickerson PW, Wood K, Bushell A. The Th1/Th2 paradigm and the allograft response. Curr Opin in Immunol. 1996; 8:688-93.

Reviews, Chapters, and Editorials:

273. **Strom TB**, Suthanthiran M. Immunobiology and immunopharmacology of lung transplantation. New Insights into Cystic Fibrosis. SynerMed. Califon, NJ. 1996; 4:1-6.

274. **Strom TB** and Suthanthiran M. Immunobiology and immunopharmacology of graft rejection. (Chapter 96) In: Diseases of the Kidney 6th ed (RW Schrier and Gottschalk CW eds) Little, Brown and Co. Boston, MA. 1996; 1:2701-12.

275. Suthanthiran M, Morris RE, and **Strom TB**. Immunosuppressants: Cellular and molecular mechanisms of action. Am J Kidney Dis. 1996; 28:159-172.

276. Pavlakis M, Lipman M, **Strom TB**. Intragraft expression of T-cell activation genes in human renal allograft rejection. Kid Intl Suppl 1996; 53:S7-S12.

277. **Strom TB**, Roy-Chaudhury P, Manfro R, Zheng XX, Nickerson PW, Wood K, Bushell A. The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol. 1996; 8:688-93.

278. Pavlakis M, Strehlau J, Lipman M, **Strom TB**. Use of intragraft gene expression in the diagnosis of kidney allograft rejection. Transplant Proc 1996; 28:2019-21.

279. Tilney NL, **Strom TB**, Paul LC. Transplantation biology: cellular and molecular aspects. Monograph: Philadelphia. Lippincott-Raven, 1996.

280. Roy-Chaudhury P, Manfro RC, Steiger J, Nickerson PW, Tian Y, Zheng XX, Li YS, **Strom TB**. IL-2 and IL-4 double knock-out mice reject islet allografts: a role for novel T-cell growth factors? Transplant Proc. 1997; 29:1083-1984.

281. Wasowska B, Hancock WW, Onodera K, Korom S, Stadlbauer TH, Zheng XX, **Strom TB**, Kupiec-Weglinski JW. Rapamycin and cyclosporine-A treatment: A novel regimen to prevent chronic allograft rejection in sensitized hosts. Transplantation Proc. 1997; 29:333

282. Manfro RC, Roy-Chaudhury P, Zheng XX, Steiger J, Nickerson PW, Li Y, Maslinski W, **Strom TB**. Interleukin-15 gene transcripts are present in rejecting islet allografts. Transplant Proc. 1997; 29:1077-78.

283. Nickerson P, Zheng XX, Steiger J, Steele AW, Steurer W, Roy-Chaudhury P, Muller W, **Strom TB**. Prolonged islet allograft acceptance in the absence of expression of Interleukin-4. In: Advances in Nephrology. (Nephrol Necker Hosp) Mosby Year Book, Inc. Chicago, IL. Vol. 26 1997; 26:171-80.

284. Nickerson P, Steiger J, Zheng XX, Steele AW, Steurer W, Roy-Chaudhury P, **Strom TB**. Manipulation of cytokine networks in transplantation: False hope or realistic opportunity for tolerance? Transplantation. 1997; 63:489-94.

285. Suthanthiran M, Garovoy MR, **Strom TB**. Immunological characterization of solid organ graft recipients. (Chapter 142) In: Manual of Clinical Laboratory Immunology. Rose NR, Conway deMacraio E, Folds JD, Lane C, Nakamura RM, Leffell MS (eds). ASM Press, Washington, DC. 1997; 1117-22.

Reviews, Chapters, and Editorials:

286. Kim YS, Li XC, Maslinski W, Zheng XX, Roy-Chaudhury P, Pavlakis M, Strehlau J, **Strom TB**. The role of novel T-cell growth factors in rejection. Curr Opin in Organ Transplant. 1997; 2:13-17.

287. Suthanthiran M, **Strom TB**. Immunoregulatory drugs: Mechanistic basis for use in organ transplantation. Pediatric Nephrol. 1997; 11:651-57.

288. Suthanthiran M, **Strom TB**. Mechanisms and management of acute renal allograft rejection. Surg Clin North Am. 1998 78:77-94.

289. Suthanthiran M, Morris RE, and **Strom TB**. Transplantation Immunobiology. (Chapter 13) In: Campbell's Urology, 7th ed. Walsh PC, Vaughan Jr. ED, Retik AB and Weiss AJ (eds). W. B. Saunders Co. Philadelphia, PA Vol. 1. 1998; pp 491-95.

290. **Strom TB**, Ettenger RB. Investigational Immunosuppressants: Biologics The ASTP Primer on Transplantation (Chapter 14), Slack, Inc. Publisher, Suki WN, Norman DJ, Turka LA (eds), Thorofare, NJ; 1998; 113-22.

291. Schachter AD, Vasconcellos L, Ophascharoensuk V, Zheng XX, Strehlau J, **Strom TB**. CTL effector mechanisms: diagnostic applications. Transplant Proc. 1998; 30:2344-46.

292. Schachter AD, **Strom TB**. Molecular diagnostic techniques for the diagnosis and prevention of incipient and established chronic rejection. Graft. 1998; 1:29-33.

293. Sharma VK, Ding R, Li B, Bologa RM, Lagman M, Eduafo A, Edouard P, Mouradian J, **Strom TB** Suthanthiran M. Molecular correlates of human renal allograft rejection. Transplant Proc. 1998; 30:2364-66.

294. Ding R, Li B, Sharma VK, Bologa RM, Lagman M, Mouradian J, **Strom TB**, Suthanthiran M. Quantitative competitive polymerase chain reaction: Design and synthesis of mRNA-specific competitor DNA templates and their clinical usage. Transplant Proc. 1998; 30:2370-72.

295. Kim YS, Maslinski W, Zheng XX, Schachter AS, **Strom TB**. Immunoglobulin-cytokine fusion molecules; the new generation of immunomodulating agents. Transplant Proc. 1998; 30:4031-36.

296. Strehlau J, Maslinski W, Chae D, Pavlakis M, Ehrich JH, **Strom TB**. Adjusting immunosuppression to the identification of T-cell activating mediators in rejecting transplants: a novel approach to rejection diagnoses and treatment. Transplant Proc. 1998; 30:2389-91.

297. Kim YS, Maslinski W, Zheng XX, Schachter AD, **Strom TB**. Immunoglobulin-cytokine fusion molecules: the new generation of immunomodulating agents. Transplant Proc. 1998; 30:4031-6.

298. Strehlau J, Maslinski W, Chae D, Pavlakis M, Ehrich JHH, **Strom TB**. Adjusting immuno-suppression to the identification of T-cell activating mediators in rejecting transplants: a novel approach to rejection diagnosis and treatment. Transplant Proc. 1998; 30:2389-91.

Reviews, Chapters, and Editorials:

299. Ding R, Li B, Sharma VK. Bologa RM, Lagman M, Mouradian J, **Strom TB**, Suthanthiran M. Quantitative competitive polymerase chain reaction: design and synthesis of mRNA specific competitor DNA templates and their clinical usage. Transplant Proc. 1998; 30:2370-2.

300. Schachter AD, **Strom TB**. Post-transplant recurrent FSGS: Molecular insights and future directions. Nephron. 1999; 82:300-05.

301. Zheng XX, Li Y, Li XC, Roy-Chaudhury P, Nickerson P, Tian Y, Sayegh MH, **Strom TB**. Blockade of CD40L/CD40 costimulatory pathway in a DST pre-sensitization model of islet allograft leads to a state of Allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts. Transplant Proc. 1999; 31:627-8.

302. Neylan JF, Sayegh MH, Coffman TM, Dannovitch GM, Krensky AM, **Strom TB**, Turka LA, Harmon WE. The allocation of cadaver kidneys for transplantation in the United States: Consensus and controversy. ASN Transplant Advisory Group. J Am Soc Nephrol. 1999; 10:2237-43.

303. Schachter AD, **Strom TB**. Post transplant recurrent FSGS: molecular insights and future directions. Nephron. 1999; 82:300-5.

304. Li Y, **Strom TB**. Reply to failure of combined costimulatory blockade in animal transplant model. Nat Med.. 2000; 6:115.

305. **Strom TB**, Suthanthiran M. Prospects and applicability of molecular diagnosis of allograft rejection. Semin Nephrol. 2000; 20:103-7.

306. Zheng XX, Li XC, Noguchi M, Li Y, **Strom TB**. The Th1/Th2 paradigm in the acquisition of peripheral graft tolerance. Curr Opin in Organ Transplant. 2000; 5:42-48.

307. Li XC, **Strom TB**. Blocking T-cell costimulation in transplantation: opportunities and challenges. Transfusion. 2000; 40:139-42.

308. Li Y, **Strom TB**. Reply to failure of combined costimulatory blockade in animal transplant model. Nat Med. 2000; 6:115.

309. Li XC, **Strom TB**. A rare find – cells that improve bone marrow transplantation. Nat Med. 2000; 6:866-7.

310. Li XC, Wells AD, **Strom TB**, Turka LA. The role of T cell apoptosis in transplantation tolerance. Curr Opin Immunol. 2000; 12:522-7.

311. Schachter AD, Strehlau J, Zurakowski D, Vasconcellos L, Kim YS, Zheng XX, Gunshin Y, Overstreet SL, Benfield MR, Tejani A, Harmon WE, Herrin JT, **Strom TB**. Increased nuclear factor-kappaB and angiotensinogen gene expression in post-transplant recurrent focal segmental glomerulosclerosis. Transplantation. 2000; 70:1107-10.

Reviews, Chapters, and Editorials:

312. Li XC, **Strom TB**. A rare find- cells that improve bone marrow transplantation. Nat Med. 2000; 6:8-9

313. Krensky AM, Blustone JA, **Strom TB**. Immunomudulators: Immunosuppressive agents and Immunostimulants. (Chapter 52) In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed, Hardman JG, Limbird LE. McGraw Hill Co. Publ. Philadelphia. 2001.

314. Wells AD, Li X-C, **Strom TB**, Turka LA. The role of peripheral T cell deletion in transplantation tolerance. Philos Trans R Soc Biol Sci. Lond. B. 2001; 356:617-23.

315. Li XC, **Strom TB**. Mechanisms of tolerance. (Chapter 5) In: Norman and Turka's Primer on Transplantation 2nd ed. Amer. Soc of Transplantation, Mt. Laurel, NJ. 2001; 35-42.

316. **Strom TB**. Targeting the IL-2 receptor with antibodies or chimeric toxins. Modern Immunosuppressives J-J Schuuman Feutren G and Bach JF (eds) Birkhauser Verlag/Switzerland. 2001; 115-22.

317. Schnipper LE, **Strom TB**. A magic bullet for cancer—how near and how far? N Engl J Med. 2001; 345:1356.

318. Li XC, Wells AD, Turka LA, **Strom TB**. Death of alloreactive T cells sets the stage for immunoregulation to act. Transplant Proc. 2001; 33:3041-3.

319. **Strom TB**, Field LJ, Ruediger M. Allogeneic stem cells, clinical transplantation, and the origins of regenerative medicine. Transplant Proc. 2001; 33:3044-9.

320. Li XC, **Strom TB**, Turka LA, Wells AD. T cell death and transplantation tolerance. Immunity. 2001; 14:407-16.

321. **Strom TB**, Field LLJ, Ruediger M. Allogeneic stem cells, clinical transplantation and theorigins of regenerative medicine. Curr Opin Immunol. 2002; 14:601-5.

322. Ferrari-Lacraz S, Zheng XX, Kim YS, Maslinski W, **Strom TB**. Addition of an IL-15 mutant/FC gamma2A antagonist protein protects islet allografts from rejection overriding costimulation blockade. Transplant Proc. 2002; 745-7.

323. Zheng XX, Maslinski W, Ferrari-Lacraz S, **Strom TB**. Cytokines in the treatment and prevention of autoimmune responses – a role of IL-15. Cytokines and Chemokines in Autoimmune Disease Santamaria P (Chapter 6)(ed) Eurekah. com. 2002

324. **Strom TB**, Field LJ, Ruediger M. Allogeneic stem cells clinical transplantation and the origins of regenerative medicine. Curr Opin Immunol. 2002; 14:601-5.

325. Ferrari-Lacraz S, Zheng XX, Kim YS, Maslinski W, **Strom TB**. Addition of an IL-15 mutant/Fc gamma2A antagonist protein protects islet allografts from rejection overriding costimulation blockade. Transplant Proc. 2002; 34:745-7.

Reviews, Chapters, and Editorials:

326. **Strom TB**, Sukhatme VP. A refined understanding of immunosuppressives and cancer risk. Kidney Int. 2003; 63:1160-1.

327. Zheng XX, Maslinski W, Ferrari-Lacraz S, **Strom TB**. Cytokines in the treatment and prevention of autoimmune responses- a role of IL-15. Adv. Exp Med Biol. 2003; 520:87-95.

328. Quezada SA, Fuller B, Jarvinen LZ, Gonzalez M, Blazar BR, Rudensky AY, **Strom TB**, Noelle RJ. Mechanisms of donor-specific transfusion tolerance: pre-emptive induction of clonal T-cell exhaustion via indirect presentation. Blood. 2003; 102:1920-26.

329. **Strom TB**, Sukhatme VP. A refined understanding of immunosuppressives and cancer risk. Kidney Int. 2003; 63:1160-1.

330. Gao W, Demirci G, **Strom TB**, Li XC. Negative T cell costimulation and islet tolerance. Diabetes Metabol Res and Rev. 2003; 19:179-85.

331. Zheng XX, Sanchez-Fueyo A, Domenig C. **Strom TB**. The balance of deletion and regulation in allograft tolerance. Immunol. Rev. 2003; 196:75-1984.

332. **Strom TB**, Field LJ, Ruediger M. Allogeneic stem cell-derived "repair unit" therapy and the barriers to clinical deployment. J Am Soc Nephrol. 2004; 15:1133-9.

333. Ricordi C, **Strom TB**. Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol. 2004; 4:259-68.

334. Walsh PT, **Strom TB**, Turka LA. Routes to transplant tolerance versus rejection; the role of cytokines. Immunity. 2004; 20:121-31.

335. **Strom TB**. Is transplantation tolerable? J Clin Invest. 2004; 113:1681-3.

336. Sanchez-Fueyo A, **Strom TB**. Immunological tolerance and liver transplantation. J Hepatol. 2004; 698-705.

337. Suthanthiran M, **Strom TB**, The immunology of transplantation. In: Oxford Textbook of Clinical Nephrology. Oxford University Press. Vol. 2, CH 13. 2. 1. 2005; 2:2039-48.

338. **Strom TB** and Suthanthiran M. Therapeutic approach to renal transplantation. (Chapter 13) In: Oxford Textbook of Clinical Nephrology. Cameron S, Davison AM, Grunfeld J-P, Kerr D and Ritz E (eds). Oxford University Press, Leeds, UK. 2005, 049-59

339. **Strom TB**, Rejection—more than the eye can see. N Engl J Med. 2005; 353(22):2394-6.

340. **Strom TB**, Suthanthiran M, Transcriptional profiling to assess the clinical status of kidney transplants. Nature Clinical Practice: Nephrology. 2006; 2(3):116-17.

341. Degauque N, Mariat C, Kenny J, Sanchez-Fueyo A, Alexopoulos SP, Kuchroo V, Zheng XX, **Strom TB**. Regulation of T-cell immunoglobulin and mucin domain proteins. Transplantation. 2007; 84 (1 Suppl):S12-16.

Reviews, Chapters, and Editorials:

342. Dwyer, KM, Deaglio S, Crikis S, Gao W, Enjyoji K, **Strom TB**, Cowan PJ, d'Apice AJF, Robson SC. Salutary roles of CD39 in transplantation. Transplantation Rev. 2007 Jan.; 21(1):54-63.

343. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, **Strom TB**, Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007 Jun 11; 204(6):1257-1265

344. Sanchez-Fueyo A, Domenig CM, Mariat C, Alexopoulos S, Zheng XX, **Strom TB**. Influence of direct and indirect allorecognition pathways on CD4+CD25+ regulatory T-cell function in transplantation. Transpl Int. 2007 June; 20(6):534-41.

345. Strom, TB. Homer W. Smith Lecture: Taming T Cells. J Am Soc Nephrol. 2007; 18(11):2824-32.

346. Dwyer, KM, Deaglio S, Gao W, Friedman D, **Strom TB**, Robson SC. CD39 and control of cellular immune response. Purinergic Signaling. 2007; 3:171-80.

347. **Strom TB**, Koulmanda M. Recently discovered T cells subsets cannot keep their commitments. J Am Soc Nephrol. (in press. 2008).

348. Porrett PM, Yuan X, LaRosa DF, Walsh PT, Yang J, Gao W, Li P, Zhang J, Hancock WW, Sayegh MH**,** Koulmanda M, **Strom TB**, Turka LA. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol. 2008; 181:1692-1699.

349. Feng G, Gao W, **Strom TB**, Oukka M, Francis RS, Wood KJ, Bushell A. Exogenous IFN-c *ex vivo* shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp31 regulatory T cells. Eur J Immunol. 2008; 38:2512–2527.

350. Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H, Bonner-Weir S, Putheti P, Degauque N, Libermann TA, Auchincloss H Jr, Flier JS, **Strom TB**. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A. 2008 Oct 21; 105(42):16242-16247

351. **Strom TB**, Koulmanda M. Cytokine related therapies for autoimmune disease. Curr Opin in Immunol. 2008,. 20:1–6.

352. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, Mitsdoerffer M, **Strom TB**, Elyaman W, Ho IC, Khoury S, Oukka M, Kuchroo VK. IL-4 inhibits TGF-β-induced $Foxp3^+$ T cells and, together with TGF-β, generates IL-9^+ IL-10^+ $Foxp3^-$ effector T cells. Nat Immunol. 2008 Dec; 9(12):1347-1355.

353. Mariat C, Degauque N, Balasubramanian S, Kenny J, DeKruyff RH, Umetsu DT, Kuchroo V, Zheng XX, **Strom TB**. "Tim-1 signaling substitutes for conventional signal 1 and requires costimulation to induce T cell proliferation. J Immunol. 2009 Feb 1; 182(3):1379-1385.

Educational Material:

Books:

1. Bach JF, **Strom TB**, (eds): The Mode of Action of Immunosuppressive Agents, 2nd edition. Amsterdam: Elsevier; 1986.

2. Lipsky PF, **Strom TB**, (eds): Immunology and Allergy Clinics of North America, Vol. 8, #1; WB Saunders, Philadelphia, PA; 1988.

3. Coe FL, Favus MU, Henderson L, Kashgarian M, Luke RG, Myers B, **Strom TB** (ed): Year Book of Nephrology 1992. Mosby-Year Book; Chicago, IL; 1992.

4. Ascher NL, Hansen JA, **Strom TB** (eds): Year Book of Transplantation. Mosby-Year Book; Chicago, IL; 1992.

5. Ascher NL, Hansen JA, **Strom TB** (eds): Year Book of Transplantation. Mosby-Year Book; Chicago, IL. 1993.

6. Austen KF, Burakoff SJ, Rosen FS, **Strom TB** (eds) Therapeutic Immunology. Blackwell Scientific; Cambridge, MA. 1996.

7. Tilney NL, **Strom TB**, Paul LC (eds) Transplantation Biology: Cellular and Molecular Aspects. Lippincott-Raven Press; New York, NY. 1996.

Patents:

Patent	Title	Name	Issue Date
U.S. #5,011,684	“Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance."	Strom TB	Issued: April 30, 1991
U.S. #5,152,980	”Induction of tolerance to a foreign antigen IL-2 receptor-binding substances.”	Strom TB, Kelley VE	Issued: October 6, 1992
U.S. #5,336,489	“Treatment of allograft rejection with IL-2 receptor-specific cytotoxins."	Strom TB	Issued: August 9, 1994
U.S. #5,510,105	“Treatment of autoimmune diseases with IL-2 receptor-specific cytotoxins."	Strom TB	Issued: April 23, 1996
U.S. #5,571,507	“Methods of treating diabetes.”	Rubin-Kelley VE, Strom TB, Bach JF, Nichols JC	Issued: November 5, 1996
U.S. #5,587,162	“Treatment of allograft rejection with IL-2 receptor-specific cytotoxins.”	Strom TB	Issued: December 24, 1996
U.S. #5,607,675	“Treatment of autoimmune diseases with IL-2 receptor-specific cytotoxin.”	Strom TB	Issued: March 4, 1997

U.S. #5,674,494	"Treating non-malignant disease states with IL-2 receptor-specific substances."	Strom TB	Issued: October 7, 1997
U.S. #5,916,559	"Use of interleukin-2 (IL-2) receptor-specific agents to treat allograft rejection."	Strom TB	Issued: June 29, 1999
U.S. #5,936,138	"Gene encoding mutant L33T4 protein which facilitates HIV infection and transgenic mouse expressing such protein."	Wieder KJ, Strom TB	Issued: August 10, 1999
U.S. #5,958,403	"Methods and compounds for prevention of graft rejection."	Strom TB	Issued: September 8, 1999
U.S. # 5,958,403	"Methods and compounds for prevention of graft rejection."	Strom TB, Libermann T	Issued: September 28, 1999
U.S. #6,001,973	"Antagonists of interleukin-15."	Strom TB, Maslinski W	Issued: December 14, 1999
U.S. # 6,165,476	"Fusion proteins with an immunoglobulin hinge region linker."	Strom TB, Zheng XX	Issued: December 26, 2000
U.S. # 6,187,534	"Methods of evaluating transplant rejection."	Strom TB, Vasconcellos LM, Suthanthiran M	Issued: February 13, 2001
U.S. #6,410,008	"Chimeric IL-10 proteins and uses thereof."	Strom TB	Issued: June 25, 2002
U.S. #6,797,263 B2	"Components and methods for achieving immune suppression."	Strom TB, Maslinski W, Zheng XX, Kim YS, Ferrari-Lacraz S	Issued: September 28, 2004
U.S. #6,900,015	"Measurement of protective genes in allograft rejection."	Strom TB	Issued: May 31, 2005
U.S. #1,015,639	"Methods of Evaluating Transplant Rejection - Transcriptional profiling for transplant patient management."	Strom TB	Issued: February 21, 2007
U.S. #7,258,853	"Antagonists of interleukin-15."	Strom TB	Issued: August 21, 2007
U.S. pending	"Vaccine compositions and methods of enhancing vaccine efficacy."	Letvin NL, Barouch DH, Strom TB, Zheng XX	